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Abstract 
 
Peste des petits ruminants (PPR) is an economically important disease of sheep and goats caused by 
infection with the morbillivirus, peste des petits rumiants virus (PPRV). The disease is characterised by 
high morbidity and mortality and is a World Organisation for Animal Health (OIE) reportable disease. 
The OIE and Food and Agriculture Organisation (FAO) have agreed to globally eradicate PPR by 2030. 
Eradication of the disease will lead to improvements in food security and livelihood stability for 
millions of subsistence and nomadic farmers in some of the world’s poorest countries. Vaccination will 
play a key role in global eradication. Live, attenuated vaccines are available for PPRV and have a long 
safety and efficacy record, however, the mechanisms of protection are not known. There are four 
genetic lineages of PPRV, but only one serotype, to improve end-user confidence in the vaccines, 
vaccination/challenge experiments were performed with the two most widely used live, attenuated 
vaccines and challenging with representative PPRV strains from all genetic lineages. Both vaccines 
provided protection against all four genetic lineages. The mechanisms of vaccine-induced protection 
have not been investigated in detail for these vaccines, so serum and peripheral blood mononuclear 
cells (PBMCs) collected during the vaccination/challenge experiments were used to study the cellular 
and serological responses to vaccination. Both vaccines induce PPRV-neutralising antibodies and 
PPRV-specific proliferative responses and interferon-γ (IFN-γ) production. To investigate the role of 
CD8+ T cells in vaccine-induced protection goats were vaccinated, injected with the anti-CD8 mAb 
CC63 and challenged whilst their CD8+ cells were almost undetectable in peripheral blood. CD8-
depleted goats did not develop signs of PPRV, but on post mortem some were found to have gut-
specific pathology. Therefore, CD8+ T cells are not the primary source of vaccine-induced protection, 
but they may play a role in tissue-specific protection.  
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Chapter 1 - Introduction 
1.1 Peste des petits ruminants 
Peste des petits ruminants (PPR) is a highly contagious and economically important viral disease of 
small ruminants and, due to its high morbidity and mortality rates, it is classified as a notifiable disease 
by the World Organisation for Animal Health (OIE) (2014). PPR is caused by peste des petits ruminants 
virus (PPRV), a member of the genus Morbillivirus in the family Paramyxoviridae (Gibbs et al., 1979). 
Other members of the genus include measles virus (MeV), canine distemper virus (CDV), phocine 
distemper virus, dolphin morbillivirus, the recently discovered feline morbillivirus (Woo et al., 2012) 
and the globally eradicated rinderpest virus (RPV) (Figure 1.1). All morbilliviruses have restricted host 
ranges of disease. PPRV causes disease in domesticated sheep (Ovis aries) and goats (Capra hircus), 
but has also been implicated in mortality of wildlife species including bharal (Pseudois nayaur) (Bao et 
al., 2012), Nubian ibex and gemsbok (Furley and Taylor, 1986), camels (Khalafalla et al., 2010), gazelles 
(Elzein et al., 2004) and Indian buffalo (Govindarajan et al., 1997). In experimental studies, cattle 
(Mornet et al., 1956b) and pigs (Nawathe and Taylor, 1979) have been infected with PPRV and, whilst 
they developed antibodies against the virus, they did not develop any clinical signs and are considered 
dead-end hosts. Cattle can certainly become asymptomatically infected in the field as well as 
experimentally, and this was detected by serological surveillance of sheep, goats and cattle for PPRV 
antibodies in Nigeria and Ghana (Anderson and McKay, 1994). 
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1.2 The history and distribution of PPR 
PPR was first reported as a separate disease in Cote d’Ivoire by Gargadennec and Lalanne who 
identified that a rinderpest-like virus was affecting sheep and goats, but that in-contact cattle were 
asymptomatic (Gargadennec and Lalanne, 1942). At first, it was assumed that PPRV was a West African 
strain of rinderpest that had lost its ability to infect cattle (Mornet et al., 1956a). Before the advent of 
PPR-specific diagnostics tools that could differentiate between RPV and PPRV, such as cDNA clones in 
1988 (Diallo et al., 1989a), it is possible that most cases of PPR in sheep and goats were misdiagnosed 
as rinderpest and that PPRV was circulating in RPV endemic areas for decades before it was identified. 
This is considered to be the case for PPRV ‘emergence’ in India, where the virus was identified in 
multiple areas of the country almost simultaneously (Shaila et al., 1989, Nanda et al., 1996). The global 
distribution of PPRV has expanded recently, with PPR currently considered endemic in West Africa, 
Figure 1.1 Phylogenetic tree of the morbilliviruses. This was created using the amino acid sequences 
of the nucleocapsid gene of different morbillivirus reference strains and the neighbour-joining 
method. Morbiliviruses included in the tree are: phocine distemper virus (PDV), canine distemper 
virus (CDV), measles (MeV), rinderpest (RPV), peste des petits ruminants (PPRV), cetacean 
morbillivirus (CeMV) and feline morbillivirus (FeMV). This image is adapted from: Sourimant, J.; 
Plemper, R.K. Organization, Function, and Therapeutic Targeting of the Morbillivirus RNA-Dependent 
RNA Polymerase Complex. Viruses 2016, 8, 251. 
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East Africa, Central Africa, and parts of Asia (Baron et al., 2016). The expansion of PPR could also, in 
part, be due to a lack of surveillance for the disease, in the case of Libya all neighbouring countries 
had reported the presence of PPR by 2011, but the national Centre of Animal Health Laboratory in 
Tripoli did not perform serological surveillance for the disease until 2013 when 59.2% of goats tested 
were positive for PPR antibodies (Almeshay et al., 2017). PPR was confirmed in Tibet in 2007, but the 
Chinese were efficient in controlling the outbreak by culling of infected animals, animal movement 
controls and increased disease surveillance (Wang et al., 2009), however there have been more recent 
disease outbreaks reported in China with a significant disease outbreak between 2013-2014 (Liu et al., 
2018). Furthermore, the occurrence of clinical PPR in Turkey (Cam et al., 2005, Yesilbag et al., 2005, 
Ozkul et al., 2002) has caused concern that the disease could spread into Europe in the near future. 
Due to the successful eradication of the closely related rinderpest, PPRV was identified as a suitable 
candidate for eradication to improve food security in developing nations. The arguments for possible 
PPRV eradication include the availability of a successful vaccine, that transmission only occurs through 
close contact of infected and naïve animals, the lack of a carrier state in recovered animals and the 
availability of diagnostics assays for surveillance. However, if eradication is to be successful it will 
require international collaboration, to this end the Food and Agriculture Organization (FAO) and the 
World Organization for Animal Health (OIE) both agreed to eradicate PPR by 2030 (2015). 
 
1.3 Pathogenesis and clinical disease in the ruminant host 
The virus is transmitted between infected and non-infected animals during close contact and it is 
believed that outbreaks in previously disease free areas are due to importation of infected animals 
facilitated by free animal movement and unregulated trade in small ruminants between neighbouring 
countries. For PPRV, the incubation period between infection and clinical signs is between 4-7 days. 
Disease progression in small ruminants is characterised by pyrexia and leucopoenia preceding a rough 
coat, nasal and ocular discharge, anorexia, pneumonia, coughing and inflammation of the mucous 
membranes of both the respiratory and digestive tract (Figure 1.2). This can be followed later by 
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diarrhea, prostration due to discomfort and in many cases death (Pope et al., 2013, Brown et al., 1991). 
PPRV causes immunosuppression (Rajak et al., 2005) and opportunistic bacterial infections can 
aggravate the disease. It is widely postulated that disease is more severe in goats than sheep. Animals 
either die from the infection or recover and mount a strong immune response, and are believed to be 
protected from re-infection for life, although experiments attempting to reinfect recovered animals 
have not been carried out. Currently there is no evidence indicating a carrier state of infection. 
Investigations into experimental routes of infection of PPRV found no statistical difference between 
the onset of clinical signs between intravenous, intranasal and subcutaneous infections {El Harrak, 
2012 #148}. However, they did find that goats infected by the intravenous and intranasal routes had 
significantly higher clinical scores than those infected subcutaneously. Natural infection is thought to 
be through inhalation of droplets via the respiratory tract, therefore the intranasal infection route is 
the most indicative of natural infection under experimental conditions. 
Cattle (Bos taurus) have been shown to develop a humoral immune response to PPRV infection either 
by natural exposure to infected sheep and goats in the field or when experimentally injected. 
However, there are no reports of clinical disease in cattle and it is assumed they play no role in 
transmission to small ruminants (Anderson and McKay, 1994). Experimental infections of pigs (Sus 
scrofa domestica) also found that whilst pigs sero-converted, they did not develop clinical signs 
(Nawathe and Taylor, 1979). 
Whilst cattle do not develop clinical signs upon PPRV infection, the Indian buffalo (Bubalus bubalis) is 
reported to develop conjunctivitis, salivation, depression and a 96% fatality rate (Govindarajan et al., 
1997). PPRV has been isolated from gazelles displaying signs of anorexia, haemorrhagic diarrhea with 
erosions and lesions on their lips and tongue, that had been kept in a zoological collection in the United 
Arab Emirates and under semi-free ranging conditions in Saudi Arabia and these wildlife species are 
considered susceptible to disease (Elzein et al., 2004, Furley and Taylor, 1986). Whilst anti-PPRV 
antibodies have been found in camel sera (Woma et al., 2015), one report links the presence of PPRV-
22 
 
specific antibodies in camels (Camelus dromedarius) in Sudan with cases of sudden death or bloody 
diarrhea and abortion (Khalafalla et al., 2010), but so far this has not been corroborated. 
 
 
  
Figure 1.2 Clinical signs of PPRV infection in goats. PPRV infection leads to ocular and nasal discharge 
(A), depression and prostration (B), diarrhoea (C) and a classical sign on post mortem is tiger striping 
in the gut (D). 
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1.4 Virus genome and proteins 
1.4.1 Genome 
Peste des petits ruminants virus particles are enveloped, pleomorphic and contain a single stranded, 
negative sense RNA genome. The PPRV genome is little studied, and our understanding of its structure 
and replication is based mostly on our knowledge of MeV, RPV and other paramyxoviruses. As with 
other Paramyxoviridae, PPRV follows the rule of six (Kolakofsky et al., 1998), the rule of six states that 
the virus can only replicate efficiently if the genome is a multiple of six nucleotides (nt) in length (Calain 
and Roux, 1993). The genome length of PPRV is relatively conserved, PPRV/Turkey/2000, the first fully 
sequenced wild type virus (Bailey et al., 2005) and the virulent field strains PPRV/Cote d’Ivoire/88 and 
PPRV/Nigeria/76/1 are all 15,948 nt long (Chard et al., 2008). However, a recently sequenced PPRV 
isolated in China has a longer genome of 15,954 nt (Su et al., 2015) this, the researchers argue, 
indicates that PPRV is continuing to evolve and vaccine escape could be possible in the near future. 
The RNA genomes of all members of the genus Morbillivirus encode eight proteins in total; six 
structural proteins and two non-structural proteins. The genes of PPRV are arranged along the single 
RNA strand in the order N-P-M-F-H-L (see Figure 1.3), each gene is separated by an intergenic region 
of three nucleotides, the distance between open reading frames (ORFs) is variable. These genes 
encode for the nucleoprotein (N) that encapsidates the RNA genome, the phosphoprotein (P) that acts 
as a co-factor for the ’large’ protein (L), which is an RNA-dependent RNA polymerase. The matrix (M) 
gene encodes the matrix protein which is thought to interact with the host cell membrane and the 
fusion (F) and haemagglutinin (H) proteins that are embedded in the viral membrane and protrude 
externally from the virion. The morbilliviruses have a transcription gradient along the genome, with 
the N protein at the 3’ end being most transcribed, and the L protein at the 5’ end being least 
transcribed (Cattaneo et al., 1987). 
Similar to other morbilliviruses, the PPRV genome also encodes two non-structural proteins, V and C; 
both proteins are encoded within the P transcriptional unit. The C protein is encoded in a second ORF 
in the first half of the P gene; this ORF is +1 nt relative to the P protein ORF. The V protein is created 
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by an internal frame shift due to the incorporation of an extra G nucleotide at a specific site during 
transcription of roughly one third of the messenger RNA (mRNA) from the P gene. 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1.3 Cartoon visualising the genome structure of PPRV. Each box represents an ORF, the black 
line represents untranslated regions. The genome of PPRV is a single strand of RNA that encodes eight 
proteins. The genes encode, in order from the 3’ end of the genome, the nucleocapsid protein (N), 
phosphoprotein (P) (the P gene also codes for the V and C proteins), the matrix (M) protein, the 
glycoproteins fusion (F) and haemagglutinin (H) and finally the large (L) protein. 
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1.4.2 PPRV Structural proteins 
The N protein is encoded in the first ORF of the PPRV genome, as a result it is the most abundant viral 
protein produced during infection, it is also highly immunogenic. The N protein encapsidates the viral 
RNA genome and each N is thought to associate with six nucleotides (Gutsche et al., 2015); it is strongly 
believed that this interaction between the N protein and genomic RNA results in the ‘rule of six’ 
(Kolakofsky et al., 1998). Another two proteins are associated with the RNA genome – the Large (L) 
protein and its co-factor the Phosphoprotein (P) (Bourdin and Laurent-Vautier, 1967). The L protein 
initiates the transcription of the PPRV genome in the host cell cytoplasm and the P protein regulates 
transcription and replication. The ribonucleocapsid is enveloped in a lipid bilayer derived from the 
host cell membrane. 
The Matrix protein (M) is thought to be located just underneath the lipid envelope, as seen in the 
Paramyxovirus Sendai virus, although studies on the more closely related MeV have suggested it may 
actually form a helical shell around the nucleocapsid (Hirano et al., 1993, Runkler et al., 2007). It plays 
a crucial role in morbillivirus viral RNA synthesis (Iwasaki et al., 2009), virus assembly and budding by 
interacting both with the nucleocapsid and possibly with the cytoplasmic tails of the viral glycoproteins 
F and H (Mahapatra et al., 2006) that are embedded in the virus envelope and protrude from the 
surface as spikes. However, the M protein of measles does not colocalise with the viral glycoproteins 
at apical membranes of infected cells, suggesting an alternative transport mechanism to the surface 
membrane (Riedl et al., 2002). The H protein is responsible for binding to a host cell that expresses a 
suitable cell surface receptor, and the F protein, using the H protein as a fusion promotor enables 
fusion of the virus envelope with the host lipid bilayer and release of the viral genome into the cell. 
 
1.4.3 PPRV Accessory proteins 
The full functions of PPRV V and C are still not fully elucidated, although they have been shown to play 
a role in immune modulation. Recent publications have demonstrated that morbillivirus V proteins 
can block Interferon (IFN) signaling, preventing an antiviral state in infected cells (Chinnakannan et al., 
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2013). This work was built upon by researchers in this group who identified that the PPRV V protein 
binds to the host MDA-5, and to a lesser extent RIG-I, suppressing IFN-β induction in infected cells 
(Sanz Bernardo et al., 2017). It has also been demonstrated that PPRV that lacks either V or C has a 
slower growth rate than the wild type and the mutant viruses were unable to replicate to the same 
titre as the parent strain, even in the absence of interferon, resulting in a log reduction or greater in 
final virus titre in the interferon-defective cell line Vero human-SLAM (Sanz Bernardo et al., 2017). 
 
1.4.4 Phylogenetic analysis and genetic lineages 
Based on partial sequencing of either the fusion or the nucleocapsid gene of PPRV, the virus strains 
can be divided into four genetic lineages called I, II, III and IV (Couacy-Hymann et al., 2002, Forsyth 
and Barrett, 1995), based on how they are grouped in phylogenetic trees (Figure 1.4), confusingly, 
when the lineages were originally identified the PPRV/Cote d’Ivoire/89 strain was referred to as in 
‘Lineage II’ and PPRV/Nigeria/75 referred to as in ‘Lineage I’ (Forsyth and Barrett, 1995, Ozkul et al., 
2002). However, in more recent papers these two lineages’ numbers were reversed (Kwiatek et al., 
2011, Kwiatek et al., 2007) based on the argument that the virus was first identified in Cote d’Ivoire, 
so this virus should be lineage I. Kwiatek and colleagues also argue that phylogenetic trees based on 
partial N gene sequence are better at clustering isolates based on geographic distribution than 
phylogenetic trees based on partial F sequences (Kwiatek et al., 2011). For clarity viruses referred to 
in this project have been assigned lineages based on the definition in Kwiatek et al., 2011.  
Originally, the genetic lineages had a fairly distinct geographic distribution with lineage II found in 
West and Central Africa, lineage I in the West African countries of Guinea, Senegal and Cote d’Ivoire, 
lineage III detected in Eastern Africa and lineage IV found across the Arabian Peninsula, the Middle 
East and Asia. However, recent outbreaks in North Africa (Kwiatek et al., 2011) of lineage IV strains 
have extended the distribution of this genetic lineage. This North African virus was shown to have 
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genetic similarity to viruses circulating in the Near and Middle East and therefore was not related to 
viruses from Sub-Saharan Africa.  
Whilst genetic sequencing has divided the known strains into four genetic lineages, there is no 
evidence that more than a single serotype exists for PPRV. This is also seen with MeV and was also 
true for the now eradicated RPV. This shows that the genetic variations between strains does not 
necessarily equate to significant changes to the proteins on the surface of the virus, thus not leading 
to changes in the neutralization binding sites on these proteins. 
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Figure 1.4 Phylogenentic tree of sequenced PPRV strains. Viruses are grouped into the four genetic 
lineages of PPRV based on sequencing of a 255 nucleotide region of the N gene. This figure is taken 
from a review by Banyard et al. 2010. 
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1.5 Viral replication 
The exact PPRV replication cycle has not been fully investigated and much is assumed from what is 
known for other morbilliviruses. Tatsuo and colleagues found that MeV and CDV use signaling 
lymphocyte activation molecule (SLAM; also known as CD150) as a cellular receptor for host cell 
binding and entry in vitro (Tatsuo et al., 2000, Tatsuo et al., 2001). The use of SLAM as an entry 
receptor for wild type RPV was confirmed a few years later (Baron, 2005), following these findings an 
entry mechanism for PPRV was also confirmed as SLAM (Birch et al., 2013). SLAM is expressed on 
activated T and B cells and dendritic cells (Bleharski et al., 2001, Kruse et al., 2001, Sidorenko and 
Clark, 1993), and the distribution of this cellular receptor partially explains the tissue tropisms of the 
morbilliviruses. Expression of SLAM on cell lines improves the ability of wild type morbilliviruses to 
grow in vitro (Adombi et al., 2011). 
Infected animals shed PPRV in their nasal and ocular secretions and coughing can spread the virus to 
animals in close proximity. It is believed that PPRV is inhaled into the respiratory tract and that the 
virus binds to SLAM expressed on dendritic cells present in the intraepithelial space and the lamina 
propria of the respiratory mucosa. These infected cells then cross the epithelium and migrate to 
draining lymph nodes where there are activated T and B cells, expressing SLAM, that the virus can 
infect and replicate in (Pope et al., 2013). From the lymph nodes, the virus then spreads through the 
lymphatic and vascular system, and viral genome can be detected in systemic blood samples as early 
as two days after experimental infection (El Harrak et al., 2012).   
To enable virus shedding at the mucosal membranes, it was recently discovered that PPRV (Birch et 
al., 2013), as well as other morbilliviruses (Muhlebach et al., 2011, Noyce et al., 2011), can use nectin-
4 to infect epithelial cells and this protein has been termed an ‘exit receptor’ for morbilliviruses 
(Leonard et al., 2008). Nectin-4 is a major component of the adherens junctions that are located 
basolateral to the tight junctions of the epithelium (Niessen, 2007). Later in infection, lesions and 
erosion of the mucosa of the mouth, nose and upper respiratory tract can be observed and it is 
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postulated that nectin-4-mediated PPRV infection of the epithelial cells causes CPE and cell death 
leading to the breakdown of the epithelial structure. 
 
1.6 Immune responses to morbillivirus infections 
1.6.1 Immune response to MeV in primates 
Whilst the limited availability of veterinary-specific reagents has hampered research into the immune 
responses to disease in ruminants, human- and primate-specific reagents have enabled researchers 
to investigate humoral and cellular immune responses for decades. MeV, another member of the 
morbillivirus genus, has been extensively studied due to its importance to human health. Human 
vaccine efficiency is determined by epidemiological changes to virus prevalence and disease incidence, 
hence the absence of known virus challenge does not allow for direct determination of protective or 
non-protective immune response to vaccination. 
The standard MeV vaccine induces both humoral and cell mediated responses, and protection is 
correlated with neutralizing antibody, but the exact determinants of protection are still not known, 
reviewed in (Griffin, 2017). Natural infections with MeV have shown that children with 
agammaglobulinemia suffer from typical measles (Good and Zak, 1956), but children with hampered 
cell mediated immunity, such as those affected by acquired immune deficiency syndrome (AIDS), 
suffer atypical, sometimes fatal disease (Markowitz et al., 1988). From these observations in children, 
it can be assumed that antibody does not play a major role in MeV clearance, but that T cell mediated 
immune responses are important for viral control in the host. 
To further elucidate the mechanism of protective immune responses to measles, several studies have 
investigated the humoral and cell-mediated immune response to MeV infection and/or vaccination in 
macaques.  
One way to determine the importance of cell mediated immune responses (CMI) is to perform an in 
vivo depletion. Depletion of CD20+ lymphocytes in macaques, followed by infection with MeV resulted 
in delayed neutralizing antibody, but the same clinical outcome and viral clearance as naïve monkeys 
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given a control antibody (Permar et al., 2004). In contrast monkeys depleted of both CD20 and CD8+ 
lymphocytes developed a more severe skin rash and prolonged measles viraemia compared to control 
and CD20-depleted monkeys. Another study by the same group focused on CD8-depletion alone in 
rhesus macaques and found that CD8 depleted animals showed higher viral loads at peak viraemia, 
more severe rash and longer duration of viraemia compared to control animals after MeV infection 
(Permar et al., 2003). These findings correspond to those observations in natural measles infection in 
children with agammaglobulinemia or AIDS. 
Furthermore, vaccination with either killed or live attenuated vaccine and subsequent challenge with 
live virus found that macaques that had been given the killed vaccine produced a short lived anti-virus 
antibody response but had no detectable cytotoxic T cell response (Polack et al., 1999). In contrast, 
those macaques receiving live vaccine had strong cytotoxic responses post-vaccination. On wild-type 
virus challenge all naïve animals developed classical measles rash while all monkeys given the live 
vaccine were protected, however two out of five monkeys given killed vaccine developed atypical 
measles (Polack et al., 1999). When the humoral immune response was assessed in these monkeys 
they were found to have high antibody levels, especially high IgE, that were not seen in naïve or live 
virus vaccinated animals. It was concluded that the killed vaccine primes a non-protective Th2 
response (Polack et al., 1999).  
Additionally, Zhu and colleagues found that vaccination of macaques with live, attenuated measles 
vaccine initially generated good neutralizing antibody titers, but that these were low nine months 
post-challenge and immediately before challenge (Zhu et al., 1997). In spite of these low antibody 
titers before challenge none of the vaccinated animals developed clinical signs of disease, indicating 
that either low neutralizing antibody was enough or another, un-investigated immune response 
provided protection against disease in these animals. 
In contrast, when the MeV vaccine Edmonston-Zagreb was administered by nebulizer to macaques 
the vaccinated monkeys developed strong MeV-specific IFN-γ responses, but had no neutralizing 
antibodies (Lin et al., 2014). When challenged these monkeys developed typical measles rash and had 
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a viraemia similar to unvaccinated control animals, however the vaccinated animals were able to clear 
viraemia in the blood faster. 
Passive transfer of serum from mice vaccinated with MeV F protein peptide and cholera toxin B 
subunit adjuvant to naïve mice before intracranial challenge with a neuroadapted MeV protected mice 
from clinical signs and 100% survived (Hathaway et al., 1998). Serum passively transferred from mice 
given the MeV F peptide alone was not fully protective with 4 out of 6 animals surviving challenge. 
Taken together these observations point to neutralizing antibody playing a role in viral control and 
CD8+ lymphocytes playing a role in measles virus clearance. Further research will have to be 
performed for live, attenuated morbillivirus vaccines to determine correlates of protection against 
disease and prevention of transmission. 
Whilst this research into MeV is informative and could be extrapolated to other morbilliviruses, 
researchers should remember that the clinical signs of measles and morbilliviruses such as rinderpest 
and peste des petits ruminants are not the same and whilst all morbillivurses cause fever and mucosal 
congestion, measles is chiefly associated with maculopapular rash and sometimes neurological 
complications, most infected individuals recover. Whereas rinderpest and PPR do not have a rash and 
are associated with nasal and ocular discharge and diarrhea, but have high mortality rates, unlike 
measles. Also, the differences in host immune responses should be taken into account, the role of 
different cell types in primates or mice are not always the same as in ruminants, so investigations into 
the other morbilliviruses in the natural host are preferable to extrapolation from MeV in primates, but 
in the absence of data extrapolation from MeV can be used to inform study design in other 
morbilliviruses. 
 
1.6.2 Immune response to RPV in cattle 
Rinderpest is another morbillivirus that infects ruminants. Research into the immune response to RPV 
is limited to studies on the vaccine strains of the virus as reported in the Veterinary Record (2013a), 
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and due to the rinderpest eradication campaign, use of the virus for experimental work was banned 
for an extended period of time and is now only carried out under licence. 
Research in this group found that vaccination of cattle with the Plowright rinderpest vaccine strain 
induced high neutralizing titres of serum antibody and RPV-specific proliferation in 3H thymidine 
proliferation assay (Holzer et al., 2016). The animals were protected against disease when challenged 
with RPV/Saudi/81. 
In an attempt to assess the efficacy of the RPV H and F proteins as subunit vaccines, both vaccines 
were expressed in a baculovirus system and the immunogenicity was assessed in mice and cattle. 
Cattle that had been vaccinated with baculovirus-expressed F or H protein of RPV seroconverted, as 
assessed by ELISA, and developed neutralizing antibodies, but were not protected from disease when 
they were challenged 4 weeks later (Bassiri et al., 1993). Cellular immune responses were not assessed 
in this experiment. Interestingly, cattle vaccinated with recombinant RPV H protein incorporated into 
an ISCOM matrix which would be expected to elicit better CMI than the baculovirus expressed PRV H 
were protected (Kamata et al., 2001). 
 
1.6.3 Immune response to PPRV in sheep and goats 
Research into the immune response to PPRV infection and vaccination has not been as extensive as 
the research into measles. However, the humoral and cytokine response in PPRV infection and 
vaccination has been investigated, and the field of knowledge in PPRV infection has recently expanded 
with improved ruminant-specific molecular biology reagents. 
The first line of defense against any infection is the innate immune system. The innate immune system 
identifies a pathogen by detecting pathogen associated molecular patterns (PAMPs) such as double 
stranded RNA using toll like receptors (TLRs). Once TLRs have been activated they lead to the 
downstream production of antiviral cytokines including type one interferons (IFN-α). Dhanasekaran 
and colleagues found that PBMCs from buffalo were less permissive to PPRV infection than those from 
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goats, and attributed this to differential expression of the innate immune cytokine IFN-α following in 
vitro infection with PPRV {Dhanasekaran, 2014 #253}. 
Natural killer (NK) cells are innate lymphocytes that are capable of cytotoxicity and IFN-γ production 
in response to encountering virally infected cells {Boysen, 2009 #256}. As a result of their ability to kill 
virally infected cells like CD8+ T cells and produce cytokines like CD4+ T cells, yet their actions are 
mediated through germline encoded receptors so they are innate cells, they are considered to bridge 
the innate and adaptive immune systems. The antiviral action of NK cells in other viral infection models 
would lead to the assumption that they would mount an anti-PPRV response during infection, but 
their role in infection has not yet been investigated. 
The humoral immune response to vaccination and natural infection in PPR has been well studied using 
both competition ELISA (cELISA) (Anderson and McKay, 1994, Choi et al., 2003, Singh et al., 2004) and 
serum neutralization tests (SNTs) to measure PPRV-specific antibody.  
Whilst ruminant-specific reagents to study protein expression are limited, researchers are gaining 
better understanding of the cellular immune response to PPRV vaccination and infection by using real-
time PCR to look at cytokine expression. A study by Patel et al. investigated the kinetics of the 
cytokines interferon-gamma (IFN-γ) and interleukin-4 (IL-4) in goats after vaccination or infection with 
wild type PPRV (Patel et al., 2012). Using IL-4 and IFN-γ expression as a correlate for a TH2 or TH1 
immune response, respectively, the authors concluded that mounting a strong TH2 response, with 
stimulation of B cells, later in infection protects animals from severe disease and promotes recovery. 
However short-comings in the methodology of the qPCR normalization strategy of this study 
necessitate these results to be treated with caution. Baron et al. investigated the expression of mRNA 
levels of twelve cytokines in goats during PPRV infection with several wild type viruses from all four 
genetic lineages and normalized expression against three housekeeping genes (Baron et al., 2014). In 
agreement with Patel et al. IFN-γ expression is increased from baseline transcription early in infection 
with all virus strains. Other genes found to be up-regulated in the first six days of PPRV infection were 
the pro-inflammatory IFN-β, IL-1β, IL-6, IL-12a, IL-12b and the inhibitory IL-10, there were no 
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significant differences in cytokine mRNA expression profile between the more pathogenic strains and 
the less pathogenic strains (Baron et al., 2014). Unfortunately, this study only investigated the cytokine 
response to wild type viruses, so it is not known if the cytokine mRNA expression profile for vaccination 
is similar. Also, due to different regulatory mechanisms acting on mRNA and protein it has been found 
that mRNA up- and down-regulation does not always correlate with protein expression (Chen et al., 
2002), so investigating the protein expression is more biologically relevant. 
Despite many years of research into the immune responses to vaccination in morbilliviruses, 
protective correlates of vaccination are still not known. Once protective correlates of vaccination are 
identified then the potential of new vaccines to confer protection might be inferred from immune 
responses in vaccinated animals without the need to expose animals to virulent challenge.  
 
1.7 Vaccines against PPR 
There are several types of vaccines in use or in development to control PPR, ranging from live 
attenuated PPRV vaccines to recombinant virus preparations expressing selected PPRV proteins in 
viral vector backbones commonly used for other vaccines and multi-valent preparations. Historically, 
sheep and goats were vaccinated with the Plowright RPV vaccine to protect them against PPRV 
(Bourdin et al., 1970). However, once the rinderpest eradication campaign was underway and 
serological surveillance was utilized to confirm rinderpest free status, this vaccine was no longer used 
to protect against PPRV and PPRV-specific vaccines were used universally. 
There are current plans to globally eradicate PPR, using the recent eradication of rinderpest as a 
model. Vaccination will play a major role in preventing and reversing the global spread of PPR, as well 
as improved detection and reporting in affected countries. 
 
1.7.1 The live, attenuated vaccines 
 In 1989 Diallo et al. reported that they had successfully attenuated a virulent strain of PPRV from 
Nigeria by serial passage first on lamb cells, then Vero cells (Diallo et al., 1989b). After 55 passages on 
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Vero cells, the virus did not produce any signs of disease when injected into goats and protected the 
animals from virulent challenge 3 weeks later. In addition, the attenuated virus was not shed to 
animals in direct contact with the vaccinees. This live attenuated vaccine, known as Nigeria/75/1, is 
used in Africa, the Near and Middle East and large parts of Asia with the exception of India (Sen et al., 
2010) and provides effectively life-long immunity to disease in small ruminants. 
Currently there are three other live, attenuated vaccines produced in a similar way to Diallo and 
colleague’s Nigeria/75/1 vaccine, which have been attenuated from Indian PPRV strains. These include 
PPRV/Sungri/96 produced by the Indian Veterinary Research Institute (Saravanan et al., 2010) and the 
PPRV/Arasur/87 and PPRV/Combatore/97 (attenuated from virus isolated from sheep and goat 
respectively) vaccines developed by the Tamil Nadu Veterinary and Animal Sciences University 
(TANUVAS) (Saravanan et al., 2010). These live, attenuated vaccines have been shown to protect 
against disease caused by field strain viruses that are circulating locally in India. The only genetic 
lineage present in India is lineage IV. Although there does not appear to be more than one serotype 
of PPRV and the (lineage II) vaccine Nigeria/75/1 is effective against viruses in all parts of the world, it 
has not been shown that the Indian vaccines can protect against viruses of heterogeneous genetic 
lineages, unfortunately, the live, attenuated vaccines are not thermotolerant and require the 
maintenance of a cold-chain from production to end user and the distribution of PPRV includes many 
equatorial and tropical countries. A slightly more thermotolerant lineage IV vaccine was created by 
Balamurugan and colleagues by attenuating the PPRV/Jhansi/2003 strain on Vero cells for 25 passages 
and then in a thermos-adapted Vero cells at 40°C (Balamurugan et al., 2014). Other efforts to improve 
thermotolerance include rapid freeze-drying of the vaccine (Worrall et al., 2000). Another group used 
two doses of binary ethyleneimine-inactivated PPRV/Morocco/2008 field strain to provide protection 
against challenge with the live virus (Cosseddu et al., 2014). However, this experiment was limited 
because two doses were used, and preferably a PPRV vaccine would work after one dose; also whilst 
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a killed virus is more thermotolerant, it is not known if an inactive virus will provide long-term 
protection from challenge or if regular booster vaccinations would be required. 
 
1.7.2 Recombinant vaccines 
Vectored vaccines only expressing selected PPRV proteins could play a significant role in the 
eradication of PPR, since these vaccines would allow the differentiation of infected from vaccinated 
animals (DIVA) on the basis that only infected animals would have detectable antibodies against all 
viral proteins. Whilst the N protein of the morbilliviruses is the most abundant and most immunogenic 
protein produced during infection, it has been observed that N-specific immune responses are not 
protective against morbiliviruses (Ohishi et al., 1999), therefore, all recombinant PPRV vaccines 
express the glycoproteins F or H. This could be utilized in the global eradication campaign because the 
combination of an N-specific assay, such as the diagnostic competition ELISA, and a recombinant 
vaccine expressing the glycoproteins of PPRV would enable DIVA. As a result vaccinate to live programs 
could be implemented because only naturally infected animals would have anti-N antibody responses, 
resulting in fewer losses of animals for farmers. 
Herbert et al. investigated the immune response to vaccination with recombinant human adenovirus 
type 5 expressing either the PPRV H or F proteins (Herbert et al., 2014). Following vaccination with 
Ad5-PPRV-H, H-specific IFN-γ-producing CD8+ cells and virus neutralizing antibodies were detected in 
all vaccinated goats. Vaccinated goats in this experiment were challenged, providing evidence for 
vaccine protection; one dose of Ad5-PPRV-H was able to protect goats against virulent challenge four 
months after vaccination. Post-challenge, virus was not detected in blood or nasal and ocular swabs 
from vaccinated goats, suggesting that vaccination prevents shedding of the virus and could prevent 
transmission, but further experiments would be required to confirm this finding.  
PPRV is often circulating in areas that are affected by other, equally devastating infections such as 
goatpox, bluetongue, Orf and foot-and-mouth disease and coinfections can occur in the field 
(Saravanan et al., 2007). The morbilliviruses MeV and CDV have been successfully combined with 
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other live viral vaccines and provided protection on challenge (Abdelmagid et al., 2004). Multivalent 
vaccines that would protect livestock against several diseases in one dose would be a cost-effective 
development for resource limited countries that do not have the infrastructure to perform multiple 
separate livestock vaccination strategies. 
Due to the similar geographical distribution of capripox and PPRV, and the thermostability of 
poxviruses, Berhe and colleagues developed a recombinant capripox expressing the PPRV F gene. 
Goats were vaccinated with the recombinant recCapPPR/F and challenged first with PPRV/Guinee 
Bissau/89 then with a capripox from Yemen and all vaccinates were protected (Berhe et al., 2003). A 
study by Chen et al. demonstrated the longevity of humoral responses in both sheep and goats 
vaccinated with a recombinant capripox vaccine that expressed the H protein of PPRV (rCPV-PPRVH), 
with PPRV-specific neutralizing antibodies still detectable one year after vaccination (Chen et al., 
2010). However, again this vaccination regimen used multiple vaccinations and the vaccinated animals 
were not challenged with a virulent strain of PPRV to demonstrate vaccine-induced protection, instead 
neutralizing antibody titre was assumed to be a correlate of protection. 
The exact correlates of protection for PPRV are not known, and until they are identified all newly 
developed vaccines will need to be tested in vaccination/challenge experiments, making development 
costly and slow. 
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1.8 Aims of the project 
Live, attenuated vaccines for PPR have been developed in endemic settings in both Africa and India, 
utilising similar methods of serial passage in Vero cells. However, for political reasons, the areas of use 
of the two major vaccines do not overlap. As a result, the Nigeria/75/1 vaccine has been distributed 
through most countries where PPR outbreaks have occurred, but the Indian vaccines have only been 
distributed in India. Due to these geographical differences in distribution, it is not known if the Indian 
vaccines can provide protection against all four PPRV genetic lineages. This restricts the potential to 
use the vaccine produced in India (available in large amounts) in other countries, where there is often 
a shortage of vaccine. If the Indian vaccine is cross protective it could be utilised wherever there is an 
outbreak, regardless of genetic lineage of the field isolate and animals could be protected from 
infection and as a result subsistence farmer’s livelihoods protected, improving food security in 
endemic areas. Due to its testing, both in laboratories and the field, it is accepted that the 
PPRV/Nigeria/75/1 vaccine can protect against all genetic lineages of PPRV, although this has not 
explicitly ever been tested at one time and in one type of animal (Diallo, A., personal communication 
to Baron, M.D.). Therefore, one of the aims of this project is to investigate the protective potential of 
a PPRV vaccine of Indian origin against all four genetic lineage of PPRV, utilising the PPRV/Nigeria/75/1 
vaccine as a control. I hypothesised that both vaccine strains would provide full protection against 
challenge with field isolates from all four genetic lineages due to all lineages falling within one 
serotype. To achieve this aim multiple vaccination/challenge experiments were performed in goats, 
utilising the Indian PPRV/Sungri/96 and Nigeria/75/1 as vaccines and challenging with PPRV isolates 
representative of each genetic lineage, where the virulence had already been assessed in previous 
experiments in goats.  
When utilised in endemic settings, it is accepted that live, attenuated PPRV vaccines provide life-long 
immunity against virulent PPRV strains. Protection provided by these vaccines is correlated with 
neutralising antibody titres, however, the mechanisms of protection have never been fully 
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investigated. In particular, there has been no evaluation of the CMI induced by PPRV vaccines. A 
deeper knowledge of the adaptive immune response to PPR vaccines is invaluable for the 
development of future vaccines against the disease. Knowledge of what immune responses are 
protective in the already available live attenuated vaccines will enable more targeted investigations 
into the immune responses generated against novel vaccines. This could result in fewer animals being 
required for in vivo protection studies and faster routes to market for vaccines with potential DIVA 
capability. To achieve this aim of understanding protective immune responses, the animals that were 
being vaccinated for the previous aim were utilised, and by taking serological and immune cell samples 
at defined time points, an improved understanding of the adaptive immune response to the 
vaccination in the days and weeks following vaccination could be realised. I hypothesised that PPRV 
vaccines would stimulate a strong CMI response, such as production of the anti-viral cytokine IFN-γ as 
well as the previously observed antibody response. 
Another aim of the project was to investigate the specific role that T cell subsets play in vaccine-
induced protection. It is not possible to perform passive transfer experiments in outbred goats due to 
the high possibility of major histocompatibility complex mismatching. However, in vivo depletion is 
possible in ruminants. The in vivo depletion of cells in an animal requires an IgG2a antibody, resulting 
in binding to the cell surface marker of choice and opsonisation of the target cells. Ideally, to 
determine the roll of specific T cell subsets in vaccine-induced protection, this would be achieved by 
depletion of CD4+ and CD8+ T cells in vivo at the time of challenge. With the T cells removed, only the 
neutralising antibodies present in serum would be active at the time of challenge. Therefore, the third 
aim of the project was to define the significance of T cells in vaccine-induced protection upon 
challenge with a virulent PPRV field strain. I predict that T cells play a substantial role in vaccine-
induced protection and that vaccinated animals that have been depleted of their T cells will develop 
clinical disease upon challenge. 
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Chapter 2 Materials and Methods 
 
2.1 Cells and viruses 
2.1.1 Cell line 
Vero cells expressing canine signalling lymphocyte activation molecule (SLAM; CD150) (Vero dog SLAM 
or VDS) were used to propagate PPRV stocks and to determine viral titres.  The cells were maintained 
as monolayers in Dulbecco’s Modified Eagle Medium (DMEM; Thermo Fisher) supplemented with 10% 
foetal bovine serum (FBS), 50U/ml penicillin, 50μg/ml streptomycin (Sigma) and 100mM sodium 
pyruvate (Thermo Fisher) and cultured at 37°C and 5% CO2. To maintain stable expression of canine 
SLAM in these cells, Zeocin™ (InvivoGen) was added every 3rd passage at 100µg/ml. These cells were 
passaged twice weekly at a 1:10 ratio. To passage the cells media was discarded and the monolayer 
was washed twice with calcium and magnesium free Dulbecco’s phosphate-buffered saline (DPBS; 
ThermoFisher), then trypsin was added and the monolayer was incubated at 37°C for 5 minutes until 
the cells detached from the plastic. To inactivate the trypsin DMEM 10% FBS was added to the cell 
suspension and a sample of the cells were added to a new flask. 
 
2.1.2 Isolation of peripheral blood mononuclear cells (PBMCs) 
Heparin-treated blood was obtained from goats by venepuncture for the isolation of peripheral blood 
mononuclear cells (PBMCs). 20ml DPBS (ThermoFisher) and roughly thirty ml heparinised blood were 
mixed, then layered over 15ml Ficoll paque PLUS (GE Healthcare) in Leucosep tubes pre-prepared 
according to manufacturer’s instructions (Greiner). All cell gradients were centrifuged at 800xg for 20 
minutes, 20°C with the brake off. Ten ml of plasma was discarded and mononuclear cells above the 
polyethylene barrier were transferred into a fresh Falcon tube. All tubes were topped up with Hank’s 
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Balanced Salt Solution (HBSS) to a final volume of 50ml and cells were pelleted by centrifugation at 
330xg for 10 minutes. 
Supernatants were discarded and cell pellets were re-suspended in 10ml 1X RBC lysis buffer (Santa 
Cruz) and incubated at room temperature for 5 minutes. Following centrifugation at 330xg for 5 
minutes cells were washed once more in 10ml HBSS. The supernatants were removed and PBMC 
pellets were re-suspended in 10ml 'Proliferation Medium' [Roswell Park Memorial Institute medium 
(RPMI-1640; ThermoFisher) supplemented with 5% FBS, MEM Non-Essential Amino Acid Solution 
(NEAA 10X; ThermoFisher), Sodium Pyruvate 100mM (ThermoFisher), 0.5 µg/ml Gentamicin (10mg/ml 
Sigma) and 2-mercaptoethanol (25µM, Sigma)]. 
The total numbers of viable PBMCs were determined in representative aliquots by adding the viability 
dye Trypan blue at a concentration of 1:10 and counting cells using the Nexcelom T4 automated cell 
counter. PBMCs for IFN-γ intracellular labelling and proliferation assays were plated into 96U well 
microtitre plates at concentrations specified for respective assays. Remaining PBMCs were centrifuged 
at 330xg for 5 minutes at 20°C. Supernatants were removed and PBMCs were re-suspended in FBS 
supplemented with 10% DMSO (Sigma) at approximately 2-3x107cells/ml, aliquoted into cryotubes 
and placed in isopropanol freezing containers (Nalgene; Mr. Frosty™) at -80°C overnight, before being 
transferred to liquid nitrogen for long-term storage. 
 
2.1.3 Viruses 
Several strains of PPRV were used in these studies (summarised in Table 2.1), including both vaccine 
and virulent field strains. Where possible PPRV field strains, originally isolated from tissues of infected 
animals, were used following only minimal passages in VDS cells, to maintain respective virulent 
phenotypes. To propagate a virus, VDS cells in suspension were infected at a multiplicity of infection 
(moi) of 0.1. Flasks were incubated at 37°C, 5% CO2 until cytopathic effect (CPE) was evident. Cells 
were scraped into a 50ml Falcon tube and subjected to one freeze/thaw cycle to release intracellular 
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virus. Tubes were centrifuged at 1500 xg for 10 minutes at 4°C. Clarified supernatant was aliquoted 
into suitable vials and labelled appropriately. All viruses were stored at -80°C.  
Table 2.1 PPRV isolates used in these studies 
PPRV isolate Genetic 
lineage 
Field isolate or 
vaccine strain 
Passage 
history1 
rPPRV-Nigeria/75/1-GFP expressing II Vaccine VDS p3 
Nigeria/75/1  II Vaccine Vero p5, VDS p1 
Sungri/96 IV Vaccine VDS p1 
Cote d’Ivoire/89 I Field isolate VDS p1 
Nigeria/76/1 II Field isolate BK p6, Vero p3, 
VDS p1 
Ghana/78 II Field isolate LK p1, Vero p1, 
VDS p1 
Sudan/Sennar/72 III Field isolate BK p1, LK p1, 
Vero p2, VDS p1 
Kurdistan/2011 IV Field isolate CV1-S p1, VDS p2 
 
2.1.4 Virus titrations 
A suspension of VDS at 5x104 cells/ml in DMEM 10% FBS was prepared and temporarily kept on ice. 
The viruses to be titrated were serially diluted 10-fold in DMEM 10% FBS and plated onto 96 well 
plates at 4 or 6 wells per dilution, adding 50µl of diluted virus per well. The bottom row was left as a 
‘no virus control’ and 50µl of medium was added to all wells in this row. One hundred µl of VDS cell 
suspension was subsequently added to all wells and the plates were incubated at 37°C, 5% CO2 for five 
                                                          
1 Cells used were: CV1-S, CV1 expressing goat SLAM; VDS, Vero cells expressing dog SLAM; BK primary bovine 
kidney; LK primary lamb kidney. ‘p’ is number of passages in each cell line. 
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days. Each well was observed for the presence or absence of cytopathic effect (CPE). The baseline 
dilution (X0) was determined as the greatest dilution where all wells are positive. The sum of 
proportions (∑P) is the sum of the fractions of each row that was positive, counting from and including 
the baseline dilution row. The TCID50/ml was calculated according to Spearman-Kaber: 
log10 𝑇𝐶𝐼𝐷50/ml = 𝑋0 - 𝑑 2⁄ + d*(∑P) 
Where d = Log10 dilution factor (when dilution factor is 10, d = 1) 
2.1.5 Heat inactivated virus 
To generate heat inactivated PPRV as antigen for T cell response assays, live virus in clarified tissue 
culture supernatant was heated in a water bath at 56°C for 2 hours. 
 
2.1.6 Antigen preparation 
To generate crude PPRV antigen preparations for T cell response assays, ten 175 cm2 flasks of VDS 
were infected either with PPRV Nigeria/75/1 or PPRV Sungri/96 at a multiplicity of infection (MOI) of 
0.1. The same number of uninfected cells were processed identically to produce negative control VDS 
antigen.  Cells were incubated at 37°C, 5% CO2 until CPE was extensive (usually 2-3 days). Using a cell 
scraper, any cells still adherent to the flasks were displaced and cell debris and supernatants were 
collected into 50 ml Falcon tubes and centrifuged at 3000 rpm [Beckman Coulter Allegra X-12R, rotor 
SX4750] for 30 minutes with the brake off. After centrifugation, the supernatants were discarded, and 
the cell pellets were re-suspended in DPBS and consolidated in a total volume of 8 ml. The suspension 
was subjected to a freeze/thaw cycle at -80°C and being allowed to thaw at room temperature. To 
heat-inactivate any viable virus, the suspension was heated in a water bath at 56°C for two hours then 
chilled to 4°C before further processing. The suspension was placed on ice and sonicated using a 
Microson™ Ultrasonic Cell Disruptor probe for 60 seconds on setting 4. Aliquots of this suspension 
were pipetted into 2 ml screw-capped Eppendorf tubes and centrifuged at 7600 rpm [Eppendorf 
5417R, rotor FA45-24-11] for 20 minutes at 4°C. The supernatants were collected into a universal tube 
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and kept on ice. The cell pellets were re-suspended in 4ml PBS and sonicated and centrifuged as 
before. The supernatants were collected from each cycle of sonication/centrifugation until minimal 
cell debris was present after centrifugation, usually following four cycles. The collected supernatants 
were then centrifuged in a 70.1 Ti fixed angle rotor (Beckman Coulter) at 28000 rpm for two and a half 
hours with the brake off. 
Supernatants were discarded and the pellet of antigen was collected in 3ml of 10% sucrose in PBS and 
sonicated on setting 4 on ice to aid resuspension. Protein concentration was determined by Coomassie 
(Bradford) Protein Assay kit (ThermoFisher). Antigen was diluted to 1mg/ml in 10% sucrose/PBS and 
aliquots of this antigen were stored at -20°C. 
2.2 PPRV RT-PCR 
All RT-PCRs were performed by the Non-Vesicular Reference Laboratory (NVRL) at The Pirbright 
Institute. RNA was extracted from EDTA blood, taken after virulent PPRV challenge, using a 
KingFisher™ Flex (ThermoFisher) extraction platform in combination with the MagVet™ Universal 
Isolation Kit (Thermo Fisher Scientific) according to the manufacturer’s instructions. 
For this assay he primer target is the PPRV N gene.In an optical reaction 96 well PCR plate, 17µl of 
master mix (see Table 2.2) was added to an appropriate number of wells, followed by the addition of 
3µl of nucleic acid from the extraction plate to each well. The wells were then sealed with an optical 
plate seal and centrifuged for 1 min at 1000rpm to uniformly bring the reaction mix to the bottom of 
the wells. Quantitative RT PCR was performed on the Applied Biosystems 7500 fast real-time PCR 
thermocycler using the following thermal profile: one cycle of reverse transcription at 50°C for 15 
minutes, one cycle of reverse transcription inactivation/Taq activation at 95°C for 20 seconds and 45 
cycles of 95°C for 3 seconds followed by 60°C for 30 seconds (Batten et. al. 2011). To display data 
graphically, the Ct value of a sample was subtracted from a value of 45. 
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Table 2.2 One step real time RT-PCR reaction master mix recipe used for PPRV.  
Component Volume per well (ul) 
EXPRESS SuperScript® qPCR SuperMix Universal 10 
Forward primer (10µM) 
[AGAGTTCAATATGTTRTTAGCCTCCAT] 
0.8 
Reverse primer (10µM) 
[TTCCCCARTCACTCTYCTTTGT] 
0.8 
Probe (5µM) 
[FAM-CACCGGAYACKGCAGCTGACTCAGAA- Tamra] 
0.4 
RNase free water 2.6 
ROX (diluted 1/10) 0.4 
EXPRESS SuperScript® Mix 2 
Total volume 17 
 
2.3 Antibodies for flow cytometry and in-vivo depletion 
2.3.1 Monoclonal Antibodies 
The monoclonal antibodies (mAbs) utilised throughout the project for flow cytometry based assays or 
in vivo depletion are summarised in Table 2.1. 
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Table 2.3 Monoclonal antibodies used in these studies. 
Antibody clone 
(isotype: species 
of origin) 
 
Source  Target protein 
(target species) 
Assay Format 
17D (IgG1: 
mouse) 
ECACC CD4 (ovine) Whole blood 
labelling and ICS 
Purified as part of 
this project  
CC58 (IgG1: 
mouse) 
The Pirbright 
Institute 
CD8 (β chain: 
bovine) 
Whole blood 
labelling and ICS 
Purified as part of 
this project 
CC63 (IgG2a: 
mouse) 
The Pirbright 
Institute 
CD8 (α chain: 
bovine) 
In vivo 
depletion 
Purified as part of 
this project for 
pilot depletion  
Produced and 
purified 
commercially for 
depletion study 
(chapter 5) 
CC21 (IgG1: 
mouse) 
The Pirbright 
Institute 
CD21 (bovine) Whole blood 
labelling 
Purified as part of 
this project 
Clone 197 (IgG2a: 
mouse) 
Basel Institute for 
Immunology 
WC1 (ovine) Whole blood 
labelling 
Purified as part of 
this project 
H42A (IgG2a: 
mouse) 
Washington State 
Monoclonal 
Antibody Centre 
MHC II (bovine) Whole blood 
labelling 
Purchased as a 
purified antibody 
CC302 (IgG1: 
mouse) 
The Pirbright 
Institute 
IFN-γ (bovine) ICS Purchased as a 
purified, pre-
conjugated 
reagent (BioRad) 
TRT1 (IgG1: 
mouse) 
The Pirbright 
Institute 
Isotype control 
(Turkey 
rhinotracheitis 
virus) 
ICS Tissue culture 
supernatant 
TRT3 (IgG2a: 
mouse) 
The Pirbright 
Institute 
Isotype control 
(Turkey 
rhinotracheitis 
virus) 
In vivo 
depletion 
Tissue culture 
supernatant 
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2.3.2 IgG purification 
Bulk hybridoma tissue culture supernatants were obtained from The Pirbright Institute, Compton. All 
buffers were made fresh, pH tested and sterile filtered through a 0.2 µm filter suitable for aqueous 
solutions prior to use. Each hybridoma supernatant was diluted with an equal volume of binding buffer 
(20 mM sodium phosphate pH 7.0) and filtered through a 0.45 µm filter. A 5ml protein G column (GE) 
was attached to a peristaltic pump in a cold room at 4°C and rinsed through with 100ml PBS. The 
diluted supernatant was then pumped through the column at a flow rate of 1.5 ml/minute, the flow-
through was retained and after the whole sample had run through the column once, it was placed on 
regeneration overnight. The following morning the column was rinsed with 100ml PBS, this flow 
through was added to the sample. Then 50ml (ten column volumes) of elution buffer (0.1 M glycine-
HCl pH 2.7) was pumped through the column at a flow rate of 1ml/minute. Elution buffer eluate was 
collected in 1ml fractions for the first 25ml and the remaining 25ml was collected in bulk into a 
universal tube. The eluted fractions were assayed for protein content on a Nano Drop 8000 at A280nm 
(Thermo Scientific). Any fractions containing protein were pooled, then dialysed against PBS 
overnight. Final protein content was determined by Coomassie (Bradford) Protein Assay kit 
(ThermoFisher). The column was rinsed with 100ml PBS, then cleaned with 25ml 70% ethanol, then 
with 50ml 20% ethanol for storage. 
 
2.3.3 Antibody-fluorophore direct conjugation 
All direct conjugations were performed according to the manufacturer’s instructions for respective 
conjugation kits. The mAbs CC58 and H42A were conjugated to AlexaFluor488 using the AlexaFluor488 
monoclonal antibody labelling kit (Invitrogen). Briefly, antibodies were diluted to 1mg/ml and mixed 
with one tenth the volume of a freshly prepared 1M sodium bicarbonate buffer. 100µl of the antibody 
was added to the reactive dye. The mixture was incubated for 1 hour at room temperature in the dark. 
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Purification resin was added to the spin column until the bed volume was 1.5ml. The spin column was 
placed into a collection tube and centrifuged at 1100 xg for 3 minutes, any buffer that had drained 
into the collection tube was discarded. The antibody/conjugate mix was then added dropwise to the 
resin bed in the spin column. The spin column, in the collection tube, was centrifuged at 1100 xg for 
5 minutes. The conjugated mAb was in the collection tube and any free dye was retained in the resin. 
All other conjugations were performed using Lightning-Link® conjugation kits (Innova Biosciences) 
according to manufacturer’s instructions. Briefly, the mAbs were diluted to 1mg/ml and mixed with 
one tenth volume of modifier reagent and this mixture was added directly to the lyophilised dye. The 
components were incubated for three hours at room temperature in the dark, then one tenth the 
antibody volume of quencher reagent was added. All conjugated mAbs were stored at 4°C. All 
antibodies were titrated on goat PBMCs and analysed on an LSRFortessa (BD) before use. A dilution 
series was created in a 96U tissue culture plate, starting at 1:1 in FACS buffer and performing twelve 
subsequent two-fold dilutions. Goat PBMCs at 1x107/ml were plated 100µl per well, washed with FACS 
buffer and the diluted antibodies were added to the cells. A viability dye was added to differentiate 
live cells. Cells were incubated with antibody for 30 minutes in the dark, washed twice and fixed. The 
labelled cells were analysed on the LSRFortessa collecting 50,000 events in the live gate. In the analysis 
software FlowJo, labelled cells were gated upon single cells, live cells and lymphocytes. For the 
antibody labelling quadrants were drawn to separate positively labelled cells from unlabelled cells, 
the mean fluorescence intensities for each quadrant were calculated by the software. The optimum 
dilution of an antibody was determined by the following equation, with the optimum dilution resulting 
in the highest value of x. 
𝑥 =  (𝑌𝛼 − 𝑌𝛽)/(2 ∗ 𝑆𝐷) 
Where Yα = median fluorescence intensity of the positively labelled population, Yβ = median 
fluorescence of the unlabelled population and SD is the standard deviation 
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Table 2.4 In-house conjugated monoclonal antibodies and respective fluorophores.  
Target protein Antibody Conjugated fluorophore 
CD8 CC58 CD8-AlexaFluor488 
CD8 CC58 CD8-RPE 
CD4 17D CD4-APC 
CD21 CC21 CD21-RPE 
WC1 Clone 197 WC1-APC 
MHCII H42A MHCII-AlexaFluor488 
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2.4 Blood and swab sample processing from PPRV vaccination and challenge 
experiments 
All samples obtained from goats during experimental studies were processed and stored as follows: 
Serum: Ten ml of blood was obtained by venepuncture into plain vacutainers® (BD) and left at room 
temperature to clot. Tubes were centrifuged at 2,000xg for 20 minutes at 4°C, then 1ml aliquots of 
serum were taken off the blood clots. Serum aliquots were stored at -80°C until assayed for anti-PPRV 
antibodies by competition enzyme-linked immunosorbent assay (cELISA) or virus neutralisation assay 
(VNT). All serum samples were heat-inactivated in a water bath at 56°C for two hours prior to 
respective assays. 
EDTA-blood: Approximately 3 ml of blood was obtained by venepuncture into EDTA anticoagulant 
treated vacutainers® after challenge. One millilitre aliquots of EDTA blood were created and frozen at 
-80°C until they could be processed by RT-PCR. For determination of lymphocyte population within 
whole blood (Section 2. 5) EDTA blood was used within 4 hours of sampling.  
Nasal swabs: swab was gently wiped just inside both nostrils of the animal, then returned to tube for 
transport. Once back in the laboratory the cotton swab end was cut off into a cryovial and 500µl PBS 
added. The contents of the cryovial were then agitated to re-suspend any sample on the swab. The 
cryovials were frozen at -80°C until they could be processed by RT-PCR. 
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2.5 Antibody response assays 
2.5.1 Competition enzyme-linked immunosorbent assay  
Serum samples were tested in duplicate for anti-PPRV N protein antibodies by competition ELISA 
(cELISA) using the ID Screen® PPR Competition kit (ID.Vet) according to the manufacturer’s 
instructions. All buffers required are supplied in the kit. Briefly, 25 µl Buffer 13 was added to all wells, 
followed by the addition of duplicates of 25 µl positive control, 25 µl negative control, or 25 µl of 
individual sample sera to the remaining wells. Plates were sealed and placed in a rotating incubator 
at 37°C for 45 minutes. The contents of the wells were removed and wells washed three times with 
300 µl wash solution. 100µl of conjugate diluted in dilution buffer 4 was added to each well and 
incubated for 30 minutes at room temperature. The contents of the wells were removed and wells 
were washed three times with 300 µl wash solution. 100µl of substrate solution was added to each 
well of the microplates and incubated for 15 minutes in the dark. 100µl of stop solution was added to 
each well of the microplates and the optical density was determined at 450nm using a Cytation 3 
(BioTek) and Gen5 software. 
The assay was considered to have passed validation if the mean OD value of the negative control 
exceeded 0.7 and the mean OD value of the positive control was less than 30% of the negative control. 
The competition percentage is defined as the mean O.D. of the test sample divided by the mean 
negative O.D., multiplied by 100. 
𝐶𝑜𝑚𝑝𝑒𝑡𝑖𝑡𝑖𝑜𝑛 𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 (%) =  
𝑂𝐷 𝑠𝑎𝑚𝑝𝑙𝑒
𝑂𝐷 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
∗ 100 
This value decreases as the level of competing antibody increases, therefore to display results 
graphically all competition percentages were transformed by subtracting from 100. 
Before the animal experiments detailed in this Thesis were performed, an experiment utilising 
Adenovirus expressing PPRV H or PPRV F as vaccines against PPRV was performed at the International 
54 
 
Livestock Research Institute, Nairobi (ILRI) Kenya. I used the samples from this experiment to practice 
the cELISA assay, and the results from this experiment have been published (see Appendix 4). 
 
2.5.2 Virus Neutralisation Test (VNT) 
Heat-inactivated serum samples were tested in quadruplicate for their ability to neutralize the PPRV 
Nigeria/75/1 and Sungri/96 vaccine strains. Respective virus stocks were diluted to obtain between 
100-200 TCID50 doses in 50µl. The titre of the diluted virus stock was determined each time the 
procedure was performed to ensure the virus was at the correct dilution. Serum samples were diluted 
across a 96 well microtitre plate starting in column 1, column 12 was left as a cell only control with 
100 µl DMEM 10% FBS. 25 µl of serum was initially diluted 1:3 in 75 µl DMEM 10% FBS. Fifty µl of this 
starting dilution was then transferred to the next column and mixed with 50 µl DMEM 10% FBS, with 
subsequent 2-fold dilutions across the plate so the final volume of diluted serum in each well was 50 
µl. Fifty µl diluted virus was subsequently added to all wells containing diluted serum, but not to the 
cell only control wells. Serum and virus were incubated at 37°C for 1 hour to allow neutralization. After 
incubation, 50 µl per well VDS at 1x105/ml were added to all wells. The plates were incubated at 37°C 
for 7 days and wells observed for cytopathic effect (CPE).  Virus neutralizing titres were calculated 
using a modified form of the Spearman-Karber equation (Spearman, 1908; Karber, 1931). 
 
2.6 T cell response assays 
2.6.1 H3 Thymidine incorporation proliferation assay 
PBMCs in ‘proliferation medium’ at 2x106/ml were plated 100µl per well in 96 well U bottomed plates. 
PBMCs were exposed in quadruplicate wells to each of the following PPRV and control antigen 
preparations: medium only, 5µg/ml Concanavalin A (Con-A; Sigma-Aldrich), 20µg/ml VDS cell control 
antigen, 20µg/ml Nigeria/75/1 antigen, 20µg/ml Sungri/96 antigen, heat inactivated Nigeria/75/1, 
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heat inactivated Sungri/96 and a heat inactivated VDS cell mock preparation, all added in a 100 µl 
volume per well. Cells were incubated at 37°C, 5% CO2 for 5 days, when 0.037 MBq 3H thymidine 
(Perkin Elmer) in 30µl RPMI-1640 was added per well and cells were incubated overnight at 37°C, 5% 
CO2. Cells were harvested onto pre-wet glass fibre filtermats (Perkin Elmer) using an automated 
harvester (Perkin Elmer). The filtermats were dried before being sealed in sample bags (Perkin Elmer) 
with 3.5ml BetaScint scintillation liquid (Perkin Elmer). Scintillation counts were recorded using a 1450 
MICROBETA TriLux (Wallac) and MicroBeta Windows Workstation V4.70.05 software. Stimulation 
indices were calculated by dividing the mean counts per minute (c.p.m.) for specific antigen by the 
mean c.p.m. for the mock antigen. Liquid and solid waste was disposed of according to local radiation 
protocols and wipe tests were carried out at the end of harvesting to monitor for contamination.  
Before the animal experiments detailed in this Thesis were performed, an experiment in cattle 
vaccinated with PPRV and challenged with RPV was performed at The Pirbright Institute. I used some 
samples from this experiment to practice the H3 Thymidine incorporation assay, and the results from 
this experiment have been published (see Appendix 4). 
 
2.6.2 Intracellular detection of IFN-γ production 
PBMCs in ‘proliferation medium’ were plated at 1x107/ml, 100µl per well in 96 well U bottomed plates. 
PBMCs were exposed in triplicate wells to each of the following PPRV and control preparations: 
medium only, 5µg/ml pokeweed mitogen (PWM; Sigma Aldrich), 20ug/ml VDS cell control antigen, 
20µg/ml Nigeria/75/1 antigen, 20µg/ml Sungri/96 antigen, VDS cell-derived mock virus, PPRV 
Nigeria/75/1 and Sungri/96, all added in a 100µl volume per well. Cells were incubated at 37°C, 5% 
CO2 overnight. The following morning the protein transport inhibitor BD Golgi Plug™ was added to all 
wells at 1µl/ml in 30µl RPMI-1640 and cells were incubated for a further 6 hours at 37°C, 5% CO2. 
Plates were centrifuged at 330xg for 5 minutes, supernatants were removed and cells were washed 
twice with 100µl DPBS (ThermoFisher). The directly conjugated antibodies, CD4:APC and CD8:RPE (see 
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Table 2.4), and the dead cell stain Zombie Aqua™ at a final concentration per well of 0.5µl (Biolegend) 
were added to wells and incubated at 4°C for 30 minutes in the dark. Plates were centrifuged at 330xg 
for 5 minutes at 4°C, supernatants were removed and cells were washed once in DPBS before fixation 
with BD Cytofix/Cytoperm™ Buffer, containing 4.2% formaldehyde, at 4°C for 30 minutes in the dark. 
Plates were centrifuged at 330xg for 5 minutes at 4°C, supernatants were removed and cells were 
washed once in DPBS before being stored overnight in 100µl DPBS at 4°C.  
The following morning the plates were centrifuged at 330xg for 5 minutes at 4°C, supernatants were 
removed and cells were permeabilised with 100 µl BD Perm/Wash Buffer for 20 minutes at 4°C in the 
dark. Plates were centrifuged at 330xg for 5 minutes at 4°C, supernatants were removed and cells 
were internally labelled with 100µl/well anti-IFN-γ:AlexaFluor488 (BioRad) diluted 1/320 in BD 
Perm/Wash Buffer and incubated for 30 minutes at 4°C in the dark. Subsequently, plates were 
centrifuged at 330xg for 5 minutes at 4°C, supernatants were removed and cells were washed twice 
with 150µl/well BD Perm/Wash Buffer before finally being re-suspended in 200µl MACS Wash Solution 
(Miltenyi) for analysis. Samples were analysed on the MACSQuant 10 Analyzer (Miltenyi Biotec) 
without compensation applied. A sample of 150µl of the 200µl per well was analysed to enable 
assessment of rare events. Single labelled cells were used for multi-colour compensation for every 
time point in an experiment, this was achieved by creating a compensation matrix in FlowJo X and 
retrospectively applying the matrix to all samples. All flow cytometry raw data files were analysed in 
FlowJo X and a representative flow cytometry gating strategy is provided in Figure 2.3. 
To identify the different cell surface marker proteins different fluorophores were used to conjugate 
the detecting antibodies. Ideally the fluorophores would be excited by different lasers in the flow 
cytometer and emit at different wavelengths, however the more fluorophores required for more 
proteins of interest in a single sample, the more likely that spectral overlap of the emission 
wavelengths will occur. Ideally fluorophores that have overlapping spectra should be used to label 
proteins that are mutually exclusive (i.e. that will not be found on the same cell), and this was applied 
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with these antibodies as much as possible, but this is not a fool proof way to prevent spectral overlap. 
To counteract spectral overlap of different fluorophores, single labelled cells were generated for every 
time point of every experiment, these single labelled cells were then used to generate compensation 
matrices in the software FlowJo that subtracted the spectral overlap from the samples by gating on 
the population of interest (lymphocytes). A compensation matrix can result in a loss of some genuine 
signal from that fluorophore to which it is applied and so the previously mentioned actions were used 
in conjunction with a compensation matrix, compensation matrices was not used exclusively to 
overcome spectral overlap. 
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Figure 2.1 Flow cytometry gating strategy to assess T cell IFN-γ responses. Following stimulation 
with antigens for 18 hours and an additional 6 hours with the Golgi transport inhibitor Golgi-Plug, 
PBMCs were labelled with the anti-membrane protein mAbs anti-CD4 and anti-CD8 and a live/dead 
stain. Cells were fixed and permeabilised then intracellularly labelled for IFN-γ. A compensation 
matrix was created from single labelled cells and applied to all samples. PBMCs were gated upon 
singlets (A), lymphocytes (B), live cells (C) and on the antibody labelling for the surface molecules 
CD8 and CD4 (D). Percentage IFN-γ+ cells were obtained for CD8+ (E), CD4+CD8+ (F), CD4-CD8- (G) 
and CD4+ (H). Flow cytometry analysis was performed in FlowJo X. 
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2.7 Whole blood cell surface membrane protein labelling 
One hundred µl of EDTA blood and 20µl of antibody cocktail (see Table 2.5) were added to polystyrene 
flow tubes (Becton Dickinson) using reverse pipetting. Tubes were then gently agitated to mix contents 
and incubated at room temperature in the dark for thirty minutes. Two ml 1X Fix/Lyse buffer 
(eBiosciences) was added to the blood/antibody mixes to lyse the red blood cells (RBC) and fix the 
samples for analysis. Tubes were incubated for a further 30 minutes at room temperature in the dark, 
after which 100µl 123count eBeads™ (Affymetrix eBioscience) were added to the tubes. Cell 
populations within respective blood samples were analysed in triplicates on the LSRFortessa (Becton 
Dickinson), with 10,000 events being obtained in the 123count eBead gate. Single labelled cells were 
used for multi-colour compensation for every time point in an experiment, this was achieved by 
creating a compensation matrix in FlowJo X and retrospectively applying the matrix to all samples. 
Flow cytometry files were analysed in FlowJo X according to the gating strategy outlined in Figure 2.2. 
Numbers of respective cell populations presented within whole blood were calculated according to 
the following formula:  
𝐴𝑏𝑠𝑜𝑙𝑢𝑡𝑒 𝑐𝑜𝑢𝑛𝑡 =  
𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡
𝑒𝐵𝑒𝑎𝑑 𝑐𝑜𝑢𝑛𝑡
∗ 𝑒𝐵𝑒𝑎𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 
Where the absolute count is the number of cells per µl of blood. 
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Table 2.5 antibody cocktail mixes used for whole blood labelling. 
Antibody cocktail for whole blood 
labelling 
Composite anti-cell surface marker monoclonal 
antibody mix (volume in 20µl staining mix) 
A CD4:APC 
(8µl) 
CD8:AlexaFluor488 
(8µl) 
CD21:RPE 
(4µl) 
B WC1:APC 
(8µl) 
MHCII:AlexaFluor488 
(8µl) 
DPBS (4µl) 
CD8 depletion CD4:APC 
(8µl) 
CD8:AlexaFluor488 
(8µl) 
WC1:RPE 
(4µl) 
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Figure 2.2 Whole blood absolute cell enumeration gating strategy. 100µl of EDTA blood was 
mixed with anti-membrane protein mAbs (see Table 2.5), cells were fixed and red blood cells 
lysed, 100µl 123count eBeads (Affymetrix eBioscience) was added to the cells. Cells were 
analysed on the LSR Fortessa. 10,000 events were collected in the 123 eBead gate (B). Gating was 
performed as follows cells were gated on singlets (A), lymphocytes (C) and mAb labelled cells 
were enumerated within the positive labelled gate. For example CD4+ (D), CD8+ (E) and CD21+ 
(F) cells. 
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2.8 Animal experiments 
All animal experiments were performed in The Pirbright Institute’s high containment isolation units 
(Figure 2.3). All animal studies were reviewed and approved by The Pirbright Institute Animal Welfare 
and Ethical Review Body and carried out under Home Office licences PPL70/7199 and PPL70/8833 in 
accordance to the Animal in Scientific Procedures Act (ASPA), UK. Outbred goats of British origin were 
sourced from commercial farms. The animals entered the isolation units 7 days before the start of the 
experiment to acclimatize, as directed in the Code of Practice for the Housing and Care of Animals 
used in Scientific Procedures. 
2.8.1 General experimental outline for vaccination and challenge experiments 
Five goats were injected with 1ml 2x104 TCID50 (VDS) of Sungri/96 diluted in DPBS (Group 1) and five 
goats were given 2x104 TCID50 (VDS) Nigeria/75/1-GFP as a subcutaneous injection (s/c) (Group 2), two 
goats were not vaccinated and acted as controls for the virulence of the challenge virus (Group 3). 
Twenty eight days after vaccination all animals were infected with a virulent field strain from either 
lineage I, II, III or IV [see Table 2.6] at 2x105 TCID50 (VDS) by s/c injection, except the first experiment 
that was i/n. Data from the first experiment with a lineage I PPRV Cote d’Ivorie/89 challenge has been 
published as part of a paper investigating the ability of PPRV vaccine strains to protect cattle against 
challenge with virulent RPV (see Appendix 4). 
Clinical assessments were carried out daily and animals were given a score from 0 to 3 based on the 
severity for specified clinical signs such as ocular, nasal and oral congestion/discharge fever, apathy, 
anorexia and diarrhoea (see Appendix 1). Animals were euthanized on ethical grounds if exhibiting 
defined clinical endpoints specified within the ASPA project license.  
Unless specified for individual experiments blood samples for serum and heparinized blood for PBMCs 
isolation was collected at days 0, 7, 14, 21, 28, 35 and 42 post-vaccination, and EDTA blood for whole 
blood cell membrane protein labelling collected on days -1, 2, 4, 6 and 8 post-challenge. All animals 
were euthanized on day 42 of the experiment by overdose of pentobarbital (Vetoquinol). 
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Table 2.6 PPRV vaccination and challenge experiments.  
Experiment 
 
PPRV vaccines used PPRV challenge strain Route of challenge 
I rPPRV Nigeria/75/1-
GFP and 
‘One dose’ Ovilis® 
(Sungri/96; MSD 
Animal Health) 
Cote d’Ivoire/89 Intranasal (i/n) 
II rPPRV Nigeria/75/1-
GFP and 
Sungri/96 
Nigeria/76 Subcutaneous (s/c) 
III rPPRV Nigeria/75/1-
GFP and 
Sungri/96 
Sudan/Sennar Subcutaneous (s/c) 
IV rPPRV Nigeria/75/1-
GFP and 
Sungri/96 
Kurdistan/2011 Subcutaneous (s/c) 
V rPPRV Nigeria/75/1-
GFP and 
Sungri/96 
Ghana/78 Subcutaneous (s/c) 
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2.8.2 Pilot study to assess CD8+ T cell depletion in vivo  
CD8 T cell depletion via inoculation of anti-CD8 mAb was trialled in goats using two different protocols. 
Two groups of two goats were treated by intravenous (i/v) anti-CD8 antibody inoculation regimes 
termed “low-long dose” and “high-short dose”. On the first day of the experiment all four goats 
received 2mg of anti-CD8 mAb (CC63) in two doses - 0.5mg of CC63 mAb in the morning and 1.5mg in 
the afternoon. After the first day, the different dosing regimens were started (Table 2.7). All goats 
received Flunixin at 1.1mg/kg (Finadyne) prior to mAb inoculation for the first 2-3 days. On day 5 of 
the experiment one animal from each group was sacrificed to obtain lymph nodes for potential future 
assessment of CD8 T cell presence in lymphatic tissues. The lymph nodes were cryopreserved in 
Figure 2.3 Housing of goats within the high containment Isolation unit at The Pirbright 
Institute. The goats were kept in groups  and provided with environmental enrichment, allowing 
them to display normal behaviours, such as climbing and browsing. 
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optimum cutting temperature compound (OCT) and flash frozen in super cooled isopropanol before 
being transported on dry ice to a -80°C freezer for storage.  
After each injection the goats were observed for at least 30 minutes to ensure they did not respond 
clinically to the mAb-induced cell lysis necessitating additional anti-inflammatory treatment. EDTA 
blood was collected on days 0, 1, 2, 3, 4, 6, 8 and 10 to determine the presence of cellular 
subpopulations within peripheral blood and assess efficiency of CD8 T cell depletion by flow cytometry 
as described in Section 2.5. Ten days after starting the experiment the remaining two goats were 
euthanized by overdose of pentobarbital and lymph nodes were cryopreserved as previously 
described. 
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Table 2.7 Dosing regimens for CC63 (anti-CD8) monoclonal antibody administered to the high-short 
and low-long dose groups of goats  
Day High, short dose 
group (mg) 
Low, long dose 
group (mg) 
1 2 2 
2 25 2 
3 20 2 
4 20 2 
5 - 2 
6 - 2 
7 - 2 
8 - 2 
9 - 2 
10 - 2 
11 - - 
 
2.8.3 Assessment of the role of CD8+ T cells in PPRV vaccine induced immunity by in vivo 
depletion  
Ten goats were vaccinated with 2x104 VDS TCID50 PPRV/Sungri/96 s/c in a 1ml volume; two goats were 
not vaccinated and acted as challenge controls. Whole blood for serum and heparinized blood for 
purification of PBMCs was collected weekly.  
Twenty six days after vaccination five of the vaccinated goats were given 2mg of CC63 (anti-CD8 mAb) 
i/v in two doses [depleted group] and four vaccinated goats were given 2mg of the isotype matched 
control mAb (TRT3) in two doses [mock depleted group] (Table 2.8). Goats were further inoculated 
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with respective mAbs on the 3 subsequent days to a final amount of 2.1 mg mAb/kg body weight 
(Table 2.8)2. Regular venepuncture was not possible for one of the vaccinated goats which therefore 
did not receive any control mAbs while blood samples from this animal were only obtainable 
intermittently throughout the study. All goats were given Flunixin (Finadyne) at 1.1mg/kg i/v prior to 
each inoculation of mAbs including the non-treated challenge controls to equalise any effects of the 
drug on subsequent PPRV challenge and respective ex vivo assays.  
Twenty eight days after vaccination all goats were infected with the virulent field strain PPRV 
Sudan/Sennar at 2x105 TCID50 in 1ml by the s/c route. To monitor cell numbers of lymphocyte sub-
populations prior, during and post mAb inoculation EDTA blood was collected at -5, -2, -1, 0, 2, 4, 6, 8, 
10 and 12dpc.  Clinical assessments were carried out daily as previously described. All animals were 
euthanized on day 42 of the experiment by overdose of pentobarbital. 
Anatomic pathological examinations of all goats were carried out post mortem by two veterinarians 
and recorded systematically (pathology recording sheet provided in Appendix 3. 
  
                                                          
2 Goats were weighed on arrival in the high security isolation unit (ISOs) and again a few days before 
depletion. All goats received the same doses of mAb in the first three injections, the final injection was 
calculated to provide a total dose of 2.1mg/kg for each animal. 
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Table 2.8 Finadyne and monoclonal antibody administration timetable for in vivo CD8 T cell 
depletion experiment.  
dpv dpc CD8 depleted (mAb 
CC63) 
Mock depleted 
(mAb TRT3) 
Controls 
26 -2 Finadyne 
+ 0.5mg 
Finadyne 
+ 1.5mg 
Finadyne 
+ 0.5mg 
Finadyne 
+ 1.5mg 
Finadyne 
27 -1 Finadyne + 20mg Finadyne + 20mg Finadyne 
28 0 Finadyne + 20mg Finadyne + 20mg Finadyne 
29 1 Finadyne + 
individual dose 
Finadyne + 
individual dose 
Finadyne 
 
 
Table 2.9 Maximum and minimum weights of goats in the in vivo CD8 T cell depletion experiment.  
 Minimum 
weight (kg) 
Maximum 
weight (kg) 
Combined 
mAb dose 
(mg) for 
26-28 dpv 
Minimum 
mAb dose 
(mg) on 
29 dpv 
Maximum 
mAb dose 
(mg) on 29 
dpv 
Total 
dosage of 
mAb 
(mg/kg) 
On arrival in 
the ISOs 
21.0 26.5     
At depletion 24.5 30.5 42 9 22 2.1 
 
 
2.9 Statistical analysis 
Statistical analysis was performed in Minitab 17 (Minitab). Where the data were normally distributed 
and fitted the analysis of variance (ANOVA), General Linear Model, statistical differences were 
determined using the and Tukey pairwise test. Animal was considered random, vaccine, dpv and 
antigen were considered fixed. Vaccine was nested within animal. For data from the 3H thymidine 
proliferation assay the counts per minute and stimulation indices were transformed by using the log 
of the value to maintain a normal distribution so the data could be analysed by ANOVA. A p value of 
≤ 0.05 was considered significant. 
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Chapter 3 – Protection against virulent PPRV strains of four different 
genetic lineages provided by administration of live, attenuated 
vaccines 
 
3.1 Introduction 
As stated in Chapter 1 there is only one serotype of PPRV and, although genome sequence 
phylogenetic analysis classes the virus into four different lineages reflecting their geographical origin 
(Kwiatek et al., 2007), there is no evidence of lineage-based differences in virulence and pathogenesis. 
Given the absence of serotypes, it is widely assumed that immunity provided by a single vaccine strain 
will protect against challenges with viruses from all four genetic lineages. 
There are several live attenuated PPRV vaccines licensed for use in endemic areas. The first live 
attenuated vaccine was produced by serial passage of the Nigeria/75/1 (lineage II) strain on Vero cells 
(Diallo et al., 1989). In addition there are a further three vaccines produced in a similar manner created 
from lineage IV viruses isolated in India, namely Sungri/96, Arasur/87 and Coimbatore/97 (Sreenivasa 
et al., 2000, Palaniswami, 2005). Of these available live attenuated vaccines, Nigeria/75/1 and 
Sungri/96 are the most commonly used for vaccination campaigns in the field, and have been reported 
to be safe and efficacious (Sen et al., 2010). 
The live attenuated Nigeria/75/1 vaccine has been heavily employed to protect small ruminants 
against PPRV in Africa, the Near East, Middle East, and in many Asian countries, while Sungri/96 has 
been specifically utilised for PPRV vaccination in India (Saravanan et al., 2010).  
Although it is widely believed that these vaccines will protect against all strains of PPRV, explicit 
vaccination trials demonstrating protection against viruses from homologous and heterologous 
lineages are sparse. Several initial studies with the Nigeria/75/1 vaccine were conducted and while a 
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single trial with multiple strains was not carried out, the vaccine was shown in different studies to 
protect against lineage II (PPRV/Nigeria/75/2), III (PPRV/Sudan/Mielliq/72 and 
PPRV/Sudan/Sennar/72) and IV (PPRV/India/94) isolates (Diallo et al., 2007, Diallo, Caufour et al., 
2014). In addition, Nigeria/75/1 has been used for successful PPRV vaccination on the African 
continent against PPRV strains from lineages I-IV, as well as in Turkey, China, Pakistan and other 
countries against circulating lineage IV PPRV (Sen et al., 2010). It can therefore be inferred from such 
experimental and field vaccination data that this vaccine might indeed induce a protective immunity 
towards viruses from all lineages. On the other hand, Sungri/96 has only been used in India and 
protection of small ruminants has thus only been demonstrated for homologous lineage IV virus 
strains under experimental and field conditions (Saravanan et al., 2010).  
The success of a global eradication campaign will be highly dependent on the availability and usage of 
safe and reliable PPRV vaccines in endemic countries and the currently available live attenuated 
vaccines are believed to be an important tool to implement better PPRV control measures. Currently 
the global supply of PPRV vaccine is limited, and efforts to implement large-scale PPRV vaccination 
will be hampered if these available vaccines are only utilised within their local region of origin, or if 
good quality vaccine from India (Sungri/96) is not accepted for use in other countries. Nonetheless, 
respective states and farming communities have to accept the offered vaccine preparations, 
otherwise vaccine coverage will be insufficient to prevent PPRV circulation. Consumer and regulator 
confidence would greatly benefit from additional direct evidence that both Nigeria/75/1 and 
Sungri/96 protect small ruminants against challenges with virulent viruses from all four genetic 
lineages. 
The aim of this chapter is the systematic comparison of the two most widely used live-attenuated 
PPRV vaccines, Nigeria/75/1 and Sungri/96, in their ability to clinically protect goats against virulent 
viruses from all four genetic lineages of PPRV. Clinical protection of vaccinated goats was assessed in 
a series of vaccination-challenge trials where key protection characteristics such as observed clinical 
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signs, viraemia and lymphopenia following virulent PPRV challenge were compared between 
Nigeria75/1 and Sungri/96 vaccinates. Virulence of the respective challenge viruses was confirmed by 
the inclusion of non-vaccinated control animals in each trial.  
 
3.2 Clinical protection of vaccinated goats based on clinical scoring 
For each experiment, 12 goats were enrolled; five goats were vaccinated with Nigeria/75/1 vaccine 
and five were vaccinated with Sungri/96 vaccine. The remaining two goats were either left 
unvaccinated or given a VDS-derived mock vaccine. Four weeks post-vaccination, all goats were 
infected with a virulent field isolate. For two weeks following challenge infection, all goats were 
observed for clinical signs and their rectal temperatures measured daily. This experimental protocol 
was repeated for virulent field strains from all four genetic lineages. Two viruses from genetic lineage 
II were tested because one resulted in subclinical disease and this was not considered a robust 
challenge of vaccination. 
 
3.2.1 Assessment of vaccine protection against PPRV/Cote d’Ivoire/89 (lineage I) 
For this experiment the Sungri/96 vaccine was unmodified commercial vaccine (“Ovilis” MSD Animal 
Health), while the Nigeria/75/1 vaccine used was a recombinant form made in our group (Hu et al., 
2012). Following infection with Cote d’Ivoire/89, the Sungri/96 vaccinates (Figure 3.1A) and the 
Nigeria/75 vaccinates (Figure 3.1B) did not develop clinical signs and their rectal temperatures 
remained stable throughout the post-challenge observation period (Figure 3.1D and E). 
The unvaccinated controls developed clinical signs 5 days post-challenge (dpc) (Figure 3.1C) and their 
rectal temperatures increased at this time (Figure 3.1F). Whilst goat C11 had a maximum combined 
clinical score of 3 throughout the post-challenge period and resolved the infection by the end of the 
two-week observation period, goat C12 developed a more acute disease and had a maximum 
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combined clinical score of 13, leading to euthanasia based on experimental humane end point (Figure 
3.1C and F). Statistical analysis of the clinical scores by Kruskal-Wallis was performed in Minitab by 
creating a cumulative total of the scores over the experiment and comparison of the means, which 
found a statistical difference between the means of the control group and the two vaccine groups (p 
= 0.000). 
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Figure 3.1 Clinical scores and rectal temperatures in experimental Cote d'Ivoire/89 infection of 
vaccinated and unvaccinated goats. Five goats were vaccinated with one dose of Ovilis PPR (MSD 
Animal Health; Sungri/96), five goats were vaccinated with 2x104 VDS TCID50 rPPRV Nigeria/75/1-
GFP and two goats were left unvaccinated. Four weeks later all goats were inoculated i.n. with 2x105 
VDS TCID50 PPRV Cote d’Ivoire/89 (lineage I). Following infection, rectal temperatures were taken 
and clinical observations were performed daily. The Sungri/96 vaccinates’ clinical scores are 
displayed in A, and rectal temperatures are D. Clinical scores for Nigeria/75/1 vaccinates are 
displayed in B and rectal temperatures are E. The clinical scores for the two unvaccinated goats are 
C and their rectal temperatures are displayed in F. 
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3.2.2 Assessment of vaccine protection against PPRV/Nigeria/76 (lineage II) 
In the next study, one of the Nigeria/75/1 vaccinates was removed from the study prior to challenge 
with virulent PPRV due to a systemic bacterial infection, this left four Nigeria/75/1 vaccinates and five 
Sungri/96 vaccinates. Also, after entry into the isolation facilities, three of the vaccinates developed 
lesions and scabs around the nostrils and muco-cutaneous areas of the lips, diagnosed as Orf by 
veterinary inspection only. Orf is a contagious zoonotic disease, caused by the Orf virus (OrfV), a 
member of the genus Parapoxvirus (Spyrou and Valiakos, 2015). The disease is characterised by 
erythematous lesions of the nose and lips and inside the mouth leading to scab formation. The 
respective animals did not display behavioural changes such as reduced appetite attributable to OrfV 
infection (K.Darpel, personal communication). Nonetheless the OrfV infection was challenging for the 
overall clinical scoring of the vaccinated goats. Following infection with the lineage II virus Nigeria/76, 
two of the five Sungri/96 vaccinates developed reddened ocular membranes (Figure 3.2A), however 
their rectal temperatures remained stable (Figure 3.2D). Three vaccinates, N1, N2 and N9, were given 
a score of one for oral lesions starting at 10 dpc, however the lesions were more typical of Orf than 
PPRV, and the rectal temperatures of all Nigeria/75/1 vaccinates remained stable (Figure 3.2D and E). 
The two mock-vaccinated goats developed reddening of the nasal and ocular membranes, with some 
nasal discharge and diarrhoea 4dpc (Figure 3.2C). Again, when the cumulative clinical scores were 
analysed by Kruscal-Wallis a significant difference between the scores of the controls and vaccinates 
was identified (p = 0.000), despite some vaccinated animals having scores for reddened ocular 
menbranes and the mildness of the challenge strain. Both mock vaccinated goats developed elevated 
rectal temperatures, goat D11’s rectal temperature was 2°C above its baseline reading at 7dpc, but 
from this time onwards both goats’ rectal temperatures started to decrease (Figure 3.2F).  
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Figure 3.2 Clinical scores and rectal temperatures in experimental Nigeria/76 infection of 
vaccinated and unvaccinated goats. Five goats were vaccinated with 2x104 VDS TCID50 Sungri/96, 
five goats were vaccinated with 2x104 VDS TCID50 rPPRV Nigeria/75/1-GFP and two goats were left 
unvaccinated. Four weeks later all goats were infected with 2x105 VDS TCID50 PPRV Nigeria/76 
(lineage II). Following infection, rectal temperatures were taken and clinical observations were 
performed daily. The Sungri/96 vaccinates’ clinical scores are displayed in A, and rectal temperatures 
are D. Clinical scores for Nigeria/75/1 vaccinates are displayed in B and rectal temperatures are E. 
The clinical scores for the two unvaccinated goats are in C and their rectal temperatures are 
displayed in F. 
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3.2.3 Assessment of vaccine protection against PPRV/Ghana/78 (lineage II) 
The Nigeria/76 challenge experiment was complicated by two significant events; the development of 
Orf in three of the experimental animals and subsequent difficulties in assigning clinical signs to PPRV 
challenge, the loss of one vaccinate due to a systemic bacterial infection, , and the low pathogenicity 
of the PPRV/Nigeria/76. Due to these complications, a repeat vaccination and lineage II PPRV 
challenge experiment was conducted using Ghana/78. None of the Sungri/96 vaccinates had a clinical 
score for the entire 14 day post-challenge observation period (Figure 3.3A) and their rectal 
temperatures stayed within normal limits (Figure 3.3D). The five Nigeria/75/1 vaccinates were also 
asymptomatic during the post-challenge period (Figure 3.3B) and their rectal temperatures also stayed 
within normal limits (Figure 3.3E). In contrast the mock-vaccinated control G11 developed an elevated 
rectal temperature 2dpc (Figure 3.3F), followed  two days later by  nasal discharge (Figure 3.3G) and 
a general reluctance to get up  (Figure 3.3H) resulting in the animal being euthanized due to humane 
end points being reached  (Figure 3.3C). On post-mortem, G11 had haemorrhaging in the lymph nodes 
(Figure 3.3I), while no other pathological findings attributable to PPRV infection were observed. The 
other mock-vaccinated goat, G12, had an elevated rectal temperature on 4dpc and developed oculo-
nasal discharge two days later (Figure 3.3C). 8dpc this mock-vaccinated animal also developed 
diarrhoea and apathy and so was also euthanized as per specified humane endpoints. This goat had 
congestion in the trachea and other signs of PPRV infection on post-mortem examination. As 
previously described Kruscal-Wallis was performed on cumulative clinical scores and a difference in 
the means of the controls and two vaccine groups was observed (p = 0.000) 
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Figure 3.3 Clinical scores, rectal temperatures and clinical signs of PPRV Ghana/78 in vaccinated 
and mock vaccinated goats. Five goats were vaccinated with 2x104 VDS TCID50 Sungri/96, five goats 
were vaccinated with 2x104 VDS TCID50 rPPRV Nigeria/75/1-GFP and two goats were left 
unvaccinated. Four weeks later all goats were infected with 2x105 VDS TCID50 PPRV Ghana/78 (lineage 
II). Rectal temperatures and clinical observations were performed daily. The Sungri/96 vaccinates’ 
clinical scores are displayed in A, and rectal temperatures are D. Clinical scores for Nigeria/75/1 
vaccinates are displayed in B and rectal temperatures are E. The clinical scores for the two 
unvaccinated goats are C and their rectal temperatures are displayed in F. On the day of peak clinical 
signs and euthanasia, the unvaccinated goat G11, had nasal discharge (G), was recumbent (H) and on 
post-mortem the sub-mandibular lymph nodes were haemorrhaged (I). 
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3.2.4 Assessment of vaccine protection against PPRV/Sudan/Sennar/72 (lineage III) 
The PPRV genetic lineage III virus, Sudan/Sennar/72 was used for challenge in another experiment. 
Again, animals were vaccinated with either Sungri/96 or Nigeria/75/1, and challenged with the wild 
type virus by s.c. inoculation at 4 weeks post vaccination. One Sungri/96 vaccinate had a cough 13dpc 
(Figure 3.4A), but all animals in this vaccine group had stable rectal temperatures throughout the 
observation period (Figure 3.4D). One Nigeria/75/1 vaccinate, S7, had a cough for three days that 
cleared and goat S9 had a cough on 7dpc but not on subsequent days (Figure 3.4B). Whilst 
Nigeria/75/1 vaccinate S6 had a higher rectal temperature than the other goats in the group it’s rectal 
temperature did not increase by more than 0.8°C from its baseline temperature (Figure 3.4E), and the 
rectal temperatures of the other goats in the group stayed within acceptable limits. The mock-
vaccinated control S11 had a rectal temperature 1°C above its baseline temperature on 4dpc (Figure 
3.4F) and developed reddening of the ocular and nasal membranes 6dpc (Figure 3.4C). The other 
mock-vaccinated goat developed an elevated rectal temperature 6dpc and a cough with nasal 
discharge 7dpc (Figure 3.4C). As previously described statistical analysis of the means of the clinical 
scores by Kruscal-Wallis found a significant difference between the unvaccinated controls and both 
vaccine groups. 
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Figure 3.4 Clinical scores and rectal temperatures of PPRV Sudan/Sennar/72 experimental 
infection of vaccinated and mock vaccinated goats. Five goats were vaccinated with 2x104 VDS 
TCID50 Sungri/96, five goats were vaccinated with 2x104 VDS TCID50 rPPRV Nigeria/75/1-GFP and two 
goats were left unvaccinated. Four weeks later all goats were inoculated with 2x105 VDS TCID50 PPRV 
Sudan/Sennar/72 (lineage III). Rectal temperatures and clinical observations were performed daily. 
The Sungri/96 vaccinates’ clinical scores are displayed in A, and rectal temperatures are D. Clinical 
scores for Nigeria/75/1 vaccinates are displayed in B and rectal temperatures are E. The clinical 
scores for the two unvaccinated goats are C and their rectal temperatures are displayed in F. 
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3.2.5 Assessment of vaccine protection against PPRV/Kurdistan/2011 (lineage IV) 
For the final experiment, the virulent strain PPRV/Kurdistan/2011 was used for the lineage IV 
challenge. All five of the Sungri/96 vaccinated goats had intermittent reddening of the ocular mucosa 
before challenge and between 4dpc and 12dpc and three of the five also had ocular discharge on some 
days (Figure 3.5A), a specific example of goat K2 can be seen in Figure 3.5G. Goats K4 and K3 had an 
initial drop in rectal temperatures of 1.5°C between 1dpc and 3dpc which then recovered within a day 
(Figure 3.5D), while goat K1 had an increase in rectal temperature of 1°C on 6dpc, which then reduced 
back to baseline the following day. All five of the Nigeria/75/1 vaccinates also had intermittent 
reddening of the ocular mucosa between 4dpc and 12dpc and occasional ocular discharge (Figure 
3.5B). Nigeria/75/1 vaccinate K7 had a drop in rectal temperature of 1.8°C 2dpc and goat K9’s rectal 
temperature dropped by 1.5°C 3dpc (Figure 3.5E), but all rectal temperatures returned to within 1°C 
of baseline by 4dpc. Both unvaccinated controls (K11 and K12) started to develop clinical signs at 4dpc. 
K11 was the only one of the two unvaccinated controls that had an increase in rectal temperature 2°C 
above baseline (Figure 3.5F), K12’s rectal temperature increased to a maximum of 0.8°C above 
baseline on 5dpc. The mock-vaccinated animal K11 displayed signs of acute PPRV infection and was 
lethargic (Figure 3.5H) and had thick oculo-nasal discharges (Figure 3.5I). Both animals developed 
diarrhoea by 8dpc (Figure 3.5C), and were therefore euthanised on the day in accordance to specified 
humane endpoints. As previously described statistical analysis of the means of the clinical scores by 
Kruscal-Wallis found a significant difference between the unvaccinated controls and both vaccine 
groups. 
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Figure 3.5 Clinical scores, rectal temperatures and clinical signs of PPRV Kurdistan/2011 challenge 
in vaccinated and unvaccinated goats. Five goats were vaccinated with 2x104 VDS TCID50 Sungri/96, 
five goats were vaccinated with 2x104 VDS TCID50 rPPRV Nigeria/75/1-GFP and two goats were left 
unvaccinated. Four weeks later all goats were inoculated s.c. with 2x105 VDS TCID50 PPRV 
Kurdistan/2011 (lineage IV). Rectal temperatures and clinical observations were performed daily. The 
Sungri/96 vaccinates’ clinical scores are displayed in A, and rectal temperatures are D. Clinical scores 
for Nigeria/75/1 vaccinates are displayed in B and rectal temperatures are E. The clinical scores for 
the two unvaccinated goats are C and their rectal temperatures are displayed in F. An example of a 
Sungri/96 vaccinate (K2) with ocular congestion and discharge is seen in image G. Contributing to 
overall clinical scores and leading to euthanasia on specified humane end points, both unvaccinated 
controls were lethargic (K11, H) and had ocular congestion and ocular and nasal discharge (K12, I). 
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3.3 Clinical protection based on viral RNA detection by quantitative RT-PCR in 
clinical samples 
In some of the experiments described, following challenge with a field isolate of PPRV, samples 
including EDTA blood and nasal swabs were obtained every other day for later detection of PPRV 
genome. Due to the large numbers of the samples obtained, it was determined that the staff of The 
Pirbright Institute NVRL would be better able to analyse the samples due to their familiarity with 
robotic extraction techniques and their training to high quality standards performing diagnostic 
techniques. 
 
3.3.1 Clinical protection based on RNAemia detected by quantitative RT-PCR 
EDTA blood samples obtained from goats following challenge were tested by The Pirbright Institute 
NVRL staff by quantitative RT-PCR for the PPRV N gene. EDTA bloods were not obtained from the 
lineage I PPRV Cote d’Ivoire/89 challenge experiment and so RNAemia data are not available for these 
animals. Neither mock vaccinated goat challenged with Nigeria/76 had detectable PPRV genome in 
the blood during the two weeks post-challenge (vaccinated animals were not tested, Figure 3.6A). In 
contrast, both of the mock vaccinated controls challenged with the lineage II Ghana/78 developed 
RNAemia on 4dpc and this continued until the animals were euthanised 6 or 8dpc respectively  (Figure 
3.6B). No vaccinated goats had detectable PPRV RNA in blood samples for any time point tested from 
0dpc - 12dpc (data not shown). Both of the Sudan/Sennar/72 challenge control animals developed 
RNAemia 4dpc and the RNAemia persisted to the last day of testing, 12dpc (Figure 3.6C). Again, the 
vaccinated goats in this experiment did not have any detectable PPRV RNA during the challenge period 
(data not shown). A similar picture was seen in the final study with PPRV RNA detected in the two 
unvaccinated controls infected with Kurdistan/2011 from 4dpc (Figure 3.6D), while the EDTA blood 
from the two vaccinated controls that were tested had no detectable PPRV RNA (data not shown). 
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Figure 3.6 PPRV N gene detection in EDTA blood by RT-PCR. Following virulent challenge, blood 
was collected every other day into EDTA-treated vacutainers; 1ml samples were created and 
frozen for later analysis. All samples were given to The Pirbright Institute NVRL for RNA extraction 
and N gene quantitative RT-PCR. Points are representative of duplicate PCR reactions, results are 
displayed as 45 - Ct value. Graphs depict the results for mock vaccinated controls infected with 
PPRV Nigeria/76 (A), Ghana/78 (B), Sudan/Sennar/72 (C) and Kurdistan/2011 (D). None of the 
vaccinated animals had detectable N gene in blood samples (data not shown). 
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3.3.2 Clinical protection based on shedding by detection of genome in nasal swabs 
It is widely assumed that PPRV is transmitted by viral shedding from infected animals to animals in 
close contact. In order to confirm that vaccinated animals do not shed viral RNA and are therefore not 
a source of infection for in-contact animals, nasal swabs were taken from all animals in the 
Sudan/Sennar/72 challenge experiment. As expected, both unvaccinated goats had detectable PPRV 
RNA in their nasal secretions from 6 dpc (Figure 3.7). None of the goats that had received vaccine prior 
to challenge, either Sungri/96 or Nigeria/75, had any detectable RNA in their nasal swabs (data not 
shown). This is consistent with the RNAemia data seen in the blood from these animals. 
Nasal swabs were also obtained from all animals in the Ghana/78 challenge study, but due to time 
constraints these samples were not analysed. 
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Figure 3.7 PPRV N gene detection in nasal swabs by RT-PCR. Following virulent challenge with 
Sudan/Sennar/72 nasal swabs were collected every other day. Swabs were agitated in PBS, then 
frozen for later analysis. All samples were given to The Pirbright Institute NVRL for RNA extraction and 
N gene quantitative RT-PCR. Points are representative of duplicate PCR reactions, results are 
displayed as 45 - Ct value. None of the vaccinated animals had detectable N gene in nasal swabs (data 
not shown). 
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3.4 Clinical protection based on whole blood antibody labelling 
Leucopoenia is a well-established consequence of PPRV infection, though it cannot be observed easily 
in the field. While the overall loss of circulating white blood cells is well established, the particular cell 
types most affected have never been studied. Utilising flow cytometric immunophenotyping of whole 
blood, with beads to allow determination of absolute cell numbers, enabled determination of not only 
the overall loss of white blood cells but also the non-granular leucocyte subsets that are affected by 
PPRV infection. Data are not available from all vaccinates due to expense and so a random subset of 
animals from each vaccination group as well as all mock vaccinated controls have been analysed. The 
respective number of CD4+ and CD8+ T cells, WC1+ cells (the major subset of γδ T cells), CD21+ B cells 
and MHC II+ cells (as a marker for antigen presenting cells) were quantified within peripheral blood 
every other day between 0 and 12 dpc.  
 
3.4.1 PPRV/Nigeria/76 (lineage II) 
The numbers of cells at 0dpc were taken as a baseline to compare with cell numbers on subsequent 
days.  Following challenge with PPRV/Nigeria/76 the two mock-vaccinated goats lost CD4+ T cells, with 
the greatest reduction seen 4dpc (Figure 3.8A) and the same reduction was seen for CD21+ B cells 
4dpc (Figure 3.8C). One mock-vaccinated goat, N11, had an increase in the numbers of CD8+ T cells in 
the blood after challenge, peaking at 4dpc (Figure 3.8B) however, in contrast, the other mock-
vaccinated animal, N12, lost CD8+ T cells during the same period. The numbers of antigen presenting 
cells (MHC II+) remained fairly stable in the two mock-vaccinated controls (Figure 3.8E). Both 
Nigeria/75/1 vaccinates had increased CD4+ T cells (Figure 3.8A) and CD8+ T cells (Figure 3.8B) that 
peaked at 4dpc, which was not observed with the Sungri/96 vaccinates. Numbers of WC1+ γδ T cells 
in the blood are relatively stable for all six animals throughout the experiment, on the day of challenge 
the vaccinated goats have more WC1+ γδ T cells than the mock-vaccinated goats (Figure 3.8D).  
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The numbers of MHC II+ cells in the Nigeria/75/1 vaccinated animals remain stable throughout the 
observation period (Figure 3.8E), the numbers of MHC II+ cells in the Sungri/96 vaccinates appear to 
reduce until 6dpc when they return to original levels. There is an apparent reduction in cell numbers 
in all six animals of all cellular populations in this experiment observed by 6dpc, but it is more 
advanced in the mock-vaccinated animals (Figure 3.8).  
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Figure 3.8 Numbers of non-granular leucocytes subsets per ml of blood from PPRV Nigeria/76 
challenge experiment. EDTA blood was obtained on the indicated days post challenge. A defined 
amount of 123count eBeads was added to each blood sample and non-granular leucocyte subsets 
were labelled with fluorophore-conjugated mAbs as described in section 2.5. Data was collected for 
10,000 events in the bead gate. The concentration of beads was used to determine the volume of 
blood analysed by the flow cytometer. Shown is the numbers of cells per ml blood that were labelled 
with antibodies against CD4 (A), CD8 (B), CD21 (C), WC1 (D) and MHC II (E). Sungri/96 vaccinates are 
shown in blue, Nigeria/75/1 vaccinates are green and the mock vaccinated goats are in black. 
0 2 4 6 8 1 0 1 2 1 4
0
21 0 0 6
41 0 0 6
61 0 0 6
C D 4 +
D a y s  p o s t c h a lle n g e  (d p c )
N
u
m
b
e
r
 o
f 
C
D
4
+
 c
e
ll
s
p
e
r
 m
l 
b
lo
o
d
0 2 4 6 8 1 0 1 2 1 4
0
11 0 0 6
21 0 0 6
31 0 0 6
41 0 0 6
W C 1 +
D a y s  p o s t c h a lle n g e  (d p c )
N
u
m
b
e
r
 o
f 
W
C
1
+
 c
e
ll
s
p
e
r
 m
l 
b
lo
o
d
0 2 4 6 8 1 0 1 2 1 4
0
11 0 0 6
21 0 0 6
31 0 0 6
41 0 0 6
C D 8 +
D a y s  p o s t c h a lle n g e  (d p c )
N
u
m
b
e
r
 o
f 
C
D
8
+
 c
e
ll
s
p
e
r
 m
l 
b
lo
o
d
0 2 4 6 8 1 0 1 2 1 4
0
21 0 0 6
41 0 0 6
61 0 0 6
M H C  II+
D a y s  p o s t c h a lle n g e  (d p c )
N
u
m
b
e
r
 o
f 
M
H
C
 I
I+
 c
e
ll
s
p
e
r
 m
l 
b
lo
o
d
0 2 4 6 8 1 0 1 2 1 4
0
51 0 0 5
11 0 0 6
21 0 0 6
21 0 0 6
C D 2 1 +
D a y s  p o s t c h a lle n g e  (d p c )
N
u
m
b
e
r
 o
f 
C
D
2
1
+
 c
e
ll
s
p
e
r
 m
l 
b
lo
o
d
N 1 1
N 1 2
N 9
N 1
N 2
N 8
A
B
C
D
E
89 
 
3.4.2 PPRV/Sudan/Sennar/72 (lineage III) 
For this experiment two EDTA blood samples were obtained prior to challenge and the average cell 
number obtained from these two time points was used as a baseline to compare with cell numbers on 
subsequent days. The numbers of CD4+ T cells in the blood of mock-vaccinated goats infected with 
PPRV/Sudan/Sennar/72 decreased after challenge to their lowest levels at 4dpc (Figure 3.9A), the 
CD4+ T cells slowly started to increase from this low, but did not recover to original numbers by the 
end of the observation period. Also, the CD8+ T cells in both the mock-vaccinated animals had reduced 
by 4dpc and remained low until 10dpc when they started to recover (Figure 3.9B). After challenge the 
numbers of CD21+ B cells also reduced in goats S11 and S12 (Figure 3.9C). As seen in the Nigeria/76 
challenge experiment, the numbers of WC1+ γδ T cells in the blood of the mock-vaccinated controls 
was relatively stable over the post-challenge period (Figure 3.9D). The numbers of MHC II+ cells 
reduced steadily over the observation period in both of the mock-vaccinated goats (Figure 3.9E). 
Following challenge with PPRV/Sudan/Sennar/72 the Sungri/96 vaccinates showed an increase in 
CD4+ T cells (Figure 3.9A), CD8+ T cells (Figure 3.9B), CD21+ B cells (Figure 3.9C) and MHC II+ cells 
(Figure 3.9E) that peaked at 8dpc. The Nigeria/75/1 vaccinates also had increases in their CD4+ T cells 
and CD8+ T cells over the same period (Figure 3.9A and B). The numbers of CD21+ B cells (Figure 3.9C), 
WC1+ γδ T cells (Figure 3.9D) and MHC II+ cells (Figure 3.9E) in the blood of the Nigeria/75/1 vaccinates 
remained relatively stable over the 14 day observation period.  
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Figure 3.9 Numbers of non-granular leucocyte subsets per ml of blood from PPRV/Sudan/Sennar/72 
challenge. EDTA blood was obtained on the indicated days post challenge (baseline is calculated as an 
average of two samples obtained before challenge). A defined amount of 123count eBeads was added 
to each blood sample and lymphocyte subsets were labelled with fluorophore-conjugated mAbs as 
described in section 2.5. Data was collected for 10,000 events in the bead gate. The concentration of 
beads was used to determine the volume of blood analysed by the flow cytometer. Shown is the 
numbers of cells per ml that were labelled with antibodies against CD4 (A), CD8 (B), CD21 (C), WC1 (D) 
and MHC II (E). Sungri/96 vaccinates are shown in blue, Nigeria/75/1 vaccinates are green and the 
mock vaccinated goats are in black. 
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3.4.3 PPRV/Kurdistan/2011 (lineage IV) 
Whole blood labelling for the Kurdistan/2011 challenge experiment was performed every other day 
until 8dpc when both unvaccinated control animals were euthanised. The numbers of cells at 0dpc 
were taken as a baseline to compare with cell numbers on subsequent days. The two unvaccinated 
controls lost substantial numbers of CD4+ T cells 4dpc, and the numbers had not recovered by 8dpc 
(Figure 3.10A). The numbers of CD8+ T cells in the unvaccinated goats were lower than in the 
vaccinated goats on the day of challenge, but also reduced over the eight day observation period 
(Figure 3.10B). Both unvaccinated controls lost considerable numbers of CD21+ B cells, WC1+ γδ T cells 
and MHC II+ cells following PPRV challenge, dropping on 4dpc (Figure 3.10C). It should be noted that 
the initial numbers of CD4+, CD8+ and WC1+ T cell subsets in the unvaccinated goats were lower than 
the vaccinates on the day of challenge (Figure 3.10). The levels of all subsets in the vaccinates 
remained more or less level throughout the 8 days of observation, apart from an increase in CD4+ T 
cells at 2dpc and a dip in CD4+ and CD8+ T cells in the Sungri/96 vaccinate at 6dpc. 
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Figure 3.10 Numbers of non-granular leucocyte subsets per ml of blood from the Kurdistan/2011 
challenge. EDTA blood was obtained on the indicated days post challenge. A defined amount of 
123count eBeads was added to each blood sample and lymphocyte subsets were labelled with 
fluorophore-conjugated mAbs as described in section 2.5. Data was collected for 10,000 events in the 
bead gate. The concentration of beads was used to determine the volume of blood analysed by the 
flow cytometer. Shown is the numbers of cells per ml that were labelled with antibodies against CD4 
(A), CD8 (B), CD21 (C), WC1 (D) and MHC II (E). Sungri/96 vaccinates are shown in blue, Nigeria/75/1 
vaccinates are green and the mock vaccinated goats are in black. 
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3.5 Discussion 
In the studies described in this chapter, I found that two different live attenuated vaccines, derived 
from different PPRV lineages (namely Nigeria/75/1 [lineage II] and Sungri/96 [lineage IV]) protected 
all vaccinated goats from developing clinical signs following challenge with five different PPRV field 
isolates regardless of the genetic lineage or virulence of the challenge virus. The data presented in this 
chapter form the first direct comprehensive comparison of vaccine efficacy in controlled vaccination-
challenge trials for these two commonly used live attenuated PPRV strains. In previous experiments 
researchers have assessed vaccine protection by presence or lack of clinical signs in vaccinates and 
seroconversion by cELISA following vaccination (Saravanan et al., 2010). More in depth studies have 
gone further including the rectal temperatures and cELISA with detection of PPRV antigen in nasal and 
ocular swabs as well as observing leukopenia (Chaudhary et al., 2009). Clinical scoring was introduced 
to quantify clinical signs following PPRV infection (El Harrak et al., 2012) and this could be utilised in 
vaccination experiments to quantify how virulent a virus is in comparison to another and what clinical 
manifestations the vaccine has provided protection against. 
The field strains used in these experiments varied in the clinical signs and experimental virulence. The 
mildest strain was the lineage II Nigeria/76, which only generated subclincal signs and both mock 
vaccinated goats recovered. Neither of the goats developed detectable viraemia during the course of 
the infection. Not all lineage II viruses are mild, as the most virulent virus in these experiments was 
also a lineage II virus, PPRV Ghana/78, which caused fever, depression and nasal discharge in the 
unvaccinated controls. It should be noted that the infection route of subcutaneous injection is not the 
natural infection route, and has been reported to result in a delay in onset of symptoms (El Harrak et 
al., 2012), however the subcutaneous route was chosen due to its more reproducible dosing regimen 
than intranasal inoculation. In these studies, the field strains, ranked from least virulent to most 
virulent were; Nigeria/76, Sudan/Sennar/72, Cote d’Ivoire/89, Kurdistan/2011 and Ghana/78. 
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All goats that received Nigeria/75 were protected from PPRV challenge-induced fever, irrespective of 
the genetic lineage of the challenge virus. The Sungri/96 vaccine was equally potent at protecting all 
goats from pyrexia with all four genetic lineage virus strains. In some of the experiments the 
vaccinated animals had reddened ocular membranes, with or without discharge. This sign was very 
inconsistent and was present one day and not present the next, and was observed in animals before 
and after challenge. It is possible that this clinical sign could have been caused by dust in the hay 
causing irritation to the eyes as the goats fed. Also, because the goats were of the white Saanen breed 
it could be that due to their natural pallor that changes in membrane colour were more obvious than 
they would be in other breeds. Perhaps, in light of these observations this clinical sign is not as 
indicative of PPRV infection as nasal discharge and elevated rectal temperatures in this breed. 
Statistical analysis of clinical scores by Kruscal-Wallis was performed for all experiments. Whilst a 
statistically significant difference between the unvaccinated controls and both vaccine groups was 
identified in all experiments, it should be noted that the non-parametric Kruscal-Wallis test is limited 
in its power, due to the fact that it only compares the means of the groups being analysed. 
Vaccination with Nigeria/75/1 protected vaccinates against RNAemia after challenge with PPRV field 
strains, with all vaccinated animals tested by RT-PCR resulting in no detectable PPRV genome in the 
blood. Also, Sungri/96 protected vaccinates against RNAemia, even with the highly virulent lineage II 
virus, Ghana/78. Protection of vaccinates against RNAemia is not normally investigated in PPRV 
vaccination/challenge experiments. It would appear that, in PPRV infection, RNAemia is very closely 
related to clinical signs, with the mock-vaccinated animals infected with Nigeria/76 only displaying 
transient clinical signs and no PPRV RNA detected in the blood during the observation period. 
However it is currently unknown if animals subclinically infected with PPRV will shed the virus to 
transmissible levels, even in the absence of detectable PPRV RNA in the blood. Other studies have 
reported the detection of viral RNA by PCR assays in ocular, nasal and oral secretions at comparable 
times to peripheral blood or blood derived cells (El Harrak et al., 2012, Hammouchi et al., 2012, Pope 
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et al., 2013). All animals which tested positive for nasal, ocular and/or oral secretion of viral RNA 
developed concurrent/ subsequent RNAaemia and clinical disease. Furthermore although PPRV 
shedding (as detected by PCR or antigen detection) by infected hosts has been reported prior to 
clinical disease or from individuals that had recovered, these animals still seemed to have been 
clinically affected at one point during the course of infection (Couacy-Hymann et al., 2002, Ezeibe et 
al., 2008).  Viral shedding in secretions such as ocular and nasal discharge, urine and faeces had 
previously been linked to viral induced pathology within respective organ systems (Bundza et al., 1988, 
Kul et al., 2007). Although ocular and nasal swabs were taken during some of the vaccination-challenge 
trials detailed in this chapter, they could not all be processed due to time constrains. As a result, only 
nasal swab data was available from the Sudan/Sennar challenge, and whilst there was no viral RNA 
detected in nasal secretions in the vaccinates and viral RNA detected in the unvaccinated controls, 
this is only from one experiment. It would have been beneficial to monitor the presence of viral RNA 
in selected secretions alongside its presence in the blood and the analysis of the other nasal swabs 
would have provided a better picture for this comparative anlaysis of the two vaccines. Conversely, 
the assessment of viral RNA secretion of individual infected animals by real time PCR in group housed 
animals might be hampered by the possibility that the mere presence of some virus shedding 
individuals (e.g. the mock vaccinated controls) could potentially indirectly contaminate external facial 
areas of pen mates. 
Overall, milder PPRV field strains which might induce subclinical infections in the absence of systemic 
RNAemia could be missed by a diagnostic strategy based on the analysis of peripheral blood samples 
by RT-PCR assay. If PPRV surveillance strategies in resource poor settings are based on such a 
diagnostic strategy alone, this could lead to mild PPRV strains circulating, which might pose additional 
challenges to the desired goal of PPRV eradication. From these observations, utilising seroconversion 
diagnostic assays alongside RT-PCR would be useful.  
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However, the live attenuated vaccines are not DIVA capable, so vaccination in the region would ablate 
the ability of an antibody-based assay to detect mild disease and would be redundant unless a novel 
DIVA vaccine diagnostic assay pairing was in place. 
The loss of leukocytes caused by morbillivirus infections is well known (Ryon et al., 2002, Rajak et al., 
2005). Morbillivirus infection leads to an extended period of immunosuppression, which persists long 
after the leucocytes have recovered, and can leave the host vulnerable to other infections, resulting 
in comorbidity.  The mechanism of this extended immunosuppression is currently unknown. One 
cause of death associated with morbillivirus infection is secondary infections (Jagtap et al., 2012). 
Previously, if researchers had intended to observe PPRV-induced leucopoenia they would have 
performed a total lymphocyte count (Rajak et al., 2005). Absolute cell counting utilising counting 
beads in flow cytometry is a novel technique in assessing morbillivirus-induced leucopoenia. This 
technique has primarily been used in humans for HIV patients to assess the numbers of CD4+ T cells 
to inform antiretroviral drug efficacy (Schnizlein-Bick et al., 2000). However, the technique is 
beginning to be utilised in the veterinary sector in other production animals, such as chickens (Seliger 
et al., 2012). The most popular product for this technique is the TruCount tube by BD which has the 
antibody cocktail and beads already in the flow tube for maximum convenience and reproducibility. 
At this time BD do not produce a ready-made cocktail of cell surface molecule-specific conjugated 
antibodies for goats, but they do supply tubes containing beads only, however, there are more 
economic alternatives to the TruCount tubes available. Using the eBioscience counting beads it was 
possible to screen possible goat cross-reactive mAbs swiftly with small volumes of blood from 
experimental animals, to design a suitable mixture of conjugated mAb to perform 
immunophenotyping to assess PPRV-induced leucopoenia over the course of the infection with 
different strains. 
Overall, it appeared that the more virulent the PPRV strain, the more cellular sub-populations were 
affected, with reductions in all cellular populations being observed in the Kurdistan/2011 challenge 
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control animals in contrast to the goats challenged with Nigeria/76, where the CD4+ and CD21+ cells 
were the most obviously reduced following challenge. Although the data post-challenge for the 
Kurdistan/2011 is only available until 8dpc the differences between the challenge controls and the 
vaccinates is striking; from these data it is clear that both vaccines have protected the vaccinates from 
PPRV-induced leucopoenia, although statistics could not be performed due to only one vaccinate in 
each vaccine group. In the PPRV/Sudan/Sennar challenge experiment, the reductions in numbers of 
the cellular sub-populations are not as obvious as in the Kurdistan/2011 infection, however the 
differences between the vaccinates and the challenge controls are still apparent, demonstrating again 
the ability of the vaccine strains to protect goats from leucopoenia caused by a PPRV virulent field 
strain. Also, it would appear that the vaccinated animals regularly had higher numbers of lymphocyte 
sub-populations on the day of challenge than the unvaccinated controls. The loss of different cellular 
populations following PPRV infection could either be caused by direct infection of cells by the virus – 
possibly because activation increases the expression of SLAM on the cell surface, or a bystander effect 
within lymph nodes caused by the release of cytotoxic substances from dying infected cells. The data 
from the Sudan/Sennar challenge experiment appears to show an increase in the numbers of cells 
expressing the cell surface proteins assayed. It is possible that this could be due to clonal expansion 
of PPRV-specific cells, but due to the limited numbers of animals assayed for this experiment a firm 
conclusion cannot be drawn at this time. 
Protection from challenge with a virulent PPRV challenge strain is an accepted test of vaccine efficacy, 
however the exact immune mechanisms involved in vaccine induced protection are not understood. 
It would be useful to examine the immune responses following vaccination, both humoral and cell-
mediated, in further detail to discover the protective immune response to challenge. Also, if the 
immune responses to the well-established vaccines for PPRV are identified, it is possible that these 
immune responses could be used as a benchmark for the assessment for new PPRV vaccines in 
development. 
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In summary, from the results in this chapter it can be concluded that both PPRV vaccines, Nigeria/75/1 
and Sungri/96 can protect against the clinical manifestations of PPRV following challenge with any of 
the four genetic lineages of virulent field strains. 
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Chapter 4 – Immune responses to vaccination with live attenuated 
PPRV vaccines 
4.1 Introduction 
Protection of PPRV vaccinated animals against virulent challenge has been reported in the field, 
however, this is regularly reported as protection from clinical signs (Diallo et al., 1989) and more in-
depth investigations are rare. In Chapter 3, I demonstrated that both Nigeria/75/1 and Sungri/96 live 
attenuated vaccines can protect against virulent field isolates from all four genetic lineages of PPRV. 
Analysis of specific immune responses to PPRV field strains as well as vaccines are still limited. It is 
generally accepted that both recovery from virulent morbillivirus infection and vaccination with live 
attenuated vaccines provides protection against re-infection for life (first observed by Panum in the 
Faroe Islands). For the vaccine strain PPRV/Nigeria/75/1 clinical protection has been demonstrated 
for at least 3 years, which is considered to be the life expectancy of sheep and goats in a pastoralist 
system (OIE Terrestrial Manual (2013), and detectable neutralising antibody titre reported in 
Sungri/96 vaccinated animals for at least 5 years (Saravanan et al., 2010). 
It is generally assumed that PPRV neutralising antibodies are the primary source of vaccine-induced 
protection and therefore most studies of vaccine-induced immune responses have focussed on 
antibody production (Saravanan et al., 2010). This assumption likely arises from the functional test for 
an active or effective batch of live PPRV vaccine as defined in the OIE Manual (2013), that a vaccine 
“must elicit a neutralising titre of at least 1:10”. However, for measles virus (MeV) the T cell response 
induced by vaccination has been investigated in more detail. Following vaccination of children with 
the trivalent MMR vaccine, researchers in Canada found that whilst MeV-specific neutralising antibody 
titres waned with time in the years following vaccination, often to ‘subprotective’ levels, 
lymphoproliferative responses were still present in 66% of children 5-8 years after vaccination 
(Bautista-Lopez et al., 2000).  
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Due to the lack of information on T cell responses to PPRV vaccination, it was therefore of both interest 
and importance to document both the antibody and T cell responses induced by live attenuated PPRV 
vaccines. In addition, a direct comparison between the two vaccine strains PPRV/Nigeria/75/1 and 
PPRV/Sungri/96 would allow me to determine if one is more stimulatory than the other either by 
inducing neutralising antibodies or stimulating T cell responses. The aim of the work described in this 
chapter was the comparison of the antibody and T cell responses elicited by the two different vaccine 
strains and their activity against both homologous and heterologous strains including recall by in vivo 
challenge with the field strains representing the four PPRV lineages.  
 
4.2 Antibody responses to PPRV vaccination and challenge 
4.2.1 Assessment of PPRV N protein-specific antibodies  
A rapid assay to determine the presence of PPRV-specific antibodies is the competition enzyme-linked 
immunosorbent assay (cELISA). The assay works on the principle of the antibodies present in the 
serum competing with a monoclonal antibody for binding sites on the specific antigen in the assay. 
The ELISA used for these experiments was the commercially available anti-PPRV N protein kit made 
by ID.vet, utilising the N protein of Nigeria/75/1, the N protein is conserved enough among PPRV 
strains that the assay is suitable for diagnostics of potential field infections, and therefore for 
experimental infections. Presence of N specific antibodies was determined in longitudinal serum 
samples taken during the vaccination/challenge experiments described in Section 2.8.1 and Chapter 
3. Most animals showed an increase in PPRV-specific antibodies at 7dpv, and all vaccinates had 
seroconverted by 14dpv (Figure 4.1). When all of the data from the vaccinates from each experiment 
prior to challenge were combined, Nigeria/75/1 vaccinates had statistically higher percentage 
inhibitions at 7dpv than Sungri/96 on 7dpv as determined by ANOVA (p = 0.008) but not at other time 
points (Figure 4.1F).  All unvaccinated controls seroconverted 7dpc/35dpv, regardless of challenge 
strain (Figure 4.1A, B, C, D and E). 
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Having examined general trends of the two vaccine groups across all experiments, unusual findings 
for specific experiments will now be discussed individually. For the experiment depicted in Figure 4.1A, 
vaccination was performed with the commercial preparation of Sungri/96 (Ovilis, MSD Animal Health) 
and a GFP-expressing recombinant PPRV/Nigeria/75/1. All other experiments were performed with 
titered VDS-grown Sungri/96, and GFP-expressing PPRV/Nigeria/75/1. In the experiments where 
Sungri/96 vaccine was the same titre as Nigeria/75/1 the two vaccines were not statistically different 
for this assay by ANOVA. For the PPRV/Cote d’Ivoire/89 challenge experiment serum was not collected 
on 7dpv and 21dpv. Also, no serum was collected from the unvaccinated controls until after challenge 
in this study. One of the unvaccinated goats was euthanised before the end of the study so no data is 
available for 14dpc/42dpv for this animal. All vaccinated goats in the Cote d’Ivoire challenge study had 
seroconverted by 14dpv, however the percentage inhibitions of the Sungri/96 vaccinates were 
significantly lower than the Nigeria/75/1 vaccinates at the time points assessed, even after challenge 
as determined by ANOVA (p = 0.013) (Figure 4.1A).  
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Figure 4.1 PPRV-N cELISA percentage inhibition data indicating seroconversion for all 
vaccination/challenge experiments. Serum was obtained on the days indicated, heat-inactivated for 
2 hours at 56°C and stored. All sera from the same experiment were assayed at the same time using a 
commercial PPRV N protein-specific cELISA. Percentage inhibitions were generated by the equation in 
Section 2.5.1. Shown are the percentage inhibitions for the experiments with challenge viruses 
PPRV/Cote d’Ivoire/89 (A), PPRV/Nigeria/76 (B), PPRV/Ghana/78 (C), PPRV/Sudan/Sennar/72 (D), 
PPRV/Kurdistan/2011 (E) and all vaccinates combined from all experiments prior to challenge (F). 
Sungri/96 vaccinates are shown in blue, Nigeria/75/1 vaccinates are green and the mock vaccinated 
goats are in black, the day of challenge is indicated by the vertical red line. Statistics were performed 
in Minitab 17, running an ANOVA general linear model and Tukey pairwise comparison. 
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4.2.2 Assessment of PPRV neutralising antibody titres 
The virus neutralisation test (VNT) is a more informative assay than the cELISA because it generates a 
titre, which is a quantitative read out of the neutralising ability of the antibodies in the serum of an 
animal following exposure to PPRV, either vaccine or field strain against the available epitopes on 
whole virus, not just the epitopes of a single protein. Also, the VNT gives a more functional readout of 
the antibodies abilities to bind, rather than their mere presence, as assessed by cELISA. However, due 
to the nature of the VNT assay, it is more time-consuming than the cELISA and results are available in 
days, not hours, and it can be especially laborious with large sample sizes. It is assumed that antibodies 
directed against the haemagglutinin or fusion proteins of PPRV are neutralising as they are present on 
the virus surface. VNTs were performed against both vaccine strains to identify any differences in 
heterologous/homologous titres. Due to lack of time, only samples from the Cote d’Ivorie/89 and 
Sudan/Sennar/72 vaccination/challenge experiments were assayed. 
Considering the Cote d’Ivoire/89 vaccination/challenge experiment first, at 14dpv sera from the 
Sungri/96 vaccinated goats were able to neutralise both vaccine strains equally. However, 
Nigeria/75/1 vaccinates had significantly higher neutralising titres against the homologous virus 
(Figure 4.2C). Neither PPRV/Nigeria/75/1 nor PPRV/Sungri/96 was neutralised by serum antibodies of 
the unvaccinated goats 7dpc/35dpv (Figure 4.2E and F). Only one of the unvaccinated animals was 
alive at 14dpc/42dpv, but this one animal had a higher neutralising titre against the vaccine strain 
PPRV/Nigeria/75/1 than against the PPRV/Sungri/96 strain (p < 0.00) (Figure 4.2D and E). 
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Figure 4.2 Virus neutralisation test titres of serum from the first vaccination/challenge experiment 
against the two vaccine strains Nigeria/75 and Sungri/96. Five goats were vaccinated with Sungri/96, 
five goats were vaccinated with Nigeria/75/1 and two goats were left unvaccinated, all animals were 
infected with PPRV/Cote d’Ivoire/89 four weeks later. Serum was obtained on the time points 
indicated. PPRV neutralising antibody titres were calculated using an adaptation of the Spearman-
Kaber equation. Shown are the titres of Sungri vaccinates against the Nigeria/75/1 virus (A), Sungri 
vaccinates against the Sungri/96 virus (B), Nigeria vaccinates against the Nigeria/75/1 virus (C), Nigeria 
vaccinates against the Sungri/96 virus (D), unvaccinated controls against Nigeria/75/1 virus (E) and 
unvaccinated controls against the Sungri/96 virus (F). Sungri/96 vaccinates are shown in blue, 
Nigeria/75/1 vaccinates are green and the unvaccinated goats are in black, the point of challenge is 
indicated by the red line. 
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Sera from the same experiment were assayed against the lineage I challenge strain PPRV/Cote 
d’Ivoire/89. All sera from vaccinated goats were able to neutralise PPRV/Cote d’Ivoire/89 to some 
extent by 14dpv with all vaccinates generating a titre of > 1/10 (Figure 4.3A and B). One of five 
Sungri/96 vaccinates (C2) had a high titre against this lineage I virus of 1/3631 which was statistically 
significant to the other vaccinates (p = 0.002), the other four animals in the group had titres of 
between 1/16 and 1/364 (Figure 4.3A). The Nigeria/75/1 vaccinates appeared to have higher titres, 
but there was no statistical significance between the two vaccine groups (Figure 4.3B). A ‘boosting’ of 
neutralising titres following challenge was not observed in either vaccine group (Figure 4.3A and B). 
The unvaccinated controls had no neutralising antibodies at 7dpc/35dpv, but the remaining animal 
had a neutralising titre of 1/5128 14dpc/42dpv (Figure 4.3C). 
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Figure 4.3 Virus neutralisation assay titres against the lineage I field strain PPRV/Cote 
d’Ivoire/89. Five animals were vaccinated with Sungri/96, five animals were vaccinated with 
Nigeria/75/1 and two animals were left unvaccinated. Serum was obtained at the time points 
indicated. Shown are the titres of Sungri/96 vaccinates (A) Nigeria/75 vaccinates (B) and 
unvaccinated goats (C) against the PPRV/Cote d’Ivoire/89 virus. PPRV neutralising antibody titres 
were calculated using a modified Spearman-Kaber equation. Sungri/96 vaccinates are shown in 
blue, Nigeria/75/1 vaccinates are green and the unvaccinated goats are in black, the day of 
challenge is indicated by the red vertical line. 
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In the next experiment (challenge with the lineage III field strain PPRV/Sudan/Sennar/72), sera were 
obtained from all animals every seven days following vaccination. As in the previous study, in general, 
the homologous neutralisation titres of Sungri/96 vaccinates against PPRV/Sungri/96 virus were 
similar to those directed against Nigeria/75/1 (Figure 4.4A and B), apart from animal S4 which had an 
unusually high neutralising titre of 1/1445 at 21dpv (Figure 4.4B). In contrast, the homologous 
neutralising titres of Nigeria/75/1 vaccinates against the virus PPRV/Nigeria/75/1 were significantly 
higher with titres of 1/1445 in 3/5 goats at 14 and 21dpv by ANOVA (p = 0.000) (Figure 4.4C). The 
heterologous titres of the Nigeria/75/1 vaccinates’ serum against PPRV/Sungri/96 were not as high as 
the homologous titres (Figure 4.4D) and were similar to the titres of the Sungri/96 vaccinates against 
either virus. Neither of the mock vaccinated goats had neutralising antibodies 7dpc/35dpv, but by 
14dpc/42dpv both mock vaccinated goats had detectable neutralising titres against both vaccine 
strains (Figure 4.4E and F). Both mock vaccinated goats developed a higher neutralising antibody titre 
against Nigeria/75/1 than Sungri/96. Goat S11 had higher titres against both viruses than S12 (Figure 
4.4E and F). Again, no increase in neutralising titres was observed in vaccinates following challenge. 
In summary, both vaccines can induce neutralising serum antibodies in goats that are capable of 
neutralising homologous and heterologous virus strains. In neutralisation assays it is apparent that 
vaccination with PPRV/Nigeria/75/1 generates higher titres of neutralising antibodies against the 
homologous virus, but titres against heterologous viruses are comparable to those induced by 
vaccination with Sungri/96. 
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Figure 4.4 Virus neutralisation test titres of serum from the PPRV/Sudan/Sennar/72 
vaccination/challenge experiment against the two vaccine strains Nigeria/75 and Sungri/96. 
Experiment was carried out as described previously in section 2.8. Sera were obtained from goats 
at the indicated times post-vaccination. PPRV neutralising antibody titres were calculated using a 
modified Spearman-Kaber equation. Shown are the titres of Sungri vaccinates against 
Nigeria/75/1 (A), Sungri vaccinates against Sungri/96 (B; n = 5 for all time points except 21dpv 
when n = 3 ), Nigeria vaccinates against Nigeria/75/1 (C), Nigeria vaccinates against Sungri/96 (D), 
mock vaccinated controls against Nigeria/75/1 (E) and mock vaccinated controls against 
Sungri/96 (F). Sungri/96 vaccinates are shown in blue, Nigeria/75/1 vaccinates are green and the 
mock vaccinated goats are in black, the day of challenge is indicated by the red vertical line. 
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4.3 T cell responses to PPRV vaccination and challenge 
Antibody production by B cells forms the humoral arm of the adaptive immune response whereas T 
cells form the cell-mediated arm. Assessing T cell responses to vaccination/infection typically requires 
ex vivo stimulation of T cells with specific antigen. To this end, during vaccination/challenge 
experiments, heparin-treated blood was obtained by venepuncture, the peripheral blood 
mononuclear cells (PBMCs) were isolated and stimulated with various PPRV-specific stimulants to 
elicit a recall response that could be detected either while fresh or after cryopreservation and later 
thawing. PBMCs were not obtained from animals in the Cote d’Ivoire/89 and Ghana/78 challenge 
experiments, so only antibody response data was available from these experiments. 
 
4.3.1 T cell assay selection and optimisation 
There are several assays that could be used to determine T cell responses elicited by vaccination of 
goats. The assays used in these experiments were chosen based on sensitivity, cost and ability to scale 
up to relative high-throughput. 
Lymphoproliferation in response to antigen-specific stimulation is one recognised outcome of T cell 
activation. There are several cellular dyes that enable flow cytometry-based proliferation assays. 
These assays are compatible with cell surface marker labelling enabling identification of specific 
cellular subsets undergoing proliferation. CellTrace violet (Thermo Scientific) was chosen for the trial 
of a flow cytometry-based proliferation dye and this was used in conjunction with anti-CD4-APC, anti-
CD8-AlexaFluor488 and a near-infrared live/dead stain. Initial experiments assessed the optimum 
period of antigen stimulation for CellTrace violet dye incorporation; the stimulation periods tested 
were four or five days before fixation and reading on the MACSQuant flow cytometer. The four day 
stimulation was chosen due to the higher cell viability (data not shown). Unfortunately, despite 
optimising the assay for cell viability, the CellTrace violet dye proliferation assay was not sensitive 
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enough to detect proliferation of lymphocyte subsets to specific PPRV crude antigens and peptides in 
vaccinated goats (data not shown).  
The more traditional method for detecting proliferation is by 3H thymidine-incorporation assay. This 
assay has been used successfully for detection of RPV-specific cellular proliferation (Lund et al., 2000, 
Holzer et al., 2016), and I sought to adapt the assay used by Holzer et al. to detect cellular proliferation 
of PBMCs from PPRV-exposed goats.  
Another way of determining anti-viral T cell responses is the detection of the production of type II 
interferon, IFN-γ. The anti-bovine IFN-γ mAb CC302 cross-reacts with goat IFN-γ and so can be used 
for either intracellular cytokine staining (ICS) or IFN-γ ELISPOT. The chosen assay to investigate IFN-γ 
production was ICS, due to the ability to also identify in which cells the IFN-γ was produced by labelling 
with anti-cell-surface molecule antibodies. In addition, the MACSQuant (Miltenyi Biotec) flow 
cytometer has a 96-well plate adapter that enables the analysis of fixed, labelled cells to be automated 
in a high-throughput manner. 
Having identified suitable assays to measure the CMI response to vaccination, it was necessary to 
identify appropriate control stimulants to use in the assays. The mitogen Concanavalin A (Con-A) was 
chosen as a positive control for the 3H thymidine proliferation assay. For the IFN-γ ICS assay, phorbol 
12-myristate 13-acetate (PMA) and ionomycin were originally used as a positive control and were very 
effective at stimulating IFN-γ production in PBMCs over a 4 hour stimulation period. However, to allow 
PPRV-specific antigen processing and presentation by professional antigen presenting cells (APCs) and 
maximum time for T cells to recognise and respond to presented antigen, an overnight incubation was 
adopted and PMA and ionomycin caused extensive cellular death over this extended incubation 
period. Pokeweed mitogen (PWM) was found to be a suitable replacement for a positive control for 
the IFN-γ ICS assay. 
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4.3.2 Evaluation of synthetic peptides representing PPRV haemagglutinin as T cell recall 
antigens 
Based on the predicted amino acid sequence of the haemagglutinin (H) protein of PPRV/Nigeira/75/1, 
a total of 120 15mer peptides were created with an overlap of 10 amino acids per peptide by the 
commercial company MIMOTOPES. The peptides were supplied lyophilised and were re-constituted 
in DMSO, then combined into three peptide pools 1-40 (pool A), 41-80 (pool B) and 81-120 (pool C). 
Using DMSO as a negative control, the peptide pools were investigated for their ability to stimulate T 
cell PPRV-specific responses by both 3H thymidine proliferation assay and IFN-γ ICS. Similar pools have 
been found to stimulate a detectable CMI response following vaccination of goats with a recombinant 
adenovirus expressing PPRV F or H (Herbert et al., 2014). 
Fresh PBMCs obtained from goats enrolled in a vaccination/challenge experiment carried out as 
detailed in Section 2.8 were incubated with DMSO or peptide pools for 18 hours, then the protein 
transport inhibitor BD Golgi Plug was added for an additional 6 hours. Cells were antibody labelled for 
the cell surface markers CD4 and CD8, fixed/permeabilised and labelled for intracellular IFN-γ. The 
percentages of CD4+IFN-γ+ lymphocytes from goats vaccinated with Sungri/96 stimulated with 
peptide pools B or C was not significantly different to the percentage CD4+IFN-γ+ lymphocytes in the 
presence of DMSO alone at any time point (Figure 4.5A). 
In a different vaccination/challenge experiment the peptide pools were used as a stimulant for the 
thymidine incorporation proliferation assay. In this pilot study, I again used only fresh cells for the 
analysis of proliferation to the PPRV-H peptide pools, PBMCs obtained from the time points 0 and 
35dpv were not analysed. None of the three peptide pools produced significantly greater mean counts 
per minute (c.p.m.) than the DMSO alone in cells from either the five Sungri/96 vaccinates (Figure 
4.6A) or the four Nigeria/75/1 vaccinates (Figure 4.6B). Neither of the two mock vaccinated goats 
responded to the peptide pools prior to challenge (Figure 4.6C). One of the two mock vaccinated goats 
responded to peptide pools A and B 14dpc/42dpv (Figure 4.6C). 
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Since 15mer peptides should be efficiently presented by APCs in circulating PBMCs, these findings 
suggest that the H protein does not represent an immunodominant T cell antigen in the context of live 
attenuated PPRV vaccination. 
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Figure 4.5 IFN-γ production by PBMCs stimulated with PPRV H peptides assessed by IFN-γ 
intracellular cytokine labelling. A vaccination/challenge experiment was performed as 
described in Section 2.8, PBMCs were purified from goat blood as described in section 2.1.2, 
plated at 1x107/ml and incubated with either DMSO or PPRV H peptide pools for 18 hours, 
then BD Golgi-Plug was added for a further 5 hours. Cells were labelled with anti-CD4-APC, 
anti-CD8-RPE, anti-IFN-γ-AlexaFluor488 and Live/Dead Aqua dead cell dye. Gating was 
performed as detailed in Figure 2.1, using FlowJo 10 (BD) software. Stimulations were 
performed in triplicate. Shown are the average percentage of CD4+IFN-γ+ cells for Sungri/96 
vaccinates (n=5; A) and Nigeria/75/1 vaccinates (n=5; B), CD8+IFN-γ+ cells for Sungri/96 
vaccinates (C) and Nigeria/75/1 vaccinates (D) and IFN-γ+ double negative cells for Sungri/96 
vaccinates (E) and Nigeria/75/1 vaccinates (F). DMSO is shown in black, peptide pool A is red, 
peptide pool B is brown and peptide pool C is orange, the day of challenge is a red vertical 
line. 
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4.3.3 Evaluation of crude antigen extract and live and heat-inactivated PPRV as recall T cell antigens 
Figure 4.6 Proliferation of PBMCs from PPRV-vaccinated goats stimulated with PPRV-H protein 
derived peptide pools assayed by H3 thymidine incorporation. Fresh PBMCs were purified from 
blood and stimulated for five days with DMSO or peptide pools, H3-thymidine was added for the 
last 20 hours, well contents were transferred onto glass filtermats and scintillation counting was 
performed using a Betacounter. Results are displayed as mean of all goats in a group; Sungri/96 
vaccinates (n = 5, A), Nigeria/75/1 vaccinates (n=4, B) and mock vaccinated goats (n=2, C). All 
stimulations were performed in quadruplicate. Error bars indicate standard deviation of goats in 
group. DMSO is shown in black, peptide pool A is red, peptide pool B is brown and peptide pool C 
is orange, the day of challenge is indicated by the red vertical line. 
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Due to the disappointing results when using PPRV peptide pools, alternative stimulatory antigens for 
CMI assays were investigated. In previous studies conducted at The Pirbright Institute a crude antigen 
preparation, based on the preparation used for the cELISA (Anderson et al., 1990), was used 
successfully to stimulate RPV-specific proliferation of PBMCs ? (Holzer et al., 2016); therefore similar 
crude antigen preparations were generated for both PPRV vaccine strains and utilised in both the 
proliferation and IFN-γ ICS assays.   
Live virus induces antiviral responses in immune cells via multiple pathways due to the presence of 
pathogen-associated molecular patterns (PAMPs). IFN-γ is produced on recognition of viral PAMPs 
and therefore addition of live virus to PBMCs should induce IFN-γ production in the cells, especially if 
the cells recognise the virus and a memory response is triggered. 
Due to concerns about the combination of live PPRV and radioactive isotopes, live virus was ruled out 
as a stimulant for the 3H thymidine-incorporation proliferation assay. Tu and colleagues used 
ultraviolet (UV) light to inactivate measles virus for use in 3H thymidine-incorporation proliferation 
assays (Tu, 1995). Due to the difficulties in purifying the pleomorphic PPRV virus particles, UV light 
may not inactivate the virus due to other debris being present in the preparation and causing 
aggregates that may shield the virus from the UV light. It was therefore decided that heat-inactivating 
at 56°C for two hours should be used instead to ensure no live virus remained in the preparation. 
The combination of these three stimulatory antigens for the IFN-γ ICS and 3H thymidine-incorporation 
assay enabled me to assess the PPRV-specific CMI in vaccinated goats. 
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4.3.4 Proliferative responses of PBMCs to PPRV antigens following vaccination 
Due to the limited yield of antigen from PPRV-infected flasks, several different batches of antigen, live 
virus and heat inactivated virus were used for completion of these assays (Table 4.1). Statistical 
analysis in Minitab found no statistical difference in the mean c.p.m. due to different PPRV-derived 
antigen batches. 
Irrespective of whether the challenge strain used in any vaccination/ challenge study was virulent or 
mild, PBMCs obtained from the blood of the vaccinates could still provide data on vaccination-induced 
responses. Proliferation assays were performed on cells from three vaccination/challenge studies. I 
will consider the data from each study separately before summarising my findings from this assay. 
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Table 4.1 Table of PPRV antigen batches and experiments 
Antigen Virus titre Assay Vaccination/ Challenge 
experiment 
PPRV/Nigeria/75/1 live 
virus A 
106.8 TCID50/ml IFN-γ ICS Sudan/Sennar/72 
challenge 
PPRV/Sungri/96 live virus 
B 
106.97 TCID50/ml IFN-γ ICS 
PPRV/Nigeria/75/1 live 
virus C 
105.13 TCID50/ml IFN-γ ICS CD8 depletion (see 
Chapter 5) 
PPRV/Sungri/96 live virus 
D 
105.97 TCID50/ml IFN-γ ICS 
PPRV/Nigeria/75/1 heat-
inactivated virus A 
N/K3 Proliferation 
assay 
Nigeria/76 challenge 
PPRV/Sungri/96 heat-
inactivated virus B 
N/K Proliferation 
assay 
PPRV/Nigeria/75/1 heat-
inactivated virus C 
N/K Proliferation 
assay 
Sudan/Sennar/72 
challenge 
PPRV/Sungri/96 heat-
inactivated virus D 
N/K Proliferation 
assay 
PPRV/Nigeria/75/1 heat-
inactivated virus E 
N/K Proliferation 
assay 
Kurdistan/2011 
challenge and CD8 
depletion (see chapter 5) 
PPRV/Sungri/96 heat-
inactivated virus F 
N/K Proliferation 
assay 
Antigen batch ‘A’ N/K IFN-γ ICS and 
Proliferation 
assay 
Nigeria/76 and 
Sudan/Sennar/72 
challenge  
Antigen batch ‘B’ N/K IFN-γ ICS  and 
Proliferation 
assay 
Kurdistan/2011 
challenge and CD8 
depletion 
 
  
                                                          
3 N/K not known 
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4.3.4.1 Assessment of T cell proliferative responses in PPRV/Nigeria/76 (lineage II) – 
vaccination/challenge experiment 2 
One Nigeria/75/1 vaccinate was not assayed due to systemic bacterial infection and euthanasia on 
ethical grounds, this resulted in five Sungri/96 vaccinates, four Nigeria/75/1 vaccinates and two mock-
vaccinated goats. The data for 35dpv was obtained from cryopreserved cells. Both vaccines stimulated 
PPRV-specific proliferation, however the mean c.p.m. for the PBMCs of the Sungri/96 vaccinates was 
statistically significantly different to the mean c.p.m. of the Nigeria/75/1 vaccinates and controls by 
ANOVA (p < 0.000) (Figure 4.7E). The greatest stimulation indices are seen at 28dpv in response to 
both of the heat inactivated viruses (Figure 4.7A). At 35dpv the Sungri/96 vaccinates have high cpm 
to both mock and PPRV-specific stimulants resulting in low stimulation indexes at this time point 
(Figure 4.7A and D). PBMCs from both mock-vaccinated goats proliferated in a PPRV-specific response 
14dpc/42dpv (Figure 4.7F). 
 
4.3.4.2 PPRV/Sudan/Sennar/72 (lineage III) – vaccination/challenge experiment 4 
In the fourth vaccination/challenge experiment, for reasons that are not clear the proliferation in 
response to stimulation with heat inactivated PPRV/Sungri/96 virus is low (Figure 4.8). On the other 
hand, the responses to the other antigens were better and more consistent than the previous 
experiment. Overall, a similar result was seen in this experiment as in the previous. In this experiment 
there was no statistical difference in the mean c.p.m. between the two vaccine groups by ANOVA (p 
= 0.094). The PBMCs from the Sungri/96 vaccinates proliferated strongly when stimulated by either 
the Nigeria/75/1 or Sungri/96 antigens, and also the heat inactivated PPRV Nigeria/75/1 (Figure 4.8A 
and D). The Nigeria/75/1 vaccinates’ PBMCs also proliferated in response to both of the antigens and 
heat inactivated PPRV/Nigeria/75/1 (Figure 4.8B and E). The Stimulation Index (SI) for both groups of 
vaccinated goats decreases from 14dpv to 28dpv, and a slight boosting effect is evident following 
challenge (Figure 4.8A and B). Again, the proliferation SI, indicating the CMI response in Sungri/96 
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vaccinates was stronger than for the Nigeria/75/1 group (Figure 4.8A and B). PBMCs obtained from 
one mock vaccinated goat demonstrated non-specific proliferation to most antigens (including control 
antigens) at 21dpv, but this did not result in a stimulation index above background (Figure 4.8C and 
F). Both of the control goats responded in a PPRV-specific manner to antigens and heat-inactivated 
virus 14dpc/42dpv (Figure 4.8C and F). 
 
4.3.4.3 PPRV/Kurdistan/2011 (lineage IV) – vaccination/challenge experiment 5 
All time points for the proliferation assays for this group were performed on cryopreserved cells; data 
is not available from 35dpv and both unvaccinated controls had been euthanised before 14dpc/42dpv, 
so there is no data from this group for this time point. Again, both groups of vaccinates show a clear 
PPRV-specific proliferative response to PPRV antigens (Figure 4.9D and E). Both groups of vaccinates 
responded to both homologous and heterologous antigen with no statistical difference (p = 0.051). 
The response to both heat-inactivated viruses are low in this experiment (Figure 4.9D and E). Neither 
of the two unvaccinated controls proliferated in response to antigens or heat inactivated virus prior 
to challenge (Figure 4.9C and F). 
  
Figure 4.7 Proliferation of PBMCs from PPRV-vaccinated goats in response to PPRV-derived antigen and heat inactivated virus for experiment 2, Nigeria/76. 
All data from fresh cells except 35dpv, which was performed on cryopreserved cells. PBMCs were purified from blood and stimulated in quadruplicate for five 
days. Shown are the mean stimulation indices (SI) for Sungri/96 vaccinates (A), Nigeria vaccinates (B) and mock vaccinated goats (C) and the mean cpm for 
Sungri/96 vaccinates (D), Nigeria vaccinates (E) and mock vaccinated animals (F). Error bars indicate standard deviation of goats in group, challenge is indicated 
by the vertical dotted red line. 
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Figure 4.8 Proliferation of PBMCs from PPRV-vaccinated goats in response to PPRV-derived antigen and heat inactivated virus for experiment 4, 
Sudan/Sennar/72. All assays were performed using fresh cells and stimulations were performed in quadruplicate. Shown are the mean stimulation indices 
for Sungri/96 vaccinates (A), Nigeria vaccinates (B) and mock vaccinated goats (C) and the mean counts per minute for Sungri/96 vaccinates (D), Nigeria 
vaccinates (E) and mock vaccinated animals (F). Error bars indicate standard deviation of goats in group, challenge is indicated by the dotted red line. 
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Figure 4.9 Proliferation of PBMCs from PPRV-vaccinated goats in response to PPRV-derived antigen and heat inactivated virus for experiment 5, 
Kurdistan/2011. Five goats were vaccinated with Sungri/96, five with Nigeria/75/1 and two were left unvaccinated, 28 days later all animals were 
challenged with the field strain PPRV/Kurdistan/2011. All assays were performed on cryopreserved cells and stimulations were performed in 
quadruplicate. Shown are the mean stimulation indices (SI) for Sungri vaccinates (A), Nigeria vaccinates (B) and mock vaccinated goats (C) and the mean 
counts per minute for Sungri vaccinates (D), Nigeria vaccinates (E) and mock vaccinated animals (F). Error bars indicate standard deviation of goats in 
group, challenge is indicated by dotted red line. 
4.3.4.4 Summary 
Overall, from the 3H thymidine-incorporation assay from these three experiments it is clear that both 
vaccines can induce PPRV-specific T cell proliferative responses. It would appear that vaccination with 
Sungri/96 vaccine produces better proliferative responses than vaccination with Nigeria/75/1. The 
PBMCs from both vaccination groups responded better to the crude antigen preparation than to the 
heat inactivated virus. 
 
4.3.5 T cell IFN-γ responses to PPRV antigens following vaccination 
Using the anti-CD4 and anti-mAbs it was possible to identify cells that are CD4+, CD8+ and CD4-CD8-. 
Whilst a large proportion of the lymphocytes will be CD4-CD8- the NK cells and γδ-T cells will be in this 
population, therefore the data from this population was graphed in case these cells are also producing 
IFN-γ in response to antigen stimulation. This assay was only carried out on PBMCs prepared during 
vaccination/challenge experiment 4 (PPRV/Sudan/Sennar/72). The gating strategy for IFN-γ+ cell 
populations was performed as detailed in Figure 2.1. The results are given as the percent of live cells 
that were CD4+IFN-γ+ (Figure 4.10A, D and G), CD8+IFN-γ+ (Figure 4.10B, E and H) or CD4-CD8-IFN-γ+ 
(Figure 4.10C, F and I). Cells were stimulated with either crude antigen (as used in the 3H thymidine 
incorporation assays) or tissue culture supernatant containing live PPRV. Again, both Nigeria/75 and 
Sungri/96 PPRV vaccine strains were used as stimulation antigens. As seen in the proliferation assays, 
PPRV-specific responses were not detected 7dpv for either vaccine group (Figure 4.10). CD4+ T cells 
from the Sungri/96 vaccinates responded to both PPRV-specific antigens and live virus at 14dpv (Figure 
4.10A, B and C). The percentages of responding CD4+ cells reduced at 21dpv and then remained 
steady, with a slight boost at 42dpv (Figure 4.10A). Unlike the high percentage of IFN-γ+ CD4+ T cells 
seen in the Sungri/96 vaccinates, the percentage of CD4+IFN-γ+ cells in Nigeria/75 vaccinates were 
low and not particularly distinguishable from responses to control antigens (Figure 4.10D). In contrast 
both sets of vaccinates showed a marked increase in the percentage of CD8+IFN-γ+ cells in response 
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to live virus stimulation from 14dpv. CD8+ cells were not stimulated by the crude antigens (Figure 
4.10E). The percentage CD4+IFN-γ+ cells in response to PPRV-specific stimulation in the mock-
vaccinated goats was not above mock stimulation, except at 14dpc/42dpv (Figure 4.10G). These 
animals showed no induction of PPRV-specific CD8+ T lymphocytes 14dpc/42dpv (Figure 4.10H). The 
highest percentages of CD4-CD8-IFN-γ+ cells in the Sungri/96 vaccinate group were in response to 
stimulation with live PPRV/Sungri/96 virus, but responses were transient (Figure 4.10C). Neither the 
PPRV live virus nor the antigen generated higher percentages of IFN-γ+ cells per well that were CD4-
CD8- in either of the mock vaccinated goats (Figure 4.10I). 
Example CD4+ and CD8+ IFN-γ+ T cell dot plots for days 7, 14 and 42 for one animal from each treatment 
group, generated in the FlowJo 10 (BD) software, are shown in Figure 4.11. 
  
 Figure 4.10 Percentages of IFN-gamma positive CD4+, CD8+ and CD4-CD8- cells following stimulation 
with PPRV-specific antigen or live virus. Blood was obtained on the days indicated, PBMCs were 
isolated from blood as described in Section 2.6.2. PBMCs were stimulated in triplicate with crude 
antigen preparations  or live virus for 18 hours, then BD Golgi Plug was added for a further 6 hours. T 
cell subsets were identified by external labelling of membrane proteins prior to 
fixation/permeabilisation and intracellular staining for IFN-γ.  Stained cells were suspended in 200µl 
analysed on the MACSQuant flow cytometer, taking up a fixed volume of 150µl per well. All data 
displayed were acquired from fresh cells. Shown are the mean data  for Sungri/96 vaccinates’ (n=5) 
percentages of IFN-γ+ CD4+ cells (A), CD8+ cells (B) and CD4-CD8- (C); the Nigeria/75/1 vaccinates’ 
(n=5) IFN-γ+ percentages of CD4+ cells (D), CD8+ cells (E) and CD4-CD8- (F); the mock vaccinated goats’ 
(n=2) percentage IFN-γ+ CD4+ cells (G), CD8+ cells (H) and CD4-CD8- cells (I). Challenge is indicated by 
the red dotted line.  
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Figure 4.11 Examples of representative flow cytometry dot plots of IFN-γ -producing CD4+ and 
CD8 T cells within live PPRV/Sungri/96-stimulated PBMCs.  Cells have previously been gated on 
single cells, lymphocytes, live cells and CD4+ or CD8+ labelling. Displayed is the forward scatter vs 
IFN-γ+ cells. One animal from each vaccine group is used as a representative for the group. In 
some animals a low AlexaFlour488 signal was evident in the cells after compensation, this was 
gated out as ‘artefact’. The top nine plots are CD4+ cells, the bottom nine plots are CD8+. Dot 
plots are displayed for 7, 14 and 42dpv. Plots were generated in FlowJo 10 (BD). 
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4.4 Discussion 
In this chapter the antibody and T cell responses of PPRV-vaccinated goats were assessed at different 
time points post-vaccination. Using two different assays to investigate the antibody immune response 
to vaccination, I found that the two vaccines, Sungri/96 and Nigeria/75/1, elicited very similar PPRV-
N specific antibody responses as measured by percentage inhibitions of the anti-PPRV-N mAb in the 
cELISA, but had different neutralising Ab titres towards the respective homologous PPRV strain. Both 
vaccines were effective at stimulating PPRV-specific T cells that would proliferate in response to PPRV-
derived recall antigens. Whilst the PPRV/Nigeria/75/1 vaccine appeared to be superior at eliciting 
neutralising antibodies (particularly against its homologous strain), the Sungri/96 strain seemed to be 
better at inducing measured T cell responses, particularly PPRV-specific CD4+ cells, as seen both in the 
proliferation assay (generally higher SI in Sungri/96 vaccinated goats) and in the IFN-γ assay. 
Although the PPRV N-protein is the most abundantly produced viral protein in infected cells, and is 
immunogenic, it is not believed that antibody responses against the protein are protective since they 
are non-neutralising (Ohishi et al., 1999). Due to its immunogenicity, antibodies against the PPRV N-
protein are a reliable diagnostic determinant of infection, forming the basis for the cELISA. Performing 
the cELISA on sera obtained over time following vaccination gives an indication of the speed of 
seroconversion of vaccinates. In this chapter it was observed that Nigeria/75/1 vaccinates had higher 
cELISA percentage inhibitions than Sungri/96 vaccinates 7dpv. This could indicate faster 
seroconversion with Nigeria/75/1 vaccination, however from 14dpv Sungri/96 and Nigeria/75/1 
vaccinates had sera with similar percentage inhibitions, demonstrating that the two vaccines were 
equally capable of stimulating seroconversion in vaccinates. In these studies seroconversion following 
virulent challenge was faster than following vaccination, with percentage inhibition values of 80% at 
7dpc in all surviving unvaccinated goats and lower values of between 0-70% 7dpv at the same time 
point for the vaccinates. 
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Virus neutralisation tests (VNTs) give an indication of the levels of neutralising antibodies present in 
serum, not just the presence of anti-PPRV antibodies. In this chapter, from the experiments where 
VNT data were available, it is clear that vaccination with PPRV/Nigeria/75/1 gave rise to high titre 
neutralising antibodies directed against Nigeria/75/1-specific domains. The data suggested that 
antibodies were directed against conserved neutralising epitopes, since sera from all vaccinates were 
effective at neutralising both Sungri/96 and Ivory Coast isolates to similar levels. When other 
researchers have performed VNTs to assess neutralising titres they have only looked at homologous 
virus neutralisation. To my knowledge, this is the first time serum from PPRV vaccinated animals has 
been assayed for its ability to neutralise PPRV virus strains from multiple genetic lineages. 
The 3H thymidine-incorporation proliferation assay is a crude assay for determining proliferation of T 
cells to specific antigens, giving the overall proliferation of PBMCs, not specific populations. Due to 
the hazards of working with radioactive isotypes it would be preferable to use an alternative assay 
that does not require the use of tritiated thymidine. There are alternative, flow cytometry-based, 
proliferation assays that are able to identify which specific cellular populations are proliferating 
without the added risks associated with radioisotopes in the laboratory. I did try the CellTrace dye as 
an alternative proliferation assay but found it was not as sensitive as 3H thymidine at identifying PPRV-
specific proliferation of PBMCs in my hands. From the three experiments from which proliferation 
data is available it is evident that lymphoproliferative responses were variable between goats, which 
may reflect the outbred nature of the animals. However the Sungri/96 vaccine seemed better than 
Nigeria/75 at inducing PPRV-specific proliferation. This underlying reasons remain to be elucidated 
but may reflect differences in attenuation between the two strains could influence the induction of T 
cell responses.  
PPRV-H peptides had previously been used as antigen to assess T cell responses of goats following 
vaccination with recombinant adenovirus expressing PPRV-H (Herbert et al., 2014). Surprisingly, these 
peptides did not stimulate T cell responses as assessed by IFN-γ ICS or the CellTrace violet or 3H 
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thymidine proliferation assays. The overlapping pentadecamer peptides used should require minimal 
processing by antigen presenting cells (APCs) before loading onto MHC class I and II to present to T-
cells. It is therefore unlikely that the incubation period of the IFN-γ ICS assay was too short to enable 
cells to produce IFN-γ in response to peptide stimulation. The incubation period for proliferation 
assays was 4-5 days but PPRV-specific responses to the peptide pools were still not seen. However, 
there was evidence of increased cell death in the DMSO only and peptide wells compared to medium 
only and antigens, suggesting that the DMSO solvent was causing cell death and any proliferation to 
the peptides may have been masked by the low surviving numbers of PBMCs at the end of the 
incubation period. Also, due to spurious responses of CD8+ cells obtained from time points that should 
not have recall responses to PPRV-specific (specifically 0dpv) the peptides were subsequently 
removed from the panel of PPRV-specific stimulants for T cell responses. I speculate that in the context 
of live attenuated PPRV vaccination, the H protein is not an immunodominant antigen and responses 
observed against crude and live/HI virus are being directed against alternative antigens, which remain 
to be elucidated. 
Multiple antigens were assessed for the IFN-γ intracellular cytokine staining (ICS) assay, but by far the 
most successful stimulant for PPRV-specific IFN-γ production was live PPR virus. Both vaccines induced 
CD8+IFN-γ+ cells in response to live virus. These data suggest efficient processing of antigen into the 
MHC class I presentation pathway. This is suggestive that PPRSV is infecting cells within the PBMC 
population and it would be interesting to explore whether this is indeed the case and which cells are 
infected. It would appear from the data presented in this chapter that the vaccine Sungri/96 is better 
than the vaccine Nigeria/75/1 at stimulating IFN-γ recall production in CD4+ T cells. These CD4+ cells 
most likely represent the difference in the proliferation assay data between Sungri/96 and Nigeria/75 
vaccinates. 
In Chapter 3 both vaccines were demonstrated to protect against clinical disease, In these assays, it 
has been demonstrated that they both induce antibody and T cell immune responses. 
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Given that the PPRV vaccines clearly elicit both B cell and T cell responses, and that nothing is known 
about the relative importance of these responses in protection, it would be interesting to investigate 
the role of lymphocytes subsets in vaccine-induced protection in more detail. 
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Chapter 5 – In vivo depletion of CD8+ T cells in goats does not abrogate 
vaccine-induced protection against virulent PPRV challenge 
 
5.1 Introduction 
In the previous chapter it was observed that vaccination with live attenuated PPRV vaccines generates 
both antibody and T cell responses while protecting goats against challenge with virulent PPRV strains 
from all four lineages. However, the relative contribution of each arm of the adaptive immune 
response to the observed vaccine-induced protection is unknown. This project therefore aimed to 
further elucidate if CD8+ T cells play a significant role in protecting vaccinated goats from subsequent 
infection and/or clinical disease manifestation following challenge with virulent PPRV. This 
information would inform the design of future DIVA-compatible PPRV vaccines, such as recombinant 
viral vectored vaccines, giving a clearer indication of whether priming of cytotoxic T cells is needed.  
Measles virus (MeV), RPV and PPRV are closely related morbilliviruses (Gibbs et al., 1979) and despite 
infecting different host species, these viruses are thought to share similarities in replication strategies, 
transmission pathways and potentially also in the induction of respective host immune responses. 
Experimental depletion of CD8+ T cells in Rhesus macaques and subsequent primary infection with 
MeV resulted in a more pronounced and longer duration of maculopapular rash, higher peak and 
longer duration of viraemia, in comparison with control animals (Permar et al., 2003). This 
demonstrates that CD8+ T cells play a crucial role in the control of primary MeV infection. However, 
the immune responses required for clearance of primary infection are not necessarily the same as 
those required for vaccine-induced protection from infection. For instance, research in macaques 
where Edmonston-Zagreb live MeV vaccine was delivered via a nebulizer, found that the vaccination 
had primed a T-cell response but not a neutralising antibody response. These animals were not 
protected against disease following virulent MeV challenge and developed rash and viraemia 
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consistent with the unvaccinated controls, but were able to more rapidly clear MeV RNA from the 
blood than the controls (Lin et al., 2014). Another experiment by the same group showed that 
following immunisation with a DNA vaccine, neutralising antibody titres and not memory cytotoxic T 
lymphocytes correlated with vaccine-induced protection against virulent MeV challenge (Polack et al., 
2000). However, research by Bassiri and colleagues utilising a baculovirus-expressed RPV subunit F or 
H protein as a vaccines in cattle found that seven out of ten vaccinated animals were unprotected 
against clinical rinderpest on challenge, despite having detectable serum neutralising antibody titres 
(Bassiri et al., 1993). Hence, the relative importance of vaccine induced cell-mediated and antibody-
mediated immune responses in protecting hosts against morbillivirus infection are still not fully 
understood.  
In vivo depletion of T cell subsets has been previously performed in ruminants such as cattle (Bruce et 
al., 1999, Carr et al., 2013) and sheep (Eriksson et al., 1999a, Eriksson et al., 1999b) to determine the 
role of these cells during viral infection. To deplete cell subsets in vivo in ruminants it has been 
reported that a complement activating murine monoclonal antibody (mAb) specific for a cell subset 
specific receptor is required (Naessens et al., 1998). While murine mAbs of the IgG1 isotype will only 
coat respective target cells, they are unable to fix complement and the cells remain viable and 
continue to circulate (Naessens et al., 1998). In contrast, appropriate murine IgG2a mAbs will bind to 
target cells and cause a rapid depletion by a complement-mediated mechanism, which will 
subsequently be targeted for degradation by phagocytic immune cells. Cytotoxic CD8+ T cells are 
specifically important in the clearance of primary viral infection and have been postulated to also play 
an important part in the protection against re-infection of some viral pathogens.  
A mAb that has been used for depletion of CD8+ T cells in cattle is CC63 (Bruce et al., 1999). CC63 
antibody cross-reacts to recognise goat CD8 T cells but its ability to deplete caprine cells in vivo has 
not been reported previously.  The anti-bovine CD4 murine IgG2a mAb CC8 does not cross-react with 
sheep or goat PBMCs and The Pirbright Institute did not have access to an alternative cross-reactive 
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anti-CD4 mAb at the time of the research, therefore CD4 T cell depletion could not be attempted in 
these experiments. 
The aim of this chapter was to further elucidate if CD8 T cells are an important part of the immune 
response induced by PPRV vaccination, which subsequently protects vaccinated animals from 
challenge with virulent PPRV. This was achieved by using mAb-treatment to deplete CD8 T cells from 
previously vaccinated goats at the time of PPRV challenge and comparing the respective clinical and 
virological protection to a control group comparably treated with an irrelevant yet isotype matched 
mAb. A pilot study was carried out to confirm that CD8 T cells can be depleted in goats in vivo by 
inoculation with CC63 mAb and to determine the treatment regime resulting in optimal CD8 depletion.  
5.2 Pilot trial to assess in vivo CD8+ T cell depletion in goats 
Initially, it was necessary to determine the most effective mAb inoculation protocol for in vivo 
depletion of CD8+ T lymphocytes in goats using the murine IgG2a anti-bovine CD8α mAb, CC63 and 
confirm depletion of this cell subset from the circulatory system in goats. Therefore, a pilot study was 
designed to compare the efficiency of CD8 T cell depletion in goats using two dosing regimens of the 
mAb. Bulk CC63 hybridoma supernatants were produced by the staff of Central Services Unit at The 
Pirbright Institute, and mAb was purified and quantified in house (see section 2.2.2). Two mAb 
administration protocols were designed as a ‘low, long dose’ consisting of 2mg CC63/day for nine days 
(goats T1 and T2; Figure 5.1), and a ‘high, short dose’ consisting of four days of injections, starting at 
2mg/day on the first day and increasing to 20mg/day on subsequent three days, resulting in an overall 
dose of 2.1mg/kg (goats T3 and T4; Figure 5.1). For both groups the initial mAb administration of 2mg 
on day 0 was further divided into two inoculations (0.5 and 1.5 mg respectively), a few hours apart.    
Prior to injection of mAb goats were prophylactically treated with the anti-inflammatory drug 
Finadyne at 2.2mg flunixin/kg bodyweight. After the second and third mAb injections, all four goats 
developed dyspnoea for several minutes before recovery. Goats in the ‘high, short dose’ group did not 
respond to the mAb injections after the second day. Animals receiving the ‘low, long dose’ continued 
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to display transient signs of respiratory discomfort after every mAb injection throughout their course 
of treatment. 
Antibody labelling of lymphocyte cell surface molecules was performed in whole EDTA blood as 
described previously (see section 2.5), using a combination of directly-conjugated antibodies 
recognising the cell surface membrane proteins CD4, CD8 and WC1 and counting beads for cell 
enumeration (Figure 5.2A, B, C and D). On day 1 of the experiment the total numbers of CD8+ T cells 
per ml had already reduced in all goats compared to values obtained on day 0 (Figure 5.2). The 
numbers of CD8 T cells reduced further over subsequent study days in all goats however differences 
in absolute CD8 T cell numbers were observed between the individuals of the two inoculation regimes 
as is evident in the percentage CD8+ cells by flow cytometry for each animal on day 3 (Figure 5.2A, B, 
C and D). Low numbers of CD8 T cells (50% of the original numbers of CD8 T cells in goat T1) were still 
detectable in goats T1 and T2 of the “low, long dose” group on days 2-4 (Figure 5.2E and F), however, 
numbers of CD8 T cells were very low (0.03% of the original numbers of CD8 T cells in goat T3) in the 
blood of individuals T3 and T4 of the “high, short dose” group for at least 4 days (Figure 5.2G and H) 
Over the first four days of the depletion, the numbers of CD4 T cells increased in both groups (Figure 
5.2E, F, G and H), but the numbers in the two remaining animals had returned to similar levels to day 
0 by day 10 of the experiment. Initially, the numbers of WC1+ cells doubled in all four animals, but by 
day 10 of the experiment the numbers of WC1+ cells had dropped to 35% of the day 0 numbers (T2, 
Figure 5.2F) and 73% of day 0 numbers (T4, Figure 5.2H). 
The ‘high, short dose’ of CC63 seemed the more effective dosing regimen as both goats in this group 
had depleted CD8 T cells for a period of four days (Figure 5.2G and H) in comparison with the ‘low, 
long dose’ group that still had 4.5x105 CD8+ cells/ml EDTA blood throughout the protocol (Figure 5.2E 
and F). For example by day 3 of the experiment the CD8+ lymphocytes were clearly still detectable by 
flow cytometry at ~ 4% or 1.5% of total lymphocytes for goats T1 and T2 respectively (Figure 5.2A and 
B) while completely absent in goats T3 and T4 (Figure 5.2C and D).  
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Figure 5.1 Experimental outline of pilot trial of in vivo CD8 T cell depletion in goats.  A small scale 
pilot study was carried out to determine the respective efficiency of CD8+ T lymphocyte depletion in 
goats by inoculation of cross-reactive anti-bovine CD8 mAb CC63 comparing two different dosage 
protocols. Two animals (T1 and T2; brown) in the ‘low, long dose’ were given 2mg daily for nine days 
whilst the other group (T3 and T4; brown) were given a ‘high, short dose’ by administering a total of 
2.1mg mAb/kg distributed over 4 days. On the first day of depletion all four goats were initially 
intravenously injected with 0.5mg CC63, followed by another dose of 1.5mg of CC63 later the same 
day. After the initial dosing on day 0 further CC63 was administered to respective goats on subsequent 
days according to their treatment protocol. Blood samples were taken every 1-2 days to quantify CD8 
T cell numbers in whole blood and compare the respective efficiency of depletion obtained by the 
different mAb treatment regimes. One goat from each regime was culled on day 4 of the study to 
cryopreserve lymphatic organs for potential future immunofluorescence microscopy while the two 
remaining goats were euthanized on day 10 of the study. 
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Figure 5.2 Numbers of CD4+, CD8+ and WC1+ T cells quantified within circulating blood of goats 
following in vivo treatment with different dosing regimens of mAb specific to ovine CD8. EDTA-
treated blood was obtained every 1-2 days and labelled to determine respective CD8, CD4 and WC1+ 
γδ T cell numbers in circulation. Cell numbers were determined by external labelling of respective 
membrane proteins with fluoresent-conjugated mAbs, subsequently detected by flow cytometry. 
Event collection was standardised by gating on a fixed number of  eBioscience 123count eBeads added 
to each samples (see section 2.5) and data were analysed in FlowJo v10 software. Representative plots 
from the FlowJo software for each of the animals T1, T2, T3 and T4 are displayed in A, B, C and D 
respectively. Calculated specific cell subset numbers are presented as mean +/- SD of three technical 
replicates for the two goats of the “low long dose” (panels E and F) and two goats of the “high, short 
dose” inoculation regime (G and H)  . The brown bars represent the ‘low, long dose’ (E & F) period of 
administration of i.v. mAb, while the purple bars represent the ‘high, short dose’ (G & H) period of 
administration of i.v. mAb.  
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5.3 In vivo depletion of CD8+ T cells in goats previously vaccinated with live 
attenuated PPRV Sungri/96 and the effects on challenge with a virulent strain of 
PPRV  
Having identified a dosing regimen that completely depleted circulating CD8+ T cells in in vivo in goats, 
a vaccination/depletion/challenge experiment was designed to investigate the role memory CD8+ T 
cells play in vaccine-induced protection against PPRV (Figure 5.3). Ten goats were vaccinated with 
2x104 TCID50 of the commercially available, genetic lineage IV, live attenuated vaccine Sungri/96, as 
previously described in chapter 4, and 5 goats each were randomly assigned to the “CD8 depletion” 
or “mock depletion” group. In accordance to previous vaccination/challenge experiments two goats 
were included as challenge control animals to confirm the severity of the PPRV field strain challenge 
and received an equal amount of a VDS-derived mock vaccine. To confirm that any potential reduction 
of clinical protection induced by vaccination in CD8+ T cell-depleted animals was due to the loss of 
these cells and not a response to the injection of murine mAb, goats in the mock-depletion group were 
inoculated with equal amounts of an isotype matched irrelevant control mAb TRT3 (specific to the to 
the Turkey Rhinotracheitis Virus). Vaccinated goats were inoculated with the respective mAbs daily 
between day 26 – 29 post vaccination as outlined in Figure 5.3.  All animals prophylactically received 
Finadyne at 2.2mg flunixin/kg bodyweight prior to every mAb inoculation. At 28 days post vaccination 
all goats, including the two mock-vaccinated challenge controls were inoculated with 1ml of 2x105/ml 
PPRV/Sudan/Senner/72. 
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Figure 5.3 Experimental protocol design for depleting CD8 T cells of PPRV vaccinated goats 
followed by virulent PPRV challenge to elucidate the role of CD8 T cells in vaccine conferred clinical 
protection. Ten goats were vaccinated with PPRV Sungri/96 on day 0 of the study and two goats 
were injected with a VDS-derived mock vaccine as challenge controls. Serum and heparinised blood 
for subsequent assays were obtained every seven days until the end of the experiment, 42 days 
post-vaccination. Twenty-six days after vaccination, the ten vaccinated goats were randomly 
separated into two groups – CD8 T cell depleted (dark purple) and mock depleted (light purple). 
Anti-CD8 mAb (CC63) or isotype-matched control mAb (TRT3) were administered intravenously at a 
final amount of 2mg/kg body weight distributed over 4 days.   The two mock vaccinated animals 
were left untreated. EDTA blood samples were taken twice prior to mAb treatment and every 1-2 
days following mAb inoculation until the end of the experiment. On day 28 post-vaccination (2 days 
following mAb injection) all 12 goats were given 2x105 TCID50 of PPRV/Sudan/Sennar/72. Treatment 
with mAbs was completed 29 days post-vaccination. On 42dpv/14dpc, all animals were euthanised 
and post-mortem examinations conducted. 
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5.3.1 Confirmation of CD8+ T cell depletion in the blood of goats inoculated with anti-CD8 
mAb  
Total numbers of CD8+, CD4+ or WC1+ T cells in the peripheral blood of goats inoculated with either 
anti-CD8 (CC63) or an isotype-matched control mAb were detected by a bead-based quantitative 
whole blood antibody labelling protocol, as described previously (Section 2.5). Representative dot 
plots of CD8+ labelled cells in blood obtained at 2dpc from a depleted goat and a mock depleted goat 
are included in Figure 5.5 for illustrative purposes.  
Commencing mAb inoculation at 2 days prior to challenge (-2dpc or 26dpv) a drop in CD8+ T cell 
numbers compared to previously determined baseline cell numbers was already apparent in all 
animals inoculated with anti-CD8 mAb at -1dpc following the initial inoculation of 2mg of mAb (see 
Figure 5.4E and F).  On the day of challenge CD8+ T cells in the blood of the goats that had been 
injected with CC63 were depleted from the circulation with an average of 850 cells/ml blood detected, 
compared to 2x106/ml at baseline (Figure 5.4E). To the contrary the goats that had been injected with 
the control antibody TRT3 still had between 1.8x106 CD8+ T cells/ml in the blood (Figure 5.4E). CD8 T 
cells remained depleted within the peripheral blood of all goats of the depletion group until 4dpc, 
returning to an average of 2x105/ml in these animals at 10 and 12dpc, still considerably lower than 
the original determined CD8+ T cell baseline until the end of the experiment. The CD8+ T cell numbers 
detected in goats of the mock depletion group remained fairly constant in 4 out of 5 animals for the 
duration of the experiment, while a drop in CD8 T cells to ~50% of the original baseline number was 
observed in animal D1 on 6 and 8dpc (Figure 5.4B). 
Prior to mAb injection, the average baseline of CD4+ T cells were 3.4x106/ml in the CD8-depleted 
group, following injections of CC63 the numbers of CD4+ T cells in the blood remained relatively stable 
and were 3.5x106/ml 0dpc (Figure 5.4C and D). This is also the case for the mock depleted goats that 
had slightly higher averages throughout, with a baseline of CD4+ T cells of 3.7x106/ml and average of 
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4.2x106 CD4+ T cells/ml 0dpc (Figure 5.4C and D). Again, goat D1 had higher initial numbers of CD4+ T 
cells than other goats until 6 and 8dpc when the numbers dropped to 3.7x106/ml (Figure 5.4C). 
The numbers of WC1+ cells in the mock-depleted goats are higher than those of the CD8-depleted 
goats for -1dpc – 10dpc (Figure 5.4H). Numbers of WC1+ cells in mock-depleted goats remained stable 
of around 1.3x106/ml over the observation period. The numbers of WC1+ cells at all time points 
following the injection of CC63 are roughly 50% of the baseline numbers in the CD8-depleted group 
(Figure 5.4G). 
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Figure 5.4 T cell subset numbers in blood of PPRV vaccinated goats inoculated with anti-CD8 or 
isotype-matched mAb prior to and post-PPRV challenge. EDTA blood samples were taken from all 
goats on the indicated days prior to and post-PPRV challenge. On -5 and -2 dpc, average cell numbers 
of CD8+, CD4+ and WC1+ γδ T cells were determined within EDTA blood samples by whole blood flow 
cytometry to create a baseline cell number of respective cell populations for each animal.  Cell 
numbers were calculated in one millilitre of blood by flow cytometry analysis utilising 123count 
eBeads and collecting 10,000 events in the bead gate. Flow cytometry dot plots from 2dpc are shown 
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as representative of CD8+ T cell labelling for a CD8+ depleted animal (A) and a mock depleted animal 
(B). Cell numbers are displayed either as mean +/- SD of 3 technical replicates for each individual 
animal (CD4+ T cells Panel C, CD8+ T cells Panel E, WC1+ γδ T cells G) or the mean cell number +/- Std 
of the respective T cell population for the CD8 T cell or mock depleted treatment groups (CD4+ T cells 
Panel B, CD8+ T cells Panel D, WC1+ γδ T cells F).  Note: Only 4 animals are displayed in the mock 
depleted group as regular blood samples could not be obtained from goat D8. 
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5.3.2 Comparison of PPRV-specific antibody responses between CD8+ T cell depleted, 
mock depleted and control goats 
To observe the development of the humoral immune response to PPRV vaccination, weekly serum 
samples from all goats were assayed by cELISA to detect the presence of antibodies recognising the 
PPRV-N protein (Figure 5.5). The majority of vaccinated individuals demonstrated measurable 
production of anti-N protein specific antibodies (defined as increase in percentage inhibition) by 7dpv 
compared to 0dpv values. Anti-N protein antibody levels of all vaccinated animals reached 70-80% 
inhibition by 14dpv, and subsequently remained fairly constant other than a small further increase of 
percentage inhibition by 7 and 14dpc  (Figure 5.5). There was no difference in percentage inhibition 
displayed by sera obtain from  CD8+ T cell depleted goats and the mock depleted goats 28 dpv, the 
day of virulent challenge and 2 days into the mAb injection protocol, when CD8+ T cell numbers were 
negligible in the depleted group. Seven days following PPRV/Sudan/Sennar/72 challenge, sera 
obtained from unvaccinated controls demonstrated similar percentage inhibition values to the 
vaccinated goats (Figure 5.5). 
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Figure 5.5 Anti-PPRV N-protein immunglobulin detection by cELISA  in sera obtained from all 12 
goats of the PPRV vaccination/CD8 T cell depeletion study. At time points 0, 7, 14 and 21 of the 
experiment all goats were either Sungri/96 vaccinates or VDS-derived mock vaccinated (black 
symbols, n = 2). On day 26 dpv the 10 Sungri/96 vaccinates were randomely divided into two 
groups of 5 animals for CD8+ lymphocyte depletion (dark purple) or mock depletion (grey) by mAb 
inocluation (indicated by purple line). On 28dpv all goats were infected with the virulent field 
strain, PPRV/Sudan/Sennar/72 (2x 105 TCID50), indicated by red vertical ine. Serum was collected 
from all twelve goats every 7 days for the six weeks of the experiment and assaysed for the 
presence of PPRV N protein antibodies by c ELISA. Displayed are the individual animals percentage 
inhibitions (A) and the means of the groups (B), error bars indicate SD. 
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5.3.3 Comparison of PPRV-specific T cell responses between CD8+ T cell depleted, mock 
depleted and control goats 
Heparin-treated blood was obtained from all goats (except goat D8) every seven days to isolate PBMCs 
for subsequent analyses of PPRV-specific T cell responses and their perturbation in CD8 T cell or mock 
depleted individuals.  
PBMCs were stimulated with mock VDS and PPRV-infected cell crude antigen preparations and heat-
inactivated mock and PPRV preparations for five days, then pulsed with H3 Thymidine to assess 
proliferation. Vaccinated animals demonstrated cell proliferation specific to PPRV antigens with peak 
stimulation indices observed on day 14 or 21dpv (Figure 5.6A and B). At these time-points proliferative 
responses to both virus antigen preparations (crude antigen and heat inactivated viral supernatant) 
as well as to the homologous or heterologous PPRV strain (Figure 5.6A, B, D and E).  
No noteworthy difference in the proliferative response of PBMCs to the antigens was observed by 
28dpv between individuals form the mock or CD8 T cell depleted vaccine groups (Figure 5.6 A, B, D 
and E), despite CD8+ T cells being almost entirely absent from the peripheral blood at this time (Figure 
5.4E and F). The mean PBMC stimulation indices observed to the different antigens were comparable 
between cells derived from mock or CD8+ T cell depleted animals at this time (SI 45 and 55, respectively 
21dpv; Figure 5.6 A and B). Antigen derived from the homologous Sungri/96 strain elicited higher 
proliferative responses compared to antigen derived from the heterologous Nigeria/75/1 strain by 
Tukey pairwise (p = 0.001) (Figure 5.6A and B). Similarly proliferative responses of PBMCs post-
challenge (35 and 42dpv) remain comparable between individuals from the mock and the CD8 T cell 
depleted groups (Figure 5.6A and B). Although the mean cpm recorded in vaccinates from either group 
(mock or CD8 T cell depleted) increased on 35 and 42 dpv (Figure 5.6D and E), the stimulation index 
remained largely constant (Figure 5.6A and B) as a result of increased cell proliferation to the 
respective control antigens. 
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The VDS mock vaccinated control animals did not mount a proliferative response to PPRV-specific 
antigens prior to challenge, further suggesting that observed T cell proliferation in PBMCs of 
vaccinated animals is a vaccine induced specific response to PPRV (Figure 5.6C & F). By 14dpc the 
PBMCs from these animals produced higher cpm to the PPRV-specific antigens over those observed 
for the mock antigens, generating SI of between 3-11 towards HI Nigeria/75/1 and 4-17 towards HI 
Sungri/96 (Figure 5.6C & F). 
 Figure 5.6 Lymphoproliferative responses to PPRV derived antigens and heat-inactivated virus following PPRV vaccination and challenge. PBMCs were 
isolated from peripheral blood of all goats and cells were cultured in the presence of crude PPRV antigen or heat inactivated PPRV and respective control 
preparations for 5 days. Cell proliferation was quantified by incorporation of 3H thymidine and scintillation counting. All PBMC stimulation cultures were 
performed in quadruple technical replicates. The data are displayed as mean stimulation indexes +/- SD of goats within the mock depleted group (A; n=4) CD8 
T cell depleted group (B; n=5) and mock vaccinated challenge control group (C; n=2) or alternatively as mean counts per minute (c.p.m) +/- SD for the 
respective groups (D, E and F).  Red dotted line indicates point of challenge.
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 Additionally the T cell IFN-ɣ response to specific PPRV antigen preparations was quantified by flow 
cytometric analysis of intracellular cytokine labelling. Freshly isolated PBMCs or cryopreserved PBMCs 
(35dpv only)were stimulated for 18 hours with either crude antigen or live PPRV preparations and 
processed to identify IFN-ɣ producing cells as previously described (section 2.4.2). By 14dpv a 
detectable proportion of CD4+ cells from all vaccinates were producing IFN-ɣ following stimulation 
with either PPRV-derived antigens or live virus, while mock antigen and mock virus stimulation elicited 
only background IFN-γ production (Figure 5.7A and B). By 28dpv live PPRV Sungri/96 generated the 
highest percentage CD4+ IFN-ɣ+ cells (Figure 5.7A and B), with responses to other stimuli contracting. 
Overall the depletion of CD8 T cells by 28dpv within the depletion group does not seem to considerably 
affect the IFN-γ production observed by CD4 T cells. The numbers of CD4+ cells labelled per well 
remained consistent over the six weeks of the experiment in the CD8-depleted (Figure 5.7D) and 
mock-depleted (Figure 5.7E) PBMC preparations for intracellular antibody labelling. At 35dpv the CD4+ 
PBMCs from the mock-vaccinated controls appeared to develop a peak in IFN-ɣ production against all 
stimuli, including the mock antigen and mock virus (Figure 5.7C), however when assessing this against 
the drop in numbers of CD4+ cells stained on this time point (Figure 5.7F) this could be an artefact of 
low CD4+ numbers generating an artificially high percentage.  
The CD4-CD8- cells from the CD8-depleted animals (Figure 5.8A) and the mock-depleted animals 
(Figure 5.8B) do not appear to produce a substantial percentage of IFN-ɣ+ cells following stimulation 
with PPRV-derived antigens or live virus. A similar result is seen for the mock-vaccinated controls 
(Figure 5.8C). The number of CD4-CD8- cells in the PBMC preparations for ICS appear to increase over 
the period of the experiment in both the CD8-depleted (Figure 5.8D) and the mock-depleted animals 
(Figure 5.8E). The numbers of CD4-CD8- cells from the mock-vaccinated goats remain stable 
throughout the experiment (Figure 5.8F). 
  
 Figure 5.7 IFN-γ producing CD4+ T cells in response to multiple PPRV antigen preparations following PPRV vaccination and challenge in CD8-depleted, 
mock depleted and control animals. PBMCs were isolated from peripheral blood of all goats and cells were cultured in the presence of crude PPRV antigen 
or live PPRV and respective control preparations for 18 hours followed by 6 hours in the presence of Golgi-Plug (BD). All stimulation cultures were performed 
in triple technical replicates. Cells were surface labelled with anti-membrane protein mAbs and labelled internally for IFN-γ. Cells were analysed on the 
MACSQuant flow cytometer and data were analysed in FlowJo X software. CD4+IFN-γ+ cells are displayed as a mean percentage (+/- SD) for the groups 
CD8-depleted (A), mock-depleted (B) and controls (C). Mean CD4+ labelled cells per well (+/- SD) are displayed per group; CD8-depleted (D), mock-depleted 
(E) and controls (F). Red dotted line indicates point of challenge. 
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Figure 5.8 IFN-γ producing CD4-CD8- cells in response to multiple PPRV antigen preparations following PPRV vaccination and challenge in CD8+ T cell 
depleted, mock depleted and control animals. PBMCs were isolated from peripheral blood of all goats and cells were cultured in the presence of crude 
PPRV antigen or live PPRV and respective control preparations for 18 hours followed by 6 hours in the presence of Golgi-Plug (BD). All stimulation 
cultures were performed in triple technical replicates. Cells were surface labelled with anti-membrane protein mAbs and labelled internally for IFN-γ. 
Cells were analysed on the MACSQuant flow cytometer and data were analysed in FlowJo X software. CD4-CD8-IFN-γ+ cells are displayed as a mean 
percentage (+/- SD) for the groups CD8-depleted (A), mock-depleted (B) and controls (C). Mean CD4-CD8- labelled cells per well (+/- SD) are displayed 
per group; CD8-depleted (D), mock-depleted (E) and controls (F). Red dotted line indicates time of challenge. 
 Only a minor proportion of CD8+ T cells in mock-depleted goats D1 and D9 produced IFN-ɣ+ to specific 
PPRV antigens above those observed for the respective control antigen preparations at 28 and 35dpv 
(Figure 5.9A and D). On the contrary consistently more than 1% of CD8+ T cells derived from animals 
D3 and D5 responded with strong IFN-γ production to the live virus PPRV/Sungri/96 preparation from 
14dpv onwards (Figure 5.9B and C). While CD8+ T cells derived from these animals also demonstrated 
IFN-γ production on certain days (especially 14 and 35dpv) to the heterologous live virus preparation 
PPRV/Nigeria/75/1, the proportion of IFN-γ production was observed in a smaller percentage of cells 
and less consistent. Taken together, CD8+ T cells from the mock depleted group of goats produced 
IFN-γ most notably to the live virus preparation of the homologous strain PPRV/Sungri/96 (Figure 
5.9E). Cell numbers of CD8+ T cells present within respective PBMC cultures, stimulated with varying 
antigens, fluctuated for individual animal in the absence of a common trend, with the exception of a 
noticeable drop in CD8 T cells numbers of all animals by 35dpv, most likely due to cryopreserved cells 
being utilised at this time point only (Figure 5.9F). 
CD8+ T cells derived from the two mock-vaccinated control animals, D11 and D12, did not respond by 
specific IFN-γ production when co-cultured with PPRV antigen preparations at any time point during 
the experiment (Figure 5.9G). The presence of IFN-γ-producing CD8+ T cells observed on day 35dpv 
appears to be non-specific against all antigens, including the respective control preparations (Figure 
5.9G) and co-insides with a considerable drop in CD8+ T cells present within the respective PBMC 
cultures (Figure 5.9H).  
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Figure 5.9 IFN-γ producing CD8+ T cells in response to multiple PPRV antigen preparations 
following PPRV vaccination and challenge in mock depleted and control animals. PBMCs were 
isolated from peripheral blood of all goats and cells were cultured in the presence of crude PPRV 
antigen or live PPRV and respective control preparations for 18 hours followed by 6 hours in the 
presence of Golgi-Plug (BD). All stimulation cultures were performed in triple technical replicates. 
Cells were surface labelled with anti-membrane protein mAbs and labelled internally for IFN-γ. 
Cells were analysed on the MACSQuant flow cytometer and data were analysed in FlowJo X 
software. CD8+IFN-γ+ cells are displayed as a mean percentage (+/- SD) for the individual animal 
D1 (A), D3 (B), D5 (C) and D8 (D). CD8+IFN-γ+ cells are displayed as a mean percentage (+/- SD) for 
the two mock-vaccinated goats (G). Mean CD8+ labelled cells in 150µl (+/- SD) are displayed for 
mock-depleted animals (n = 4) (F) and controls (n = 2) (H). 
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Prior to depletion, a proportion of CD8+ T cells within PBMC obtained from 3 of the 5 goats within the 
depletion group (animals D2, D4 and D6; Figure 5.10 A, B, C) produced detectable levels of IFN-γ above 
background mostly to the live Sungri/96 preparation. At 28dpv, the day when CD8 T cells seemed 
almost entirely absent from the peripheral blood (Figure 5.4), frequencies of IFN-γ producing CD8 T 
cells present in PBMC cultures of two animals from the depletion group (D2 and D10 – Figure 5.10A 
and E) seemed to be comparable to those observed in individuals prior to depletion. However, the 
overall cell number of total CD8+ T cells present within PBMC cultures was, indeed, very low at 28dpv 
(Figure 5.10G), hence the percentage of IFN-γ producing CD8+ T cells within individuals of the depletion 
group at this time point reflected a very low absolute number of respective cells (Figure 5.11). 
Following challenge, IFN-γ production by CD8+ T cells from animals from the depleted group was 
mostly observed non-specifically against all antigen preparations, including the mock controls. 
Furthermore, CD8 T cell numbers present within respective PBMC cultures remained low, with minor 
recovery of CD8 T cell numbers observed only for animal D7 by 42dpv/ 14dpc (Figure 5.10G) . 
To further demonstrate that the presence of IFN-γ producing CD8 T cells at similar frequencies post 
depletion compared to prior depletion is indeed based on a very low number of IFN-γ producing cells 
within a much reduced CD8 T cell population, flow cytometry panels outlining IFN-γ detection are 
presented in Figure 5.11. CD8 T cells within PBMCs obtained from animal D2 (depletion group) 
producing IFN-γ in response to culture in the presence of PPRV/Sungri/96 live virus are shown prior 
(14dpv and 21dpv; Figure 5.11A and B, respectively) and post depletion (28dpv; Figure 5.11C). A small 
percentage of CD8 T cells within PBMCs mounted a clear IFN-γ production to PPRV/Sungri/96 virus at 
14 and 21dpv prior to depletion. Although a comparable percentage of IFN-γ producing CD8 T cells 
was recorded at 28dpv, this percentage was based on the presence of 4 IFN-γ positive cells only, 
expressing IFN-γ at low levels (Figure 5.11A, B and C). For comparison a consistently well-defined 
population of IFN-γ producing CD8 T cells can be detected at 14, 21 and 28dpv within PBMC cultures 
of animal D5 from the mock depleted group (Figure 5.11D, E and F).  
156 
 
Nonetheless, CD8 T cells are present, albeit at much reduced numbers, within cultured PBMCs at 28 
and 35dpv, despite their presence per ml of peripheral blood being negligible over the same period 
(see Figure 5.4).  
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Figure 5.10 IFN-ɣ producing CD8+ T cells in response to multiple PPRV antigen preparations 
following PPRV vaccination and challenge in CD8-depleted goats. PBMCs were isolated from 
peripheral blood of all goats and cells were cultured in the presence of crude PPRV antigen or live 
PPRV and respective control preparations for 18 hours followed by 6 hours in the presence of Golgi-
Plug (BD). All stimulation cultures were performed in triple technical replicates. Cells were surface 
labelled with anti-membrane protein mAbs and labelled internally for IFN-γ. Cells were analysed on 
the MACSQuant flow cytometer and data were analysed in FlowJo X software. CD8+IFN-γ+ cells are 
displayed as a mean percentage (+/- SD) for the individual animal D2 (A), D4 (B), D6 (C), D7 (D) and 
D10 (E). The mean CD8+IFN-γ+ (+/- SD) (F). Mean CD8+ labelled cells per 150µl (+/- SD) are displayed 
for CD8-depleted animals (n = 5) (G).  
Figure 5.11 Example flow cytometry dot plots of IFN-γ producing CD8+ cells in response to live 
PPRV/Sungri/96 in a CD8-depleted and mock-depleted animal. Plots are representative of raw 
data already displayed in Figure 5.10. Example plots showing percentage and numbers of CD8+IFN-
ɣ+ cells from a depleted animal, D2, that were stimulated with PPRV/Sungri/96 at 14 (A), 21 (B) and 
28dpv (C). Example plots for the same cell population of a mock depleted goat, D5, cells were also 
stimulated with PPRV/Sungri/96 at 14 (D), 21 (E) and 28dpv (F). 
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5.3.4 Comparison of clinical signs post-challenge in CD8+ T cell depleted, mock depleted 
and non-vaccinated control goats 
Following infection with the virulent field isolate PPRV/Sudan/Sennar/72, all 12 goats were observed 
daily for clinical signs  by Animal Services staff, these signs were recorded and scored according to the 
PPRV clinical score sheet (see Appendix 1). The mock depleted goats did not display any outward 
clinical signs during the challenge observation period (Figure 5.12A & B) and their rectal temperatures 
did not increase above baseline observations (Figure 5.12B). Three out of five of the CD8+ cell-
depleted goats developed loose faeces during the two week observation period (Figure 5.12C), but 
they did not develop nasal or ocular congestion, also their rectal temperatures remained within 1°C 
of baseline (Figure 5.12D). Clinical signs were first observed in the VDS mock vaccinated controls on 
4dpc (Figure 5.12E); the rectal temperatures of both goats increased by 1°C above baseline 
observations (Figure 5.12F). On 7dpc the two mock-vaccinated control goats further developed nasal 
congestion (Figure 5.13B), and subsequently also developed diarrhoea. 
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Figure 5.12 Clinical scores and rectal temperatures of goats following PPRV vaccination and 
subsequent challenge in CD8-depleted, mock depleted and control animals. All goats were observed 
daily and given a clinical score for individual clinical signs that were combined for an overall daily 
clinical score for mock depleted group (A), CD8+ T cell depleted group (B) and mock vaccinated/ 
challenge controls (C). Daily rectal temperatures are displayed independently for the respective 
groups of mock depleted animals (D), CD8+ T cells depleted animals (E) and mock vaccinated challenge 
controls (F).  
0 1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4
0
2
4
6
8
D a y s  p o s t c h a lle n g e  (d p c )
C
o
m
b
in
e
d
 C
li
n
ic
a
l 
S
c
o
r
e D 1
D 3
D 5
D 8 *
D 9
0 1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4
3 7 .0
3 7 .5
3 8 .0
3 8 .5
3 9 .0
3 9 .5
4 0 .0
4 0 .5
4 1 .0
4 1 .5
4 2 .0
D a y s  p o s t c h a lle n g e  (d p c )
R
e
c
ta
l 
te
m
p
e
r
a
tu
r
e
 (

C
)
D 1
D 3
D 5
D 8 *
D 9
0 1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4
0
2
4
6
8
D a y s  p o s t c h a lle n g e  (d p c )
C
o
m
b
in
e
d
 C
li
n
ic
a
l 
S
c
o
r
e D 2
D 4
D 6
D 7
D 1 0
0 1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4
3 7 .0
3 7 .5
3 8 .0
3 8 .5
3 9 .0
3 9 .5
4 0 .0
4 0 .5
4 1 .0
4 1 .5
4 2 .0
D a y s  p o s t c h a lle n g e  (d p c )
R
e
c
ta
l 
te
m
p
e
r
a
tu
r
e
 (

C
)
D 2
D 4
D 6
D 7
D 1 0
0 1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4
0
2
4
6
8
D a y s  p o s t c h a lle n g e  (d p c )
C
o
m
b
in
e
d
 C
li
n
ic
a
l 
S
c
o
r
e D 1 1
D 1 2
0 1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4
3 7 .0
3 7 .5
3 8 .0
3 8 .5
3 9 .0
3 9 .5
4 0 .0
4 0 .5
4 1 .0
4 1 .5
4 2 .0
D a y s  p o s t c h a lle n g e  (d p c )
R
e
c
ta
l 
te
m
p
e
r
a
tu
r
e
 (

C
)
D 1 1
D 1 2
A B
C D
E F
161 
 
 
Figure 5.13 Selected clinical and pathological signs in goats following PPRV vaccination and 
subsequent challenge in CD8+ T cell depleted, mock depleted and control animals. An example of 
a mock depleted goat, D5, is healthy with clear eyes and nose (A), this is in contrast to the crusty 
nasal discharge seen in mock-vaccinated goat D11 (B). At post-mortem a healthy jejunum from a 
mock-depleted animal (C) and the CD8+ lymphocyte-depleted goat D4 had tiger striping in the 
jejunum (D). 
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Following challenge, EDTA blood was obtained by venepuncture every two days from all goats (except 
the mock depleted animal D8), these samples were frozen for detection of PPRV-N gene RNA by qRT-
PCR. PPRV diagnostic of the samples by RNA extraction and qRT-PCR was performed by The Pirbright 
Institute NVRL. Only the two unvaccinated goats had detectable RNAemia post-challenge (Figure 
5.14), while all vaccinated goats remained negative for the presence of PPRV genome irrespective of 
CD8 T cell depletion (data not shown). 
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Figure 5.14 Detection of PPRV N gene RNA by real time RT-PCR in EDTA blood samples obtained 
from PPRV vaccinated and control goats post-challenge. Twenty-eight days post-vaccination with 
either PPRV/Sungri/96 (n = 10) or a VDS-derived mock vaccine (n = 2) all 12 goats were inoculated with 
the virulent field strain PPRV/Sudan/Sennar/72. EDTA blood samples were obtained from all goats 
every two days starting on the day of challenge and stored at -80°C until processed for PPRV 
diagnostics by RNA extraction and RT-qPCR. PPRV N gene RNA was detected in both of the 
unvaccinated control animals (goats D11 and D12) from four days post challenge and was still 
detectable 14 dpc. PPRV RNA was not detected in EDTA blood in either mock-depleted (n = 5) or CD8-
depleted goats (n = 5) at any time post-challenge (data not shown). The amount of viral RNA is 
expressed as 45 (cycles) - CT value. Values are shown for individual animals. 
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At the end of the study (14dpc/42dpv) full anatomical pathology examinations of all animals were 
carried out post-mortem by two veterinarians, one of them fully blinded to the study grouping. No 
obvious differences in pathological changes were observed between individual goats of the mock or 
CD8 T cell depleted group (see table 5.1; personal communication B. Sanz-Bernardo and K. Darpel).  
The pathology examination protocol focused on key lymphatic organs (lymph nodes, tonsil, spleen) 
and the respiratory and digestive tract (Appendix 3 for pathology recording sheet). At 14dpc minor 
pathological changes were overserved in the prescapular lymph nodes (Table 5.1) and mucosa of the 
small intestine (duodenum, jejunum and ilium) of individuals in both the CD8 T cell and mock depleted 
group. However while two individuals from each group displayed mucosal congestion of the jejunum 
only 1 individual from the CD8 depleted group (“D4”) showed vertical haemorrhagic striping (Figure 
5.13D and Table 5.1), a pathological finding commonly reported for PPRV in small ruminants. 
The two mock-vaccinated challenge controls also only showed mild pathological changes at this stage 
post-infection. Small focal haemorrhages in the prescapular lymph node was observed in one animal 
(Table 5.1), while the second animal showed chronic longitudinal haemorrhagic striping of the colon 
(Table 5.1).  Several animals displayed emphysema and congested lung areas, including the presence 
of froth in the trachea. As these pathological changes were deemed a consequence of the euthanasia 
and post mortem processing these findings were not analysed or displayed.  
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Table 5.1: Summary of pathological finding of vaccinated goats previously either CD8 T cell or mock 
depleted at 14 days post challenge with PPRV/Sudan/Sennar/72 
Organ CD8 T cell depletion 
group (N=5) 
 
Pathological findings 
in number of animals  
Mock depletion group 
(N=5) 
 
Pathological findings 
in number of animals 
Unvaccinated controls 
(N=2)  
 
Pathological findings 
in number of animals 
Mandibular LN1  0/5 0/5 0/2 
Tonsil 0/5 0/5 0/2 
Prescapular LN Focal haemorrhages: 
3/5 
Focal haemorrhages: 
1/5 
Focal haemorrhages: 
1/2 
Bronchial LN  0/5 0/5 0/2 
spleen 0/5 0/5 0/2 
Mesenteric LN 0/5 0/5 0/2 
Intestine outside# 0/5 0/5 0/2 
Mucosa and PP2/ 
Jejunum 
Slight congestion: 
2/5 
Vertical haemorrhagic 
striping: 
1/5 
PP raised:2/5 
Slight congestion: 
2/5 
Vertical haemorrhagic 
striping: 
0/5 
PP raised: 1/5 
Slight congestion: 
0/2 
Vertical haemorrhagic 
striping: 
0/2 
PP raised: 0/2 
Mucosa and PP2/ ilium Slight congestion: 
0/5 
Vertical haemorrhagic 
striping: 
0/5 
PP raised:2/5 
Slight congestion: 
1/5 
Vertical haemorrhagic 
striping: 
0/5 
PP raised:2/5 
Slight congestion: 
0/2 
Vertical haemorrhagic 
striping: 
0/2 
PP raised: 0/2 
Mucosa colon Slight congestion: 
0/5 
Horizontal 
haemorrhagic striping: 
0/5 
Slight congestion: 
0/5 
Horizontal 
haemorrhagic striping: 
0/5 
Slight congestion: 
0/2 
Horizontal 
haemorrhagic striping: 
1/2 
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Note: Numerous animals displayed congestion and emphysema of the lung and the presence of froth in the 
traches. As these pathological changes were believed to be a consequence of the euthanasia/ post mortem 
process these organs have been excluded from this table 
# = hyperaemia deemed to be associated with post mortem stasis was excluded 
1LN = lymph nodes 
2PP= Payer’s patches 
  
Other observed 
abnormalities 
Small lip/ mouth 
ulcers: 0/5 
Small lip/ mouth 
ulcers: 3/5 
Small lip/ mouth 
ulcers: 0/2 
Petechia duodenum 
1/2 
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5.4 Discussion 
In the study reported here it was demonstrated for the first time that PPRV vaccinated goats remained 
clinically protected against challenge with the PPRV/Sudan/Sennar/72 strain despite the successful 
depletion of CD8+ T cells from the peripheral blood immediately prior and at the time of challenge.  
Assessing the role of CD8 T cells in vaccine induced protection against virulent PPRV challenge was 
achieved by successfully depleting this cell population from the peripheral blood in vivo via the 
inoculation of a bovine anti-CD8 mAb of the IgG2a isotype (CC63), which had not been reported for 
goats prior to this study. 
The pilot CD8+ T cell depletion study was successful in identifying a suitable dosing regimen for CD8+ 
cell depletion in goats utilising a total amount previously reported to also deplete T cells within tissues. 
Utilising CC63 as the depletion antibody and CC58 as the detection antibody was advantageous due 
to their different specificities; CC63 targets the CD8α chain and CC58 targets the CD8β chain of the 
heterodimer CD8 membrane protein. Due to the different binding epitopes on separate chains, the 
likelihood of epitope masking is reduced, whereas using the same depletion and detection antibody 
would rely on the depletion antibody not occupying all of the available binding sites. 
In the pilot depletion study the ‘high, short dose’ animals had roughly 300 CD8+ T cells/ml blood at 
day 4 whereas the ‘low, long dose’ had 1x105/ml CD8+ cells in the blood on the same day. The goats 
in the ‘low, long dose’ regimen continued to physically react following injection of CC63, implying that 
there were still CD8+ cells in the blood that were being destroyed by complement activation triggered 
by IgG2a binding to cell surface markers. The ‘high, short dose’ animals did not display adverse signs 
after the second day, indicating that almost all of the CD8+ cells had been removed from the 
circulation. The reaction of the ‘low, long dose’ animals to antibody injection confirms the results seen 
in the whole blood labelling.  
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Lymph nodes were taken from goats in the pilot CD8+ in vivo depletion study at days 4 and 10, initially 
to compare the depletion of CD8+ in tissues if both regimens had been successful at depleting CD8+ 
cells in the blood. However, due to the differences in CD8+ cell numbers observed in the blood during 
depletion between the two dosing regimens, this was considered to no longer be a priority, as the 
‘high, short dose’ was the only regimen that had led to significant depletion of the CD8+ T cells in the 
blood. However, it would still be highly beneficial to confirm in the future if the utilised mAb amount 
of 2mg/kg also effectively depleted CD8 T cells in lymphatic tissue. 
In the vaccination/depletion experiment the CD8+ lymphocytes were successfully depleted from the 
circulation as detected by whole blood labelling. However, by 6dpc (5 days after the last injection of 
CC63) CD8+ T cell numbers had increased but remained at low levels until the end of the experiment. 
Experiments investigating the role of T cells in primary maedi visna virus in sheep, depleted CD8+ T 
cells in vivo by a course of 25 daily injections of mAb, the depletion was successful for eight days but 
the CD8+ T cells started to return at low levels 10 days into the protocol (Eriksson et al., 1999b). In 
experiments in cattle it has been observed that following treatment with CC63 the CD8+ T cells are 
successfully depleted, however, CD8+ lymphocytes returned 10 days after injections began, albeit at 
low levels (Bruce et al., 1999). Taken together, this could imply that CD8+ cells were not fully depleted 
in the lymphatic tissues following mAb injection, resulting in a rapid re-population of the circulatory 
system. Lymphoid tissues were taken from all animals at post-mortem, but due to time constraints 
they have not been assayed by immuno-labelling and imaging to determine the proportion of CD8+ T 
cells in the T cell zones of the tissues following re-population of CD8+ T cells in the blood. Obviously, 
these tissues would not give an indication of CD8+ T cells in the organs at time of challenge because 
they were harvested 14dpc. 
Serum obtained in the vaccination/depletion experiment was analysed for PPRV-N protein-specific 
antibodies by the cELISA. High levels of N-specific antibodies were induced by the live, attenuated 
PPRV vaccine, Sungri/96, and the challenge strain in the unvaccinated controls, as seen in previous 
168 
 
experiments. Unfortunately, virus neutralisation assays were not performed due to time constraints 
so specific neutralising titres are not available. It cannot be ruled out that antibodies already present 
in the circulatory system were able to bind and neutralise the challenge virus particles before they 
were able to infect target cells and replicate, thus protecting the CD8+ lymphocyte-depleted animals 
and mock depleted animals. So, in this scenario it would appear that neutralising antibody following 
vaccination can confer protection from challenge. In order to truly dissect the role of neutralising 
antibody in protection either antibody or memory B cell adoptive transfer experiments would be 
necessary, but that is beyond the scope of this research. 
Research performed at The Pirbright Institute into the role CD4+ T cells play in FMDV vaccination with 
the vaccine A22 Iraq, found that CD4+ T cell-depletion following vaccination in calves lead to 
significantly lower FMDV-specific antibodies than mock depleted animals (Carr et al., 2013). The CD4+ 
T cell-depleted calves in this experiment were also vaccinated with BHV-1 antigen and depletion of 
CD4+ T cells also resulted in a loss of proliferative responses to the BHV-1 antigen suggesting that the 
antigen is CD4+ T cell-dependant. If CD8+ T cells are not the primary source of vaccine-induced 
protection in PPRV, and CD4+ T cells are important in vaccine responses to other viruses, perhaps a 
future experiment investigating the role of CD4+ T cells in PPRV vaccine-induced protection would be 
a natural progressive step from the research presented in this chapter. 
In the INF-γ ICS assay CD4+ T cells from vaccinated goats produced IFN-γ in response to co-culture 
with PPRV-specific antigens and virus. In the proliferation assay there is still PPRV-specific proliferation 
over responses to corresponding mock 28dpv/0dpc, when CD8+ T cells are at very low levels in the 
blood. Taken together it could be assumed that the proliferation seen at 28dpv are not CD8+ T cells, 
but in fact CD4+ T cells that are responding both by IFN-γ release and proliferation. 
Prior to depletion, CD8+ T cells respond to PPRV-specific antigens by IFN-γ release, most prominently 
at 14dpv and 21dpv. In the IFN-ɣ ICS flow cytometry panels a population appears within the CD8+ T 
cell gate in the CD8+ lymphocyte depleted animals on days 28 and 35. It is likely that these cells are 
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low expressers of the cell surface molecule that have not been depleted. Research in calves using both 
the murine CC63 and a bovine chimaeric antibody chCC63 by Bruce et al. (1999) also observed that 
PBMCs expressing low levels of CD8 were not depleted by mAb injections. 
All time points for the IFN-ɣ ICs were performed on fresh cells except 35dpv/7dpc, which was 
performed on cryopreserved cells. From the cell numbers for CD4+ cells and CD8+ cells in the TRT3-
treated animals it would appear that cryopreservation destroys the CD4+ and CD8+ cells more readily 
than the CD4-CD8- cells. This gives rise to unnaturally high mock IFN-ɣ+ cell percentages due to lower 
starting numbers following cryopreservation. Taking this into account it becomes difficult to discern 
actual IFN-ɣ response and high background on this time point. This also interferes with the data from 
the mock-vaccinated animals as it may be compounded by leucopoenia caused by PPRV infection. 
Following challenge with PPRV/Sudan/Sennar/72 EDTA blood samples from all animals in the 
vaccination/depletion study were assayed by RT-PCR for PPRV N gene RNA. PPRV RNA was only 
detected in the two unvaccinated controls. Therefore, despite a lack of CD8+ T cells in the depleted 
goats, all Sungri/96 vaccinates were protected from RNAemia. This might indicate that the challenge 
virus was neutralised by antibody in the vaccinates before it was able to enter target cells and 
replicate, thus not being able to generate enough RNA to be detected in the blood. Possibly, the 
challenge virus replicated in specific tissues in the vaccinated goats and RNA was not detected in the 
blood. As mentioned in Chapter 3, PPRV/Sudan/Sennar/72 was not the most virulent strain used in 
these experiments. It is possible that with a more virulent challenge strain than the one used in this 
experiment, such as Kurdistan/2011 or Ghana/78 that clinical signs could have been present in the 
CD8+ T cell depleted group resulting in differences in protection between the depleted and mock 
depleted animals. The exact mechanisms of virulence for PPRV are not know, possibly a more virulent 
strain would be fitter and able to overcome barriers that prevented PPRV/Sudan/Sennar/72 from 
causing RNAemia, but this is speculation. 
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Although two animals within each group (CD8 depleted and mock depleted) demonstrated congested 
mucosa of parts of the jejunum (small intestine) only one goat of the CD8 depleted group had 
developed vertical haemorrhagic stripping (“tiger strips”) of the jejunal mucosa, a  pathological 
observation classed as a highly common during PPRV infection. The combination of loose faeces and 
haemorrhagic stripes in areas of the small intestine might suggest that the depletion of CD8+ cells in 
vivo enables PPRV infection to affect the gut. In primary infection PPRV can be detected in the faeces 
and infection causes clinical changes in the intestinal tract. However, these findings in vaccinates 
might suggest that vaccination is not fully protective in specific tissues such as the intestines, but the 
sample size in this experiment was small and more work would need to be done to confirm. 
Both PPRV and MeV are Morbilliviruses, and if PPRV in goats is considered a suitable animal model for 
measles in humans, this data could be used to extrapolate for live, attenuated measles vaccines in 
humans. 
In summary, from the data in this chapter it is clear that in vivo depletion of CD8+ T cells in a vaccinated 
goat does not prevent the host from mounting a protective immune response on challenge with a 
virulent strain of PPRV. Thus, it could be concluded that CD8+ lymphocytes are not the dominant 
source of vaccine-induced protection in PPRV vaccine-induced protection. 
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Chapter 6 – Discussion 
In this body of work I have shown that: 
 Both the Nigeria/75/1 and Sungri/96 live attenuated PPRV vaccines can protect goats against 
virulent challenge with field strains representative of all four genetic lineages. 
 Both Nigeria/75/1 and Sungri/96 vaccines induce PPRV-N-specific antibodies in vaccinates as 
assessed by cELISA. 
 Both Nigeria/75/1 and Sungri/96 vaccines elicit PPRV neutralising antibodies (nAbs) two 
weeks after vaccination, with Nigeria/75/1 generating higher titres of homologous virus-
neutralising antibodies than Sungri/96. 
 Vaccination with either Nigeria/75/1 or Sungri/96 primes PPRV-specific T cells that respond to 
in vitro stimulation with PPRV antigens by proliferation. In this assay Sungri/96 vaccinates had 
higher stimulation indexes than Nigeria/75/1 vaccinates. 
 Flow cytometric analysis of antigen-specific T cells showed that both vaccines induce strong 
IFN-γ production in CD8+ T cells when cultured in the presence of live PPRV. Sungri/96 
vaccinates had higher percentages of PPRV-specific CD4+IFN-γ+ cells than Nigeria/75/1 
vaccinated goats indicating that the Sungri/96 vaccine is more effective at stimulating the cell 
mediated immune response than the Nigeria/75/1 vaccine. 
 Depletion of CD8+ T cells in vivo by mAb treatment did not result in a loss of vaccine-induced 
protection, demonstrating that these cells are not the primary source of vaccine-induced 
protection in this experimental model. 
Currently, the vaccine Nigeria/75/1 is used across Africa, the Near and Middle East, whereas Sungri/96 
is currently only used in India. Whilst the Nigeria/75/1 vaccine strain has been tested in several 
countries (Diallo et al., 1989), and Sungri/96 has been tested in India (Saravanan et al., 2010), this is 
the first standardised experiment where both Nigeria/75/1 and Sungri/96 have been assessed under 
the same conditions using the same challenge viruses. 
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As previously stated, the Nigeria/75/1 vaccine is lineage II and Sungri/96 is lineage IV. One of the 
primary arguments for using lineage-specific vaccines is the fear that a vaccine could revert to 
virulence and lead to multiple genetic lineages of PPRV circulating in the field (Sen et al., 2010). This 
seems an unfounded concern as the live attenuated vaccines have been tested and used for decades 
in multiple countries with no adverse effects, including no adverse events in pregnant animals (A. 
Diallo personal communication to M.D. Baron). Another fear associated with PPRV is that lineage-
specific vaccines must be used in a vaccine matching scenario to prevent the local circulating field 
strains from escaping vaccine-induced protection. Vaccine matching is essential in foot-and-mouth 
disease control due to multiple serotypes of the virus (type O, A, South African territories (SAT)1 and 
SAT2) and a lack of cross-protection between these serotypes (Paton et al., 2005). Similarly, current 
vaccines to bluetongue virus are serotype specific and only protect ruminants against infection by 
strains of the homologous serotype, requiring continuous vaccine development as new serotypes 
emerge (Feenstra and van Rijn, 2017). However, there is only one known serotype of PPRV and vaccine 
matching should not be necessary for this virus. Now that this research has been completed and 
demonstrates that two vaccine strains, one originating in Nigeria and the other originating in India are 
both capable of protecting goats against challenge with representative strains from the four known 
genetic lineages, the argument for vaccine matching for PPRV has been undermined, and suggests 
that any live attenuated PPRV vaccine that is available should be utilised to enable protection of 
livestock irrespective of the local circulating strains. 
In Chapter 3 the presence of PPRV RNA in the blood following challenge was assessed by RT-PCR. None 
of the vaccinated goats had detectable genome in the blood. Nasal and ocular swabs were taken at 
the same time as blood samples, but only nasal swabs from one experiment were assessed for PPRV 
shedding due to a lack of detectable viraemia in vaccinates. This was based on the assumption that 
vaccinated animals would not shed virus in detectable amounts if viral genome was not detectable in 
the blood. It would be instructive to assay more of these nasal swabs and the ocular swab samples to 
confirm if vaccinated animals do not shed PPRV following challenge. 
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It is widely assumed that neutralising antibodies are the primary determinant of vaccine-induced 
protection against PPRV, as with many other viral infections. The focus on neutralising antibodies is 
further adopted by regulatory authorities such as the OIE stating that PPRV vaccination has been 
correctly administered if the animal has a neutralising titre of greater than 1:10 (OIE Terrestrial 
Manual, (2013). Measuring vaccine-induced antibodies is comparatively easy and cost-effective, 
requiring sera from vaccinated animals and corresponding antibody detection assays which either 
determine the presence of protein-specific or neutralising antibodies. However, work to determine 
the exact mechanisms of vaccination-induced protection have not been performed for PPRV.  
Indeed, there is relatively little known about immune mechanism of vaccine-induced protection for 
the most-studied morbillivirus, MeV. The standard live MeV vaccine (the Edmonston strain) induces 
both humoral and cell-mediated immune responses, and protection is correlated with neutralising 
antibody, but the determinants of vaccine-induced protection are not fully known (Griffin, 2017). 
There are few experiments looking at the cell-mediated immune responses to the RPV vaccine. 
Experiments performed with the live RPV Plowright vaccine in cattle showed that crude RPV antigen 
induced specific proliferation in the 3H thymidine incorporation assay (Holzer et al., 2016). More 
particularly, vaccination with RPV induced CD4+ T cell responses to all of the structural RPV proteins 
expressed in adenoviruses, and specifically stimulated CD4+ T cell proliferation (Lund et al., 2000). 
Whilst little is known about the immune responses to live morbillivirus vaccines, experiments have 
been performed with recombinant vaccines that could shed light on correlates of vaccine-induced 
protection. Vaccination with baculovirus-expressed F or H protein of RPV generated neutralising 
antibodies, but the animals were not protected from virulent challenge (Bassiri et al., 1993). Also, it 
has been observed that recombinant poxvirus vaccinated animals with low or undetectable PPRV-
specific serum neutralizing antibody levels before challenge have been protected on challenge with 
wild type viruses (Jones et al., 1993, Romero et al., 1995), indicating that the cell mediated immune 
response could be an important source of protective immunity in PPR. 
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This work has sought to characterise both antibody and T cell responses to live PPRV vaccines. Both 
vaccines led to seroconversion as assessed by cELISA. This is in keeping with other studies on PPRV 
where the cELISA has been used to identify seroconversion following vaccination (Faris et al., 2012). 
Following on from the PPRV-N-specific cELISA assays performed in Chapter 4, only serum from two 
animal experiments were assessed for virus neutralisation, and only against the two vaccine strains 
and for one experiment, the challenge strain. Given more time it would have been informative to assay 
all sera obtained over all experiments, not only against the PPRV vaccine stains, but also against all 
available PPRV challenge strains used in the experiments to confirm cross-neutralisation of all 
lineages. 
I investigated T cell responses by performing proliferation assays with PBMCs from vaccinated goats. 
As I have already stated, research into the cell-mediated immune response to morbillivirus vaccines is 
rare, even in MeV. As far as I am aware, this is the first time that CMI responses to PPRV vaccines has 
been investigated in conjunction with the humoral response. Both vaccines stimulated the CMI, as 
demonstrated by proliferation of PBMCs in the presence of PPRV antigens, and production of PPRV-
specific IFN-γ. Interestingly, goats given the Sungri/96 vaccine had higher proliferative responses and 
higher CD8+ IFN-γ production following in vitro stimulation with PPRV-specific antigens than the 
Nigeria/75 vaccinates. The exact causes for these differences was not determined by these studies, 
but further work to determine if this is caused by genetic or antigenic differences between the two 
vaccines would be a valuable future experiment. 
The majority of in vivo cell depletion experiments seek to understand the role of a specific cell type in 
the response to a primary infection (Eriksson et al., 1999, Permar et al., 2004). There are very few 
experiments where in vivo depletion has been performed in vaccinated animals; a CD4-depletion 
study has been performed in foot-and-mouth vaccinated cattle to determine their role in antibody 
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production following vaccination (Carr et al., 2013). My work is novel in that it sought to determine 
the role of T cells in vaccine-induced protection upon challenge. 
In this work I attempted to determine the vaccine-induced protective response by performing in vivo 
depletion of CD8+ cells in vaccinated goats. Unfortunately, the vaccine-induced protective response is 
still not determined at this time, but there are other studies that could be performed to improve the 
understanding of vaccine-induced protection in PPRV. It should be noted that for the in vivo CD8-
depletion that I did not confirm that CD8 cells were depleted in the lymph nodes and other tissues. 
Whilst the majority of published, in vivo depletions do not analyse secondary lymphatic organs for the 
successful depletion of respective cell population, this would still be informative to determine if 
depletion was as complete as is assumed from the whole blood labelling data. Nonetheless few studies 
carrying out T cell depletion in ruminants via inoculation of mAbs have reported the successful 
depletion of T cell populations in lymphatic tissues in correspondence with their absence in the blood 
using respective dosages of 2-2.5mg mAbs/kg bodyweight, similar to the dosage employed here.  
PPRV vaccination induces high neutralising antibody titres that persist for several years following 
vaccination (Saravanan et al., 2010), depleting the CD8+ T cells four weeks following vaccination and 
then challenging with a field strain soon after will have been complicated by the presence of high titres 
of neutralising antibodies (nAbs). It is possible that the challenge field strain could have been 
neutralised by nAbs before infecting target cells, thus limiting the role of cytotoxic CD8+T cell 
responses in  preventing viral replication and dissemination. Hence it would be interesting to carry out 
similar studies following extended time between vaccination and respective depletion/challenge 
when nAbs have waned to investigate if CD8+ T cell responses could prolong vaccine induced 
protection against re-infection and/or disease manifestation. The challenge of the CD8-depleted 
animals could have been altered to infect via intranasal insufflation to closer mimic natural infection 
and potentially avoid circulating IgG in the blood. Also, use of a higher dose or a more virulent virus 
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could have overcome the circulating neutralising antibody and lead to infection and replication in 
target cells. 
As stated in Chapter 5 the original aim was to perform both CD4- and CD8-depletions in goats, but at 
the time of performing the CD8+ depletion a suitable anti-CD4 IgG2a mAb that would cross-react with 
goat CD4 was not available from the hybridoma stocks held by the Institute. Since the experiment was 
performed, a goat anti-CD4 IgG2a mAb has become available at affordable cost which might be 
suitable for CD4 T cell depletion in goats. This antibody is clone GC1A and is available from Washington 
State University Monoclonal Antibody Center. If the funds were available it would be beneficial to the 
data presented in this body of work to have the additional experiment of a CD4-depletion 
vaccination/challenge experiment to determine if the CD4+ T cells provide a more substantial role in 
protection than the CD8+ T cells. 
In order to fully understand PPRV vaccine-induced protection the humoral immune component cannot 
be ignored. To investigate the role that antibody plays in protective immune response I would perform 
a passive transfer experiment by injection of immunoglobulin or antiserum into a group of naïve 
animals and challenge them soon after to observe if PPR clinical signs occur or if the animals were 
partially or fully protected. However, antibody will not persist for extended periods in a goat following 
passive transfer, therefore another approach would be to give memory B cells from a vaccinated goat 
to a PPRV-naïve goat. Due to goats being outbred and the high likelihood of MHC-mismatching in an 
outbred population, this experiment would have to be performed using twins, twins are not 
uncommon in popular milking goat breeds so sourcing enough twins would not be onerous. It is likely 
that PPRV vaccine-induced protection is achieved by a combination of both humoral and cellular 
immunity, and therefore future vaccine candidates should seek to stimulate both immune responses. 
In chapter 5 full post mortem analysis of all CD8 T cell depleted and mock depleted goats was carried 
out to investigate if CD8 T cell depletion would result in more pronounced PPRV induced local 
pathology even in the absence of systemic clinical manifestation. Although it was observed that one 
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CD8-depleted goat had developed haemorrhagic stripping of the small intestine mucosa, the limited 
number of animals as well as minor gut pathology present in several animals of both treatment group 
does not allow for any wider conclusions. The pro-inflammatory cytokine interferon-λ (IFN-λ) has been 
shown to act specifically on the epithelial cells of the respiratory and gastrointestinal tract (Mordstein 
et al., 2010). Furthermore, IFN-λ has been demonstrated to play a role in rotavirus infection – one of 
the most common causes of gastroenteritis in humans (Pott et al., 2011). Working on the assumption 
that PPRV enters the host via the respiratory tract and affects the gut during infection (and exits via 
the epithelial layer of the gut and respiratory tract), it is plausible that IFN-λ would play a significant 
role in prevention of shedding of the virus in these tissues. Therefore, it would be interesting to 
investigate the role of IFN-λ in both PPRV infection and vaccination-induced protection. This could be 
performed either by immunohistochemistry of the gut and respiratory tract following intranasal PPRV 
infection or by intracellular cytokine staining of PBMCs from vaccinated goats, using the same protocol 
for IFN-γ described in Chapters 4 and 5. For the same reason that IL-17 is also associated with 
protection against infection at mucosal surfaces (Onishi and Gaffen, 2010), it would be interesting to 
investigate the role of this pro-inflammatory cytokine in PPRV infection as well as IFN-λ. 
Natural killer (NK) cells are considered to bridge the gap between the innate immune system and the 
adaptive immune system, in that they are not pathogen-specific but they can perform similar roles to 
some T cell populations, such as production of cytokines, including IFN-γ (Lund et al., 2013). NK cells 
in cattle can be identified by their expression of the cell surface protein NKp46, the majority of bovine 
NK cells also express CD8α+. In the CD8-depletion experiment the antibody used, CC63, would have 
bound to the CD8α expressed on both CD3+CD8+ T cells and CD8α+ NK cells. It would have been 
interesting to include labelling for NKp46 in the IFN-γ intracellular labelling assay to determine what 
proportion of the CD4-CD8β- cells were NK cells and if they were producing IFN-γ in response to the 
same stimuli as the CD4+ and CD8β+ cells that were investigated in this research. Further investigations 
into NK cells in PPRV infection are warranted, and this would make interesting future work. 
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In Summary, these findings have broadened the knowledge of immune responses to vaccination with 
live PPRV vaccines. More work is still required, but the findings presented here will inform policy 
decisions towards PPRV eradication in the field and could inform the development of next-generation 
vaccines of PPRV. 
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Appendix 1 – PPRV Clinical score sheet for goats  
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AS-FORM-117 
Q Pulse Document Number 
1 
Revision No. 
PPRV Clinical Observations Score 
Sheet for goats 
Page 1 of 1 
 
Request No:………………….. Room ……. NACWO check by………….  Animal number: 
 
Date:       
Recorded by:       
Temperature & 
score 
≤ (initial+0.1) =0 
(Initial+0.1)< to 
≤(initial+2)=1 
> (initial+2) =2 
      
Nasal signs 
Congestion = 1 
Discharge =2 
      
Ocular signs 
Congestion = 1 
Discharge = 2 
      
Oral signs 
Congestion gums/ 
papillae=1 
1 or 2 vesicles in 
gums = 2 
Necrotic vesicle(s) 
=3 
      
Diarrhoea 
Any=1 
Bleeding = 2 
      
Respiration 
Cough=1 
Noise when 
breathing = 2 
      
Behaviour 
Apathetic = 1 
Recumbent = 2 
      
Total score       
Additional signs- insert Yes or No and include a brief explanation under summary 
Off food/water       
Behaviour 
changes 
      
Secondary 
infection 
 
 
      
Summary       
 
 
The Institute is grant-aided by the Biotechnology and Biological Sciences Research Council. It is a company limited by guarantee, registered in England No.559784 
Registered Office: Pirbright, Surrey GU24 0NF.  Charity Commission Reference Number 228824 
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Appendix 2 – IFN-γ percentages in non-granular leucocytes for 
individual animals from the vaccination/challenge CD8-depletion 
study 
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Supplementary Figure 1 Percentages of IFN-γ positive CD4+ T cells following stimulation with PPRV-
specific antigen or live virus. Blood was obtained on the days indicated, PBMCs were isolated from 
blood as described in Section 2.6.2. PBMCs were stimulated in triplicate with crude antigen 
preparations  or live virus for 18 hours, then BD Golgi Plug was added for a further 6 hours. T cell 
subsets were identified by external labelling of membrane proteins prior to fixation/permeabilisation 
and intracellular staining for IFN-γ.  Stained cells were suspended in 200µl analysed on the MACSQuant 
flow cytometer, taking up a fixed volume of 150µl per well. Displayed are percentage CD4+IFN-γ+ for 
individual mock-depleted animals D1 (A), D3 (B), D5 (C) and D9 (D). 
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Supplementary Figure 2 Percentages of IFN-γ positive CD4-CD8- cells following stimulation with 
PPRV-specific antigen or live virus. Blood was obtained on the days indicated, PBMCs were isolated 
from blood as described in Section 2.6.2. PBMCs were stimulated in triplicate with crude antigen 
preparations  or live virus for 18 hours, then BD Golgi Plug was added for a further 6 hours. T cell 
subsets were identified by external labelling of membrane proteins prior to fixation/permeabilisation 
and intracellular staining for IFN-γ.  Stained cells were suspended in 200µl analysed on the MACSQuant 
flow cytometer, taking up a fixed volume of 150µl per well. Displayed are percentage CD4-CD8-IFN-γ+ 
for individual mock-depleted animals D1 (A), D3 (B), D5 (C) and D9 (D). 
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Supplementary Figure 3 Percentages of IFN-γ positive CD4+ T cells following stimulation with PPRV-
specific antigen or live virus. Blood was obtained on the days indicated, PBMCs were isolated from 
blood as described in Section 2.6.2. PBMCs were stimulated in triplicate with crude antigen 
preparations  or live virus for 18 hours, then BD Golgi Plug was added for a further 6 hours. T cell 
subsets were identified by external labelling of membrane proteins prior to fixation/permeabilisation 
and intracellular staining for IFN-γ.  Stained cells were suspended in 200µl analysed on the MACSQuant 
flow cytometer, taking up a fixed volume of 150µl per well. Displayed are percentage CD4+IFN-γ+ for 
individualCD8-depleted animals D2 (A), D4 (B), D7 (C),D6 (D) and D10 (E). 
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Supplementary Figure 4 Percentages of IFN-γ positive CD4-CD8- T cells following stimulation with 
PPRV-specific antigen or live virus. Blood was obtained on the days indicated, PBMCs were isolated 
from blood as described in Section 2.6.2. PBMCs were stimulated in triplicate with crude antigen 
preparations  or live virus for 18 hours, then BD Golgi Plug was added for a further 6 hours. T cell 
subsets were identified by external labelling of membrane proteins prior to fixation/permeabilisation 
and intracellular staining for IFN-γ.  Stained cells were suspended in 200µl analysed on the MACSQuant 
flow cytometer, taking up a fixed volume of 150µl per well. Displayed are percentage CD4-CD8-IFN-γ+ 
for individualCD8-depleted animals D2 (A), D4 (B), D7 (C),D6 (D) and D10 (E). 
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Appendix 3 – Post mortem record sheet for CD8-depletion study 
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Post mortem sheet Depletion study 2017  Goat number:  
Organ  Enlarged? Lesions?  Other comments 
Mandibular 
lymph nodes 
   
 
 
 
Tonsil   
 
 
 
 
Prescapular 
lymph node 
  
 
 
 
 
Bronchial 
lymph node 
  
 
 
 
 
Trachea, 
bronchii, Lung 
 
 
 
 
 
  
spleen  
 
 
 
  
Mesenteric 
lymph node 
 
 
 
 
  
Intestine 
overview 
outside 
   
Mucosa and 
Peyersche 
Plaque small 
intestine  
   
Mucosa and 
Peyersche 
Plaque Ilium 
 
   
Mucosa colon    
 
 
 
 
Any other 
abnormalities 
observed 
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